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ABSTRACT
Diseased heart valves are commonly replaced by mechanical, bioprosthetic, or
allograft heart valves. These replacements provide major improvements in cardiac
function and quality of life, but have significant limitations and eventually require surgical
replacement within 15-20 years. These risks are particularly prominent in pediatric
patients and young adults. The field of tissue engineering and regenerative medicine,
which combines scaffolds and cells, holds great promise in developing living replacement
heart valves that would self-repair and grow in size along with the growing children.
The long-term goal of this project is to generate living, tissue-engineered heart
valves from biological scaffolds and autologous stem cells – a goal that hinges on our
ability to create tissue devices that withstand mechanical stresses immediately upon
implantation without posing risks of immunological rejection. We hypothesized that
these valves can be generated by optimal integration of three main factors: acellular heart
valve root scaffolds, autologous stem cells, and construct preconditioning in a bioreactor.
Furthermore, we hypothesized that the valves would not be generated without advanced
bioreactor systems for the development, conditioning, and translation to clinical practice.
To reach this goal, we developed integrated platform technologies for complete
aortic valve root (AVR) decellularization, stem cell seeding, and dynamic conditioning
before implantation. Unique features include universal “no touch” valve-mounting devices,
decellularization in a purpose-designed pulsatile perfusion system, and techniques for in
vitro re-vitalization with adipose tissue-derived stem cells (hADSCs) followed by
progressive conditioning in our heart valve bioreactors. Acellular porcine AVRs seeded
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with autologous (sheep) ADSCs were implanted in 10 sheep as right ventricle to
pulmonary artery shunts with complete clamping of the pulmonary aorta.
Results showed perfect decellularization of the entire porcine AVR and almost
complete seeding with ADSCs. Bioreactor studies revealed stem cell pre-differentiation
into cells resembling valvular interstitial cells as a response to dynamic stimulation.
Animal studies with follow-ups to 12 months are ongoing.
Novel customized devices and bioreactor systems are vital to the successful
development of tissue engineered heart valve products, especially in preparation for
clinical translation. Herein is described some of the basic equipment and expertise
necessary for the successful development of tissue-engineered cardiovascular products.
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PART 1: INTRODUCTION AND BACKGROUND
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CHAPTER 1: BACKGROUND INFORMATION
1.1 Anatomy and Physiology
1.1.1 Cardiac Anatomy and Physiology
The heart has two double-chambered pumps pictured in Figure 1-1, which
demonstrates the pressures and flow through the chambers. The right pump pushes blood
through the lungs, where waste gases are exchanged for nutritional gasses while the left
pump propels blood through the peripheral organs. Within each pump, blood first enters
the superior chamber, the atrium, which moves the blood through an atrioventricular
valve into the ventricle, the inferior chamber. When these ventricles contract, blood
propels through the pulmonary (right side) valve or ventricular (left side) valve and
through the rest of the body. Following contraction, the pulmonary and aortic valves
close to prevent blood flow back
through the heart.[1]
The pumping heart is a
dynamic feedback system that
changes its physical and chemical
outputs according to the body’s
needs.

Under

average

normal

resting conditions, the heart beats
about 70 times per minute (bpm),
ejecting 70 mL (stroke volume) of Figure 1-1: Blood flow through the heart

Normotensive blood pressures are given in the green boxes for
each chamber or area of the heart. However, these values can
its left ventricular volume of 120 vary greatly and still be considered normal.[1,180]
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mL (end-diastolic volume) each beat.[2,3] This results in a total of about 4.9 liters of
blood flow per minute. The ventricles’ cyclic contractions create pressures that drive the
blood through the circulatory system. Upon contraction, the pressure in the left ventricle
increases to approximately 120 mmHg. Almost simultaneously, the aortic valve snaps
shut and blood flows away from the heart along the pressure gradient. As the pressure in
the aorta drops toward 80 mmHg, the left ventricle has begun its contraction to pump
another bolus of blood and return the pressure to 120 mmHg. Figure 1-2 shows the left
ventricular volumes and pressures as described above.[1]

Figure 1-2: The cardiac cycle for the left heart
By studying the pressure and volume correlations with time, we can understand the function and
performace features of the heart that allow it to perform incredibly over a person’s lifetime.[1]
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1.1.2 Valvular and Cellular Anatomy
Aortic Valves, Cusps, and Extracellular Matrix
The heart valves are excellent examples of durability, design, and adaptability not
found in man-made materials. The physiological composition of a human aortic heart
valve is optimized to withstand rigorous physical stresses and to respond to small
pressure changes during the diastolic and systolic stages of the cardiac cycle. It is
constructed with very strong, yet very pliable fibrous tissue with three heterogeneous
cusps attached to an annular ring and wall
of the aorta (Figure 1-3a).[4] With every
beat of the heart, the aortic valve, which
acts as a one-way check valve, is opened to
progressively move blood through the
pulmonary and systemic circulation of the
body and closed to prevent retrograde flow
during diastole.[1,5] The continuous
performance at 850 milliseconds per cycle
leads to a lifetime average of more than
three billion cycles.[6,7] Further, the
trans-valvular pressures across the aortic
valve change from roughly zero to 120
mmHg in the course of only 17-20
milliseconds that is required for the valves Figure 1-3: Aortic valve anatomy
to

close.

This

leads

to

a

a) Aortic valve dissected for viewing.[181] b) cross

13% section of a cusp, showing the three layers.[182]
Page | 4

circumferential and a 24% radial cusp stretch.[7] As a result, the heart valves are
unequivocally the most mechanically stressed tissues in the body.[8]
The cusps themselves have almost no blood vessels, but are thin enough to be
nourished predominately by diffusion from blood.[1] They also have no active part in
opening and closing, but act solely in a passive manner in response to flow and pressure
differentials. When they open during systole, they press against the aortic root wall and
when they snap close at the start of diastole, they perfectly align to create a seal that can
prevent backflow even with the 100 mmHg transvalvular pressure difference.[1] The
free edge of each cusp attaches to the portion of the aortic root surrounding one of the
three aortic sinuses. The indentations of these sinuses change the fluid dynamics of the
valve and likely cause the formation of vortices that aid valve closure.[9] Two of the
sinuses lead to coronary arteries and are therefore named the left coronary, right coronary,
and noncoronary sinuses.
The aortic valve cusps are comprised of three distinct layers: the ventricularis,
spongiosa, and fibrosa. These layers contain valvular endothelial cells (VECs), valvular
interstitial cells (VICs), collagen, elastin, and glycosaminoglycans (GAGs) in a formation
that provide the necessary biomechanical properties to withstand the 40 million rigorous
cycles of loading each year. Figure 1-3b shows a view of the aortic valve and a crosssectional view of a cusp. Error! Reference source not found. displays each component’s
locations and major functions. Collagen gives the valve strength to withstand the
pressures when closed while maintaining coaptation. Elastin extends and recoils in every
valve cycle as the cusp moves. GAGs absorb the shear forces between the ventricularis
and fibrosa layers.[10]
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Valvular Endothelial Cells
Although VECs are very similar to other endothelial cells at their basic structural
and functional levels, they are phenotypically distinct from endothelial cells in various
locations in the circulatory system, even in locations in close proximity, such as the
adjacent aortic wall. Their differences possibly allow VECs to interact with VICs to
mediate disease and maintain valve tissue integrity. An example of differences between
VECs and other endothelial cells is their alignment perpendicular to flow while most
endothelial cells align parallel to flow and their transcriptional gene expression profiles
differ under the same mechanical environment. Differences even go so far as to distinguish
between transcriptional profiles of endothelial cells on the aortic side versus the
ventricular side of cusps.[10,11]
Table 1-1: Key cellular and extracellular matrix components of the aortic valve
Although not isolated in regions, many components of the aortic valve have primary locations and
functions.[10,183,184]
Component
Location
Putative Function
Comments
Provide
Lining inflow and
Role in transducing shear and
Endothelial
thromboresistance,
outflow valve
modulating VIC function; Functional
cells (VECs)
mediation of
surfaces
differences from vascular wall EC
inflammation
Deep to surface,
Synthesize and
Currently considered the major
Interstitial
throughout all
remodel matrix
modulator of long-term valve durability
cells (VICs)
layers
elements
and a key mediator of disease
All layers;
Provides strength and
Likely the most important structural
Dense and
stiffness to maintain
element; Crimp and alignment provide
Collagen
circumferentially coaptation against the
directional anisotropy of properties
aligned in fibrosa
pressure gradient
and accommodate cyclical cuspal shape
layer.
during diastole
changes
Absorb shear and
Glycoscushion shock
aminoConcentrated in
Distribution of forces aid in longevity of
between ventricularis
glycans
spongiosa layer
valve components
and fibrosa during
(GAGs)
cyclical valve motion
Maintains valve
Concentrated and
resilience and allows
Elastin
radially aligned in
Extend in diastole, recoil in systole
stretch in response to
ventricularis layer
pressure changes
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Valvular Interstitial Cells
VICs are the most abundant type of cell in the heart valve. Under normal
conditions, they synthesize extracellular matrix (ECM), and express matrix-degrading
enzymes such as matrix metalloproteinases (MMPs) and MMP tissue inhibitors (TIMPs).
These syntheses explain how VICs mediate the remodeling of the ECM structural
components, thereby continuously repairing functional damage to collagen and other
ECM components in the valve.[11] In all, five distinct phenotypes of VICs have been
classified, providing a diverse and dynamic population of cells in the valve. They include
embryonic progenitor endothelial/mesenchymal cells (eVICs), quiescent VICs (qVICs),
activated VICs (aVICs), postdevelopmental/adult progenitor VICs (pVICs), and
osteoblastic VICs (obVICs).[12] Error! Reference source not found. gives a brief
overview of the characteristics of all five phenotypes of VICs.
A vast majority of adult VICs in situ are qVICs, having characteristics of
fibroblasts. qVICS phenotypically change into myofibroblast-like aVICs upon external
Table 1-2: Characteristics of VIC phenotypes
CD34 and CD133 are stem cell markers; S100 is an intracellular calcium-biniding protein.[11,12]
Cell Type
Location
Function
Give rise to resident qVICs, possibly through an activated
Embryonic cardiac
eVICs
stage; EMT can be detected by the loss of endothelial
cushions
markers and gain of mesenchymal markers
Maintain physiological, normal valve structure and function
qVICs
Heart valve leaflet
and inhibit angiogenesis in the leaflets
Enter valve or are resident in valve to provide aVICs to
Bone marrow, circulation,
pVICs
repair the heart valve, may express CD34, CD133, and/or
and/or heart valve leaflet
S100
α-SMA containing VICs with activated cellular repair
processes including proliferation, migration, and matrix
aVICs
Heart valve leaflet
remodeling; respond to valve injury caused by pathological
conditions and abnormal hemodynamic/mechanical forces
Mediate calcification, chondrogenesis, and osteogenesis in
obVICs
Heart valve leaflet
the heart valve; secrete alkaline phosphatase, osteocalcin,
osteopontin, bone sialoprotein
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macroscopic stimuli such as alterations in the mechanical environment, certain chemical
signals, or in response to injury. aVICs are characterized by an increase in stiffness,
expression of alpha smooth muscle actin (α-SMA), and increased ECM biosynthesis.[13]
This phenotypic change is healthy at a small scale for repair, but is widespread during
development, after abrupt changes in the mechanical stress state of valves, and in disease
states.
In conditions that promote valve calcification, qVICs and possibly pVICs can
differentiate into obVICs, which actively participate in the valve calcification process.
There is currently no evidence that obVICs are a separate cell population from aVICs,
but the osteoblastic differentiation and calcification promotion of VICs significantly
differs from normal aVIC activity, thereby warranting its own category.[12]
Summary of VIC Phenotype Markers
eVICs are present in development. Similar processes are thought to be present in
the initial stages of disease, but a distinct cell type is not anticipated in these mature
sources.
qVICs show two types of intercellular junctions: gap junctions and adhesion
junctions, as seen by the expression of transmembrane gap junction proteins Connexin26 and -45. Cell-cell adhesion junctions are especially present between the long processes
of adjacent cells as detected by small amounts of N-Cadherin and desmoglein.[12]
pVICs are found as other cell types in the body such as endothelial progenitor cells
(EPC) and dendritic cells (DC). EPCs can be identified by stem cell markers such as
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CD133 and CD34, a high proliferative capacity, and the ability to form blood vessels. DCs
are identified by an intracellular calcium binding protein, S100.[12]
aVICs are most often characterized by expression of α-SMA, which is normally

not found in qVICs. They also have the features of myofibroblasts: increased contraction,
prominent stress fibers, and other contractile proteins. Activated VICs also increase the
secretion of cytokines, such as TGF-β.[12]
obVICs express markers that characterize osteoblasts in bone such as alkaline

phosphatase, osteocalcin, and osteopontin. There is no clearly defined method of
identifying a VIC in the osteoblastic state.[11]

1.2 Aortic Valvular Disease
1.2.1 Worldwide Prevalence
Although most people’s heart valves will last their entire lifetime and cycle about
3 billion times, about 2% of the American population will be affected by heart valve
disease.[14] By 2011, it was estimated that roughly four million people in the United
States were diagnosed annually with a heart valve disorder.[15] Worldwide, over
300,000 heart valves are replaced every year.[15–17]
However, this number is not representative of the actual number patients in need
of valve replacements. Statistically, 80% of all cardiovascular disease occurs in developing
countries,[18–20] but 85% of all open-heart procedures are performed in developed
countries representing 11% of the world population.[21,22] In developing countries,
economies cannot support the vast number of open heart surgeries or valve replacements
that would actually help the population. Furthermore, in those developing countries, we
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see that it is children and young adults[20,21] that are the demographic most affected,
not the population over 65 as is seen in the United States.[23]
While the majority of causes for heart valve diseases in industrialized nations is
degenerative pathology, inhabitants of developing nations also often suffer from the
persistent burden of rheumatic fever.[15,24] However, As the economies of these
developing countries grow, so will healthcare. The cause of valve degeneration will shift
and cardiac surgery will become increasingly more accessible to potentially millions more
who are in need of valve replacements.[21]
1.2.2 Causes for Valve Disease
In a normal heart valve, the cyclical stresses (which are often exacerbated in cases
of genetically malformed valves) and other systemic conditions[20,25] damage the valve
in the form of micro tears and calcific deposits that must be continuously repaired by the
specialized valvular interstitial cells (VICs).[7,12,26–29] Mechanical cues play an
important role in this delicate regulation.[30–33] When an imbalance occurs in this
damage-repair cycle,[20,34,35] the valve can become diseased.[35–37]
Valve disease most often occurs in the aortic valve and is commonly classified into
two main types of abnormalities that disrupt blood flow: regurgitation and stenosis. In
aortic stenosis, the left ventricle fails to empty adequately following contraction due to
the aortic valve not opening properly This creates a reduction in the valvular orifice. In
aortic regurgitation, blood flows backward into the left ventricle after contraction due to
the aortic valve failing to close properly. This can be caused by stenosis as well as other
factors.[1]
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The most frequent cause for aortic regurgitation is stenosis, which occurs when
the cusps thicken, stiffen, or fuse together, most often due to calcific nodule formation.[38]
This is most often a result of many risk factors that increase with age, but can also be
seen in younger patients, especially those with congenital defects such as improper valve
size, malformed leaflets, or an irregularity in the way the leaflets are attached.[24,39,40]
In fact, evidence of a high percentage of valve replacement surgery patients having
congenital abnormalities[41] suggests that patients with a congenital valve defect are
predisposed to valve disease.[14] Stenosis may also be caused by damage acquired after
birth as described above such as calcific deposits, changes in the structure of the valve, or
infections like infective endocarditis and rheumatic fever.
While there are various causes for each of these problems, the final outcome is the
same. Both stenosis and regurgitation lead to a reduction in the net stroke volume output
of the heart, causing it to work harder to pump the same amount of blood through the
body. Patients suffering from valvular heart disease will eventually need surgical
intervention to repair or, more frequently, replace the damaged heart valve.[1]

1.3 Valvular Interstitial Cell Contributions to Stenosis
1.3.1 Curing Valve Stenosis
The ability to stop progression, if not completely reverse calcification would be
the optimal cure for stenotic valvular heart disease. This cure would help the roughly
30% of patients[42] previously classified as untreatable because they were unable to
undergo the necessary surgery due to their age, poor health, or immune compromised
status. The option of a pharmaceutical approach instead of surgical treatment would
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reduce the factors that often accompany surgery such as hospital recovery, infection, and
anxiety of open heart surgery.
This relatively new idea of medicinal treatment has developed in the last 10-15
years as researchers have found evidence that valvular stenosis is not a passive deposition
of calcium with degeneration, but is actually an active biological process involving
endothelial dysfunction, lipid accumulation, inflammation, ostegenic processes, and
multiple ubiquitous cellular pathways.[14,43,44] Some research in human aortic valves
and in vivo animal models even suggest that degenerative valvular aortic stenosis is the
result of active bone formation in the aortic valve that may be mediated by osteoblast-like
differentiation processes.[45]
As the evidence grows for an active process of calcification rather than a passive
occurrence, novel areas are being investigated such as how to identify and classify the
types of valvular interstitial cells (VICs), determining which exogenic factors contribute
to calcium formation, and determining which endogenic pathways are involved in the
pathology of this disease.
1.3.2 Factors Contributing to VIC Phenotype Shifts and Calcification
In normal valve function, the macroscopic mechanical stimuli like shear and solid
stresses are translated into microscopic forces that impact VIC and VEC function. Sensing
the local tissue microenvironment in response to the external factors, they transduce
forces through cell-cell and cell-ECM interactions that mediate normal valve function
and pathobiology. They also respond by transdifferentiating to perform phenotypespecific duties of maintaining homeostasis, adapting to altered stress states, and repairing
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ECM components.[10] This phenotypical shift in VICs is a normal occurrence under
many circumstances. However, certain factors have been identified that excessively
promote this effect and even cause the cells to start producing calcium, as in obVICs. The
pathways of this transdifferentiation are shown in Figure 1-4, showing known and
possible transitions. While there is not a complete knowledge base on every transition,
some factors have been identified that contribute to certain changes in phenotype.[12]
Embryonic Progenitor VICs (eVICs)
eVICs are present during the developmental stages of life. Studies have shown
that transforming growth factor beta (TGF-β), bone morphogenetic proteins (BMPs),
Notch, and vascular endothelial growth factor (VEGF) have significant regulatory effects
on eVICs becoming normal qVICs through the course of valve development. Correct
levels of each are necessary to properly guide the differentiation.[12]
Quiescent VICS (qVICs)
Evidence shows that over several passages in cell culture, qVICs are activated and
become aVICs, but these culturing conditions have not been deeply investigated in an
isolated manner. Isolated
factors

that

found

to

have

been

initiate

this

phenotypic shift in vitro
include cyclic mechanical
stretch

and

TGF-β
Figure 1-4: Known and probable pathways of VIC transdifferentiation
Hatched arrows depict possible transitions for which there is currently
no solid evidence.[12]
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treatment.[11] Moreover, these two factors are synergistic.[46]
Post-developmental Progenitor VICs (pVICs)
In response to injury, the number of VICs present increases quickly. This is now
thought to be a result of pVICs from bone marrow-derived cells, circulating cells, and
resident valvular progenitor cells being activated to become aVICs. It is not known
whether pVICs go through the qVIC stage before becoming aVICs.[12] Two specific
types of pVICs are the endothelial progenitor cell (EPC) and dendritic cell (DC). It is
possible that these cells share a common circulating progenitor cell: the CD34+
hematopoietic stem cell. They have been shown to express mRNA for procollagen α1 and
differentiate with morphological similarities to native VICs when engrafted into recipient

heart valves.[47] Progenitor cells from the pulmonary valve have been isolated and
shown to transition to VIC-like cells in response to TGF-β2. Interestingly, VEGF causes
these same cells to become endothelium rather than mesenchymal VIC-like cells.
Activated VICS (aVICs)
aVICs are the master cells of valves. Under conditions of pathological injury or
unusual hemodynamic or mechanical stress, qVICs become aVICs and take on the features
of myofibroblasts. The characteristic marker for aVICs is α-SMA, which is normally not

found in qVICs. In culture, many VICs may express α-SMA, while exhibiting a number

of different morphologies. It is believed that under the exogenic factors of injury or
unusual stress, VECs and macrophages/foam cells are activated, releasing chemokines
and growth factors that stimulate qVIC activation.[12] The process surrounding aVIC
activation and leading to valvular heart disease can be seen in Figure 1-5.
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The normal adult heart valve is well adapted to its physiological environment,
able to withstand the unique hemodynamic/mechanical stresses under standard
conditions.

Under

conditions

of

pathological

injury

or

abnormal

hemodynamic/mechanical stresses, VICs become activated through activation of VECs
and by inflammation and associated cytokine and chemokine signals. Macrophages will
also be activated. aVICs increase matrix synthesis, up-regulate expression of matrixremodeling enzymes, migrate, proliferate and undergo apoptosis, and undergo osteoblast
transformation. These processes are regulated by a variety of factors, several secreted by

Figure 1-5: Pathways of clinical valve disease
Pathological injury or abnormal hemodynamic/mechanical stresses can facilitate VICs activation through
activation of VECs and by inflammation and associated cytokin and chemokine signals, which will also lead
to macrophage activation. As a result, aVICS increase matrix synthesis, up-regulate expression of matrixremodeling enzymes, migrate, proliferate and undergo apoptosis, and undergo osteoblast transformation
. under the regulation of a variety of factors including those secreted by the aVIC. Progressive clinical valve
disease can then result from these cellular processes, angiogenesis, chronic inflammation, fibrosis, and
calcification.[12]
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the aVIC. If the aVICs continue to promote these cellular processes, angiogenesis, chronic
inflammation, fibrosis, and calcification result, leading to progressive clinical valve
disease.[12]
Osteoblastic VICs (obVICs)
Currently, there is no evidence that obVICs are a separate cell population from
aVICs, but they can be classified as VICs that undergo osteoblastic differentiation and
promote calcification as seen when VICs are cultured in osteogenic and chondrogenic
culture medium. This classification is useful when considering the evidence of
cartilaginous nodule and mature lamellar bone presence in explanted valves. Associated
proteins such as osteopontin, bone sialoprotein, alkaline phosphatase, and BMP-2 and -4
have also been found.
Numerous factors have been identified that promote the active calcifying action of
VICs: TFG-β, 25-hydroxycholesterol, and BMP-2 increased the rate of nodule formation
when cultured in growth medium supplemented with organic phosphate; Oxidized
cholesterol stimulates calcified nodule formation; BMPs and TGF-β caused osteoblastic
differentiation of VICs; VIC calcification and ECM degradation is induced by MMPs and
may be promoted by Tenascin and early growth response-1 (Egr-1); Oxidized lipids,
tumor necrosis factor-α (TNF- α), and hyperglycemia may all mediate osteoblast

differentiation and thus, valvular calcification through pathways activated by BMP2; and
VECs may transduce external signals to VICs, regulating the aVIC or obVIC
function.[12]
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1.3.3 Pathology and Pathways
Along with factors that affect the individual VIC phenotype and actions, there are
many larger-scaled factors that contribute to VIC phenotype shifts and calcification.
General risk factors include age, male gender, hypertension, diabetes mellitus, smoking,
renal disease, hypercholesterolemia, hyperparathyroidism, and decreased bone mineral
density.[45] Some literature suggests that the molecular mechanism resembles that of
atherosclerosis[48] with hypercholesterolemia playing a role in this calcification,[45]
but statin treatments have had mixed results. Therefore, the overall valvular tissue
response to disease, which further exacerbates the problem, can be characterized by four
major processes: 1) accumulation of VICs and inflammatory cells, 2) neovascularization
or angiogenesis, 3) increased matrix production, and eventually 4) fibrosis and
calcification.[12] Figure 1-6 shows some of the factors and mechanisms that will be
discussed.
Cells
In response to injury, the number of VICs present increases quickly. This process
is discussed above. Under normal conditions, when valve repair is complete, excess cells
undergo apoptosis to restore the balance of cells in the valve. However, in α-actin-positive

cells, mRNA and protein levels of the G1 and G2 cell cycle checkpoint genes

p21WAF1/CIP1 and 14-3-3 sigma are down regulated several-fold, possibly giving rise
to the observed increase in cellular density.[12,48]
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Angiogenesis
Normal valves are avascular, but a dramatic increase of angiogenesis in diseased
conditions has been reported in a close association with valvular stenosis and
inflammation. Endothelial cells in stenotic valves exhibit CEACAM1, a cell adhesion
molecule involved in angiogenesis expressed in angiogenic but not quiescent endothelial
cells. Angiogenic factors, VEGF and MMPs, have also been shown to play a role in valve
pathology.[45] While the presence of these factors contribute to angiongenesis, down
regulation of the angioinhibitory factor, chondromodulin-I (chm-I) has been seen to
permit pathologic angiogenesis in coronary artery endothelial cells. The work partly
described in Figure 1-6 is the basis for a newly proposed mechanism for the onset of aortic
valve degeneration where angiogenesis is the main contributing factor.[48]
ECM
Certain proteins have been found in the matrix of cardiovascular calcifications that
are not present in normal cardiovascular tissue. These include osteocalcin, osteopontin,
osteonectin, TNF-α, BMPs, and many MMPs. Some components, such as the
extracellular proteins tenascin C and cystatin C, alkaline phosphatase, Egr-1 (induces
tenascin-C), are present in low levels in normal tissues, but have been found in higher
levels in calcific valves.[45]
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Figure 1-6: Degenerative mechanisms in the cardiac valve
The putative degenerative mechanisms for superficial endothelial cells, valvular interstitial cells, and
extracellular matrices are shown (A–E). The table is a summary of several factors, including the function,
mechanism (corresponding to A–E above), and effect on degeneration of the cardiac valve.[48]
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obVIC Differentiation
Some work has been done to identify which genes are expressed in obVICs.
Characteristic gene expression includes those encoding osteocalcin, Sox9, Cbfa-1, Runx2,
Osterix, Msx2 oteopontin, and bone sialoprotein. Additional genes that have been studied
are receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin (OPG).
RANKL promotes matrix calcification and induces the expression of osteoblastassociated genes, transitioning VICs toward an osteogenic phenotype. OPG is present in
normal valves, but without it, calcification occurs.[14,45]
Many signals present for cardiac valvulogenesis during development are also
reported to be present in valve degradation. These include Wnt, TGF-β1, BMP, and
Notch. In general, the overexpression of these signals results in valve disease and
calcification.[48]
1.3.4 Current State
New observations in human aortic valves support the hypothesis that
degenerative valvular aortic stenosis is the result of active bone formation in the aortic
valve, which may be mediated through a process of osteoblast-like differentiation in these
tissues.[45]
Some underlying mechanisms have been demonstrated including TGF-β1,
tenascin-C, VEGF, angiogenesis, inflammation, and MMPs. However, a defining
molecular target for heart valve disease has not been defined and significant gaps in this
knowledge still exist. At this time, suppressing inflammation and preventing obVIC
differentiation appear to be the best ways to prevent calcific progression in valves.
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Progress needs to be made in the areas of VIC activation, valve stem cell contributions,
initiation of an osteogenetic gene expression profile, aggravators and inhibitors of valve
degeneration, what steps precede end-stage stenosis and calcification, and how valve
calcification can be lessened or reversed. Measures to identify AoV disease earlier and
treat AoV disease pharmacologically or with less invasive approaches would be a
significant improvement over the current standard of care. These advances will only be
possible with a better understanding of the molecular mechanisms underlying valve
development and disease.[14,45,48]

1.4 Current Treatments
1.4.1 Pharmacological
Once diagnosed with aortic stenosis, there is currently little one can do to reverse
the damage done to their valve. In the early stages, drugs can be used to ease the pain and
treat the symptoms, thereby attempting to stop progression of the disease. Examples
include diuretics to decrease the heart’s workload, beta-blockers to control the heart rate
and decrease blood pressure, and anticoagulants to decrease the risk of clots forming on
the diseased heart valve.[38,49] Studies have investigated using statin treatment to treat
stenotic aortic valves because many of the same processes are characteristic of
atherosclerosis.[44,45,48] However, there have been mixed results with some showing
that the use of a statin stopped progression of aortic stenosis[50] while others have
shown no effect on stenotic progression.[51,52]
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1.4.2 Replacement Heart Valves
Ultimately, the only current treatment available for aortic valve stenosis is to
repair[53,54] or replace the valve, leading to the second most common type of open heart
surgery in the western world. Without this surgery to replace the valve, 50% of patients
with aortic stenosis die within two or three years of diagnosis.[42] Repair may involve
removing calcium deposits, reinforcing a valve that does not close properly, or
mechanically altering a congenitally defected valve.[38]
Most diseased valves cannot be repaired. Instead, they are replaced by mechanical
heart valves (general practice for younger patients), bioprosthetic heart valves (general
practice for older patients), or allograft heart valves (special cases when available).
However,

these treatments each have major drawbacks (see Figure 1-7).

Thrombogenicity of the artificial surfaces and induced turbulent flow regimes necessitate
lifelong antithrombotic therapy for patients with mechanical valves.[55,56] The reliance
upon an expensive drug therapy
and the necessity of close patient
monitoring is undesirable and the
main

factor

that

has

kept

mechanical valve replacement out
of

developing

Additionally,

countries.

pregnancy

and

surgical procedures may require Figure 1-7: Complications with current valve replacements

Mechanical valves have a very low risk of reoperation, but
carry a high risk of a major bleeding event that increases with
temporary suspension of this implant age. Bioprosthetic valves last a limited amount of
time, so are the choice for older patients who will likely die of
antithrombotic
treatment.
A other causes before the valve implant fails.[62]
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solution to the thrombogenicity of
mechanical valves was the advent
of bioprosthetic valves (BHVs) that
are made from either porcine aortic
valves or bovine pericardium that
has been chemically fixed to crosslink the tissue and mask the
antigens present in the xenogeneic

Figure 1-8: Patient survival after valve replacement
materials. These devices do not Long term survival rate for patients receiving either type of
replacement valve is less than 50% after 25 years. While
mechanical valves can last well beyond that point, they often
require the anticoagulation drug lead to other adverse events.[63]

regimen, but are predicted to last
only about 15-20 years due to calcific degeneration[57,58] and even less in younger
patients.[11] Allograft or homograft valves are good choices for valve replacements, but
they also suffer from degradation, chance of rejection, and general lack of availability.[59]
With these severe limitations, the current treatments have high risk of
complications (Figure 1-8Figure 1-7) and are not ideal procedures.[60–64] Furthermore,
they are sub-par solutions for young adults and children needing valve replacements
because of infections or birth defects.[24,39,40] In this demographic, multiple revision
surgeries will be necessary to accommodate the increased degradation rate seen in
younger patients and lack of device growth along with a growing child,[14,39,40,65]
which is still a very frequent need in less developed nations.[66,67]
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1.4.3 Valve Replacement in Children
The general drawbacks of current heart valve replacements are accentuated when
considering that, in contrast to the United States, children and young adults in developing
nations are the most affected demographic.[20,21,23]
Current methods of non-replacement treatment for children include repair of the
valve, reconstruction of the aortic valve with autologous pericardium, or the Ross
procedure, whereby the patient’s pulmonary valve is moved to the aortic position and
replaced with a pulmonary homograft.[39,40] This is usually a sufficient short-term
solution; the pulmonary valve does not have the robustness of an aortic valve, and as such,
will eventually need replacing with a more traditional option. In recent trials,
decellularized xenograft valves have even been used in the pulmonary position,
demonstrating a preliminary shift toward a tissue engineering approach. However, none
of these solutions are ideal.
Alternatively, the field of tissue engineering and regenerative medicine holds
great promise[15,20,68] in developing replacement heart valves that would function just
as native, healthy valves: not requiring antithrombotic or other pharmacological therapy,
repairing themselves as micro-damages are incurred, and growing in size along with a
growing child. As has been eloquently said,[40] “future advances with tissue-engineered
heart valves […] may change the landscape for valve repair in the paediatric population.”
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1.5 Heart Valve Tissue Engineering
1.5.1 Long-Term Goal
Tissue engineering approaches are being developed that seek to make curative
solutions for patients in need of long-term treatment of disease and tissue degeneration.
The constructs that are being researched and tested will not simply compensate for the
damaged tissue, but rather create living tissue that can be implanted into a human that
would function just as a native, healthy valve: not requiring antithrombotic or other
pharmacological therapy, repairing itself as micro-damages are incurred, and growing in
size along with a growing child.
Ideally, a tissue engineered heart valve will resemble both the size and shape of
the native valve, be durable and fully functioning with good hemodynamics, be nonimmunogenic, non-inflammatory, non-thrombogenic, and non-obstructive, respond to
mechanical and biological cues appropriately, grow in size with the recipient, and adapt
to changing conditions throughout the life of the recipient and valve. A valve such as this
would dramatically change the way we treat heart valve disease in children and young
adults all over the world.
1.5.2 Valve materials & various approaches
Multiple methods of creating the above valves are foreseeable and many are being
thoroughly investigated and developed, such as decellularized animal valves,[69–73]
polymers,[15,74,75] layered composites,[76–78] and 3D printing.[79,80] Among the
most researched and advanced methods are those that utilize a decellularized xenographic
aortic valve as a scaffold.[20,68,81] Combining those easily accessible scaffolds with the
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patient’s own stem cells before conditioning in a bioreactor and implanting would provide
a replacement that is fully functional from initial implantation while able to maintain
matrix homeostasis and reduce valve thrombogenicity for the lifetime of the patient.
Current progress of xenographic valve preparation has been widely successful in
decellularizing pulmonary and aortic valve cusps.[82–87] However, when reported,
investigators note that the aortic wall and sinus wall have not been completely
decellularized[84] or they do not give definitive proof of complete decellularization.[88]

1.6 Valve Seeding and Animal Implantations
The key to achieving an implant capable of repairing itself in response to micro
tears is the presence of cells to remodel the matrix as necessary.[35,37] In cases where
the valve implant does not have the adequate mechanical properties to function properly
upon implantation, in vitro cellular remodeling must prepare the valve scaffold prior to
implanting.[89–91] Multiple groups have demonstrated cell seeding on the exterior
surface of valve cusps and some have even achieved some interstitial seeding, though full
revitalization has not been realized.[92–94] The surfaces of some valves have even been
repopulated after implantation in animal models,[95,96] but the same is not guaranteed
in the human system. Even if the valve can be initially covered with cells,[73,97,98] it is
likely that these cells will need some sort of progressive conditioning to remain attached
after implantation since application of sudden shear forces can detach cells. Overall, more
progress is needed to achieve full and consistent external and internal recellularization of
the cusps and to determine what methods are needed to allow the cells to remain, but
autologous adult stem cells provide a promising source for this application.[99,100]
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1.7 Heart Valve Bioreactors
Another major obstacle to the creation of such tissue engineered heart valves seen
in many experimental approaches of biodegradable polymer scaffolding[4] is inadequate
mechanical properties to withstand in vivo forces after implantation.[69] Conversely,
many stabilized tissues have more than adequate mechanical properties, but are unable to
degrade appropriately to facilitate the formation of a natural valve or have chemical
properties that do not facilitate cellular in-growth.[101] As a result, research is being
focused on decellularized valves that will allow the recipient patient’s cells to infiltrate
the extra-cellular matrix, repopulate the valve, and eventually replace the slowly
degrading donor scaffold with newly fabricated extra-cellular matrix.[11,13,57,102,103]
Bioreactors can be generally defined “as devices in which biological and/or
biochemical processes develop under closely monitored and tightly controlled
environmental and operating conditions” such as pH, temperature, pressure, nutrient
supply, and waste removal.”[104] Bioreactors for heart valves can use these monitored
and controlled conditions to help develop well-functioning valves.[105] Requirements
for such bioreactors and examples of previous aortic valve bioreactors are discussed below.
1.7.1 Bioreactor Requirements
Freed[106] says that a bioreactor must be able to perform at least one of the
following five functions:
(1) Establish a uniform distribution of cells on a three-dimensional scaffold
(2) Maintain the desired concentration of gases and nutrients in the culture
medium
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(3) Provide efficient mass transfer to the growing tissue
(4) Expose developing tissue to physical stimuli
(5) Provide information regarding the formation process of 3D tissues, which
originate from the isolated cells.
One of the most important controls of a bioreactor is to supply an adequate
amount of oxygen to a 3D tissue construct. Other biochemical factors, such as carbon
dioxide and wastes also require adequate transport. In conventional cell culture, this is
most often done by creating a large liquid to sterile air interface to facilitate the diffusive
transport of oxygen. In a bioreactor, where the volume of culture medium present is much
larger than in standard cell culture, additional methods must be used. These methods
range from a sterile filter open to the external environment in combination with flow of
the culture medium[107] to coiling gas-permeable tubing inside a culture medium
reservoir.[108]
Physical stimuli such as tension, compression, shear stresses, pressure,
temperature, and pulsatile flow of culture medium improve the structure and mechanical
properties of engineered tissues.[109,110] These mechanical forces have an integral part
in regulation of cell phenotype and growth and the repair or degradation of tissues.[109]
Control of trans-valvular pressure, pulsatile forces, flow rate, frequency, stroke rate, and
stroke volume are all important design parameters of bioreactor to ensure that the
necessary physical stimuli are integrated into the design.[110]

Page | 28

1.7.2 Current Bioreactors
Many bioreactor systems have been developed[94,107,111–118] to test and
precondition valvular constructs prior to implantation. Although they vary in design,
footprint, capabilities, and valve-holding mechanisms, they each share common attributes
to be functional.
Current heart valve bioreactors are designed to test a single valve in vitro at
different levels of pulsatile flow under controlled conditions in a standard humidified
incubator at 37°C and 5% CO2. Figure 1-9 shows the common main components of aortic
valve bioreactors, which include the fundamental components of a driving force to move
the fluid, a reservoir, a valve holder, a capacitance chamber, a resistive element following
the capacitance chamber, and a method of gas exchange.[118]
This schematic gives one representative layout of these components, but many
bioreactors in use today have variations on placement, type, and extent of use of these
components. Most bioreactors have control over parameters such as flow, pH, and stroke
volume and can change those parameters as desired to create varying environments for
the valves. One use of the controllable parameters is progressive adaptation, where
increasing amounts of mechanical stimuli are applied to aid strengthening of the tissue
construct and prevent immediate failure upon implantation.
There are currently numerous individual laboratories across the country using
heart valve bioreactors. Many reviews[8,104,106,109,110,119,120] contain extensive
comparison and assessment of the variations between them. The bioreactors range in
design, complexity, and function, performing at various levels and accuracy. Valve
mounting methods and modes of assembly vary, often with little options or ability to
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Figure 1-9: Schematic diagram of a model pulsatile flow bioreactor
Pulsatile flow loops for heart valve bioreactors all contain these minimum components. However, the form
and means of use they take may vary from system to system.[110]

accommodate abnormal valve shapes.[8] While many bioreactors are very powerful and
can achieve high pressurization, few are able to simultaneously subject valves to actual
physiological conditions of flow and pressure.[108,113,121] Those that can are very
cumbersome to set up and operate for the duration of an experiment, especially while
maintaining sterile conditions. Furthermore, independent control of those physiological
conditions is elusive.[122] Overall, much progress has been made in the area of heart
valve bioreactors. However, there is still room for improvement.
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CHAPTER 2: PROJECT RATIONALE
2.1 Introduction to Project
Most diseased heart valves cannot be repaired. Instead, they are replaced by
mechanical, bioprosthetic, or allograft heart valves. These treatments each have major
drawbacks and none are ideal for a growing child or young adult. The field of tissue
engineering & regenerative medicine holds great promise in developing replacement
heart valves that would function just as native, healthy valves: not requiring
antithrombotic or other pharmacological therapy, repairing themselves as microdamages are incurred, and growing in size along with a growing child. We hypothesized
that implantable tissue engineered heart valves can be generated by optimal integration
of three main factors: acellular heart valve root scaffolds, autologous stem cells, and
construct preconditioning in a bioreactor.
In our preliminary studies we have developed a heart valve bioreactor and tested
it with a variety of valves[117] under physiological pressures, but flow rates and shear
stresses were suboptimal. We have successfully decellularized cusps by simple immersion,
but not the aortic and sinus walls. We have experimented with interstitial and external
stem cell seeding followed by dynamic preconditioning, but the surface cells were not well
retained under flow. Planning for large animal studies has revealed multiple
translational challenges.
To address these shortcomings, we proposed to optimize the bioreactor
performance through engineering design improvements, to achieve full decellularization
of valve roots by novel, perfusion, pressure, and decellularization methods and devices,
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and to mechanically precondition stem cell seeded roots under optimal adaptation
conditions before implantation in large animals. Furthermore, we aimed to demonstrate
that translational regenerative medicine is feasible with autologous stem cells for tissue
engineering replacement therapy – a vital stage in the ability to remove barriers in
commercializing tissue engineered products.[68,123–125]

2.2 Specific Aims
2.2.1 Aim 1: Heart Valve Bioreactor Optimization
Goal
To modify the heart valve bioreactor system to achieve physiological levels of flow,
pressure, and shear stresses.
Approach
Alternative components (compliance chambers, reservoirs, restrictor valves, etc)
were developed to allow for physiological levels of flow at pulmonic pressure conditions.
Shear stresses were increased by adding dextran to the culture media. The controlling
hardware and software was upgraded to allow simultaneous and independent operation
of multiple bioreactors and accurate monitoring of the flow and pressure conditions.
Novelty & Innovation
Multiple heart valve bioreactors were simultaneously run under physiologic
conditions with independent controls.
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2.2.2 Aim 2: Aortic Heart Valve Root Scaffold Preparation
Goal
To decellularize all areas of the aortic valve roots (cusps, sinuses, ascending aorta,
and muscular tissue near cusps).
Approach
Cusps were subjected to immersion conditions. The sinuses and ascending aortas
were subjected to a transmural pressure gradient and cyclical mechanical stretching.
Muscular areas were subjected to a pressure gradient and large flow through their tissues.
This variety of techniques was simultaneously applied to the individual areas of the valve
using a custom-built decellularization device. Histology and DNA analysis was used
to evaluate the removal of cellular components. Mechanical tests were used to compare
the valve scaffold with native tissue.
Novelty & Innovation
A novel device was designed, manufactured, and used to apply individualized
conditions to multiple areas of the valve roots. We revealed, for the first time, fully
acellular aortic valve root scaffolds.
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2.2.3 Aim 3: Dynamic Conditioning of Cell-seeded Heart Valve Scaffolds
Hypothesis
Progressively pre-conditioning stem cell seeded acellular valve scaffolds in the
improved bioreactor will allow internally seeded cells to migrate within the cusps and
externally seeded cells to maintain confluent coverage.
Approach
Adipose-derived stem cells were manually injected directly and after preinflation into multiple areas of each cusp. Valves were rotated in a cell suspension for
external coverage. Valves were placed in the bioreactors and flow, pressure, and viscosity
conditions slowly increased until physiologic levels were reached. Recellularization, cellular
migration, and cell retention were evaluated using histological and surface microscopy
techniques.
Novelty & Innovation
A novel rotational device was used for external cell seeding of all valve surfaces.
For the first time, heart valves revitalized with cells adapted to physiologic conditions
were prepared for implantation.
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2.2.4 Aim 4: Translation to Pre-Clinical Large Animal Testing
Goal
To overcome hurdles encountered while translating tissue engineered heart
valves into clinically relevant products.
Approach
Acellular valve scaffolds were prepared, seeded with autologous adipose-derived
stem cells and pre-conditioned using the bioreactor. Valves were implanted in young
adult sheep in a right ventricle to pulmonary artery shunt position. A valve mounting system
was modified to allow for integrated exchanges between decellularization, sterilization,
cell seeding, and valve conditioning steps before implantation with minimal handling of
the valve itself. Methods of aims 2-3 were continuously adjusted as necessary and reverified to accommodate the clinical situation.
Novelty & Innovation
Stem cell seeded heart valves were implanted in an animal model. Products created
in labs were effectively translated from bench to bedside, demonstrating translational
feasibility with autologous stem cells.
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PART 2: PLATFORM TECHNOLOGIES AND DEVICES
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CHAPTER 3: A SELF-ADJUSTING, NO-TOUCH DEVICE FOR
INTEGRATED PROCESSING AND HANDLING OF
HEART VALVES
3.1 Introduction to Need
Advances in replacement heart valves available on the market have been relatively
stagnant since the introduction of bioprosthetic heart valves in the 1970s. Although
mechanical valves typically last a patient’s lifetime and bioprosthetic valves do very well
for a limited time in patients who cannot be on anticoagulants, there is still a need for a
tissue-engineered valve that can repair itself to last the lifetime of a young adult and grow
along with a growing child.
Whether for study or implantation, natural and synthetic heart valve tissue is
generally subjected to multiple treatment regimes. For instance, xenograft valve tissue
must be decellularized to remove the native cells prior to either testing or implantation
and it is common for some of the tissues to become thinner and drastically reduce in
strength during these processes. In addition, mechanical testing by use of a conditioning
system can be carried out to examine and alter tissue strength or to ensure suitable
strength prior to implant.
Some researchers believe the key to a lasting tissue-engineered heart valve
replacement lies not only in a mechanically durable scaffold that will function immediately
upon implantation, but also requires the presence of cells. While some researchers are
leaving recellularization until after implantation in large animals, others are revitalizing
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natural or synthetic scaffolds with various cell types in vitro. These cells must not be
removed through the normal handling of the valve tissue.
When these products reach the market or even clinical trials, they will also
undergo the scrutiny of physicians needing a product that will hold up to the conditions
required

for

implantation.

Whether

transcatheter deployment or open-heart
surgery is the route of implantation,
clinicians

often

desire

a

“no-touch”

product. These products are held by
external objects up-to and sometimes
during implantation.
It has been common to secure valve
tissue during the various treatment
regimens by temporarily suturing or
clipping the tissue to mounting rings
(Figure 3-1). Unfortunately, physically
attaching the tissue to the holding device
can

damage

the

tissue

and

cause

mechanical weakening or physical change
of the tissue. Moreover, securement
systems generally do not provide a method
Figure 3-1: Valve holder requiring intense suturing

for securing the tissue with a tight seal and Diagram (A) and picture (B) of an example valve

holder requiring many sutures in standard locations

fluid leakage around the tissue during the to hold a heart valve during testing.[113] (C) A second
example of a common valve tissue holder.[185]
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treatment protocols can prevent effective conditioning and/or testing. For instance
decellularization can lead to a loss of tissue volume, and presently known systems do not
account for the physical changes of the tissue associated with a volume loss. Thus, with
present systems, the tissue can become loose in/on the holder and/or leaks can form
between the tissue and the holder as decellularization takes place.
Regardless of the stage of the valve replacement technology, researchers and
clinicians are in need of a device that can effectively grip a heart valve root through the
entire process of valve preparation, testing, and implantation to prevent damage and
facilitate easier product development and use. We have developed a device that provides
for a totally no-touch procedure after initial mounting, secure retention during multiple
treatment regimens, and self-adjustment to accommodate natural changes in tissue
volumes. This device is of great benefit for natural or synthetic heart valve tissues alike.

3.2 Device Materials and Resulting Benefits
Initially, multiple valve bracing ring designs (Figure 3-2) were used for each of
various valve preparation devices. Although the initial bracing rings share common sizes
and some design features, they require constant user intervention when installing or
transferring valves between devices. Furthermore, the purpose of certain devices required
some bracing rings to have features that are incompatible with use in other devices. For
instance, during recellularization, it is necessary to allow flow across the rings outside of
the valve, but during bioreactor testing, this allows flow to bypass the lumen of the aortic
root, thereby nullifying the purpose of the bioreactor.
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Figure 3-2: Bracing rings for heart valves
Multiple sizes, styles, and holding techniques are used for the various bracing rings. (A) and (B) were
designed initially with various internal diamters and two external diameters for various bioreactors and
testers. (C) was designed explicitly for the seeding chambers. (D) was designed to be used in the selfadjusting device for aortic valves while (E) and (F) (courtesy of Chris deBorde) were designed for use in the
self-adjusting device with mitral valves.

3.2.1 Initial Bracing Rings
Figure 3-2A shows the initial bracing rings with offset ridges to clasp the tissue.
These are held in place by the initial bioreactor pieces with six bolts (Figure 3-3) and
require delicate maneuvering to install in place. These are used after tissue
decellularization and subsequent recellularization and require significant manipulation of
the tissue to function, thereby risking the sloughing of cells from the tissue surfaces.
Furthermore, the tissue is at risk of drying out during the valve mounting and assembly
of the bioreactor that follows. With the development of a larger bioreactor for potential
use with cow heart valves, larger bracing rings (Figure 3-2C) were created that allowed
for valves up to 60 mm in outer diameter to be tested, but these pose the same problems
as the smaller rings.
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3.2.2 Bracing Rings for Cell Seeding
When a device was developed to aid external cell seeding of heart valves[126] by
a master’s student in the lab (see section 5.2.3), additional bracing rings were designed.
These bracing rings contain holes around the outside of the center hole to allow a cell
suspension to flow around the external surfaces of the valve roots and through the valves
during

rotation

of

the

seeding chamber (Figure
3-2C). After cell seeding,
the

bracing

rings

are

replaced by new bracing
rings

not

additional

containing
holes

before

placing the valve into the
bioreactor as above. While
the transfer of the valve
from one set of rings to
another is easier because of Figure 3-3: Valve mounting procedure with initial bracing rings

Details of mounting procedures for stented valves, mechanical valves

the indentations made in and un-stented valves are shown. e) The basic valve holder, f) holder

with one o-ring placed in the machined groove (arrow), g) bottom

the tissue, it still requires mounting ring placed on top of the o-ring (arrow). h) A stented valve

was placed on top of the bottom mounting ring (arrow), i) a second

handling of the valve that mounting ring placed and o-ring over it and j) pushed slowly. k) Shows

a mechanical valve (arrow) after mounting between the two rings. l)
contributes to the removal Porcine aortic valve root ready for mounting in bioreactor; m-o) valve
mounted into a silicone root using 6-10 bottom sutures and 3-6 upper
sutures (arrows). p) The valve was placed on the holder prepared as
of cells from the external shown in (g); q) a second ring slid onto the root (arrow), r) a second oring added on top and s) the entire mount inserted into the aortic
tissue surfaces.
chamber (arrow).[117]
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3.2.3 Heart Valve Quick-Tester
Even with these slight improvements, the process of tightly clamping a heart
valve root between the bracing rings and mounting them in the bioreactor for testing is
complicated, difficult, and time-consuming. While it was necessary for work with sterile
valves, a faster and simpler method was desired for testing iterations of synthetic and
alternative valve designs under non-sterile conditions.
A novel tester was designed and built in cooperation with an undergraduate
student for quick assembly and testing to assess integrity and function of valves. As
shown in Figure 3-4, the primary components in the design are a ventricular chamber,
bracing rings, an aortic chamber, and a cap. The tester is made from clear acrylic, allowing
a clear view from all angles of the valve being tested. To manipulate the valve, the user
operates two bellows so that when the ventricular bellow is squeezed (collapsed), fluid
moves through the valve into the aortic chamber and the valve opens. The user then
squeezes the aortic bellow to shut
the valve and the fluid travels
through the external tubing to
return to the ventricular chamber.
The aortic chamber is attached to
the ventricular chamber via three
adjustable draw latches that can
quickly secure the two chambers Figure 3-4: Manual heart valve tester

This tester can be very quickly assembled and is used for quick
valve testing. Valves are placed between the bracing rings and
while allowing for adjustments in the metal latched hold all other components together with a
quick latch. The two rubber bellows are used to pump fluid
height for different valve designs. through the valve to evaluate opening and closing.
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Three screws are used to ensure the cap stays in the correct position and a seal is
maintained. The tester utilizes the same set of bracing rings as previously described,
which are placed between the two chambers and held in place by o-ring tension instead
of bolts. Thus, this heart valve quick-tester results in faster and fewer steps to assemble
than the bioreactor and thereby provides a faster alternative than previously possible
when evaluating new valve designs.
3.2.4 Self-Adjusting, No-Touch Valve-Mounting Device
While the quick-tester decreased the time and work necessary to test iterations of
non-sterile valves, there was still a need for a device that would clasp a valve for mounting
without damaging it, adjust to maintain a constant holding force on the valve tissue, and
allow for no-touch manipulation and transfer of the valve between devices. A valveholding device was designed (Figure 3-5) from the ground up that meets these desires.
While the bracing rings operate
under the same clamping principal
as the above bracing rings, their
clasping

mechanism

was

redesigned to improve hold during
assembly, eliminate slip during use,
and provide a better seal around
the tissue in all processes.
The rings for this quickmount (Figure 3-2D) can

Figure 3-5: Self-adjusting, no-touch valve mountng device
Photograph (A), isometric (B), and blow-out (C) views of the
be new device to quickly mount heart valves and provide notouch handling throught the preparation process.
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created in multiple sizes and shapes to hold various heart valve sizes and even types, such
as the mitral valve (Figure 3-2E&F). In the current configuration, an angled series of
ledges match together with a precise gap between the two bracing rings to clasp the final
thickness of the tissue that remains after decellularization. The series of ledges create a
clasping force that adequately seals around the tissue base. Grooves on the lower bracing
ring are engaged by co-radial bumps on the upper bracing ring. Those bumps help
prevent the tissue from slipping during processing as well as during mounting of the
valve in the mounting device. They puncture the surface of the tissue and prevent slippage
even when the lower bracing ring is not engaged, as seen in Figure 3-7G, which
demonstrates the stepwise assembly of an aortic valve into the mounting device.
After clasping of the tissue, the bracing rings are held in place between two
interacting threaded casing rings and a spring. The threaded casing rings can be adjusted
to apply the desired initial amount of force on the clamped tissue. The spring allows that
force to remain relatively constant during decellularization and the resulting dramatic
thinning of the clamped tissue. The threaded casing rings contain holes around the
outside of the center hole. The external ring of holes are used to engage with the
tightening tools during assembly. The tightening tools have teeth with the appropriate
heights to rotate the tissue and both bracing rings while not interfering with the
tightening of the casing rings. In addition to facilitating the tightening of the casing rings,
the holes can be aligned with one another. In this configuration, the holes allow a cell
suspension to flow around the external surfaces of the valve roots and through the valves
during rotation of the seeding chamber, just as with the bracing rings for cell seeding. If
the external flow is not desired, an o-ring can be placed under the lower external casing
Page | 44

ring to prevent passage of fluid from the internal hole to the external series of holes. This
is beneficial during decellularization to create a pressure differential between the inside
and outside of the aortic root and during conditioning to cause the culturing medium to
flow through the valve instead of around it.
3.2.5 Distal Aortic Root Constrictor and Stabilizer
When the pressure differential between the inside and outside of the aortic root is
desired, a plug with a controlled outflow (Figure 3-6A) can be inserted into the distal
portion of the aortic root and secured with cable ties. This outflow plug has a groove near
its base in which the tissue and cable ties are seated to prevent tissue slippage. The
outflow portion of the plug has a barbed fitting that is connected to tubing and can be
constricted as desired by using external clamps.
While culturing the aortic root in a bioreactor setting, this plug is replaced by a
two-piece stand (Figure 3-6B) to keep the valve root from collapsing under the
backpressure applied during the bioreactor functioning. The first part of the stand
consists of a ring with holes or grooves
that is placed around the exterior of the
aorta. It is attached to the most distal
portion of the aorta via suturing or an
internal retaining ring spring. The second

Figure 3-6: Distal aortic root constrictor and stand
part of the stand is the supporting ring The aortic flow constrictor (A) has a groove around
which the aorta and cable ties can be tightened to
with feet that surround the aortic root, yet hold the aorta in place for internal pressurization of
the aortic root. The support stand (B) attaches an
upper ring to the distal aortic root and uses a support
do not interfere with the coronary arteries. stand to prevent the root from collapsing inward
from the back pressure in the bioreactor.
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The ledge on the first part of the stand rests on the top of the second part and by turning
the first part “upside down,” it can accommodate longer or shorter aortic roots without
the need for a larger or an alternative piece.

3.3 Method of Device Assembly and Mounting of Fresh Valves
The method of mounting an aortic heart valve into the self-adjusting, no-touch
valve-mounting device is described below. While the description uses the most up to date
bracing rings, it should be noted that the small initial bracing rings, large initial bracing
rings, and cell seeding rings could all be used in their place. The upper casing ring
contains counterbore cutouts corresponding to each size. It should also be noted that in
certain designs, the upper and lower bracing rings may be combined with the upper and
lower casing rings.
3.3.1 Tissue Cleaning and Preparation
Fresh porcine aortic valve roots with ascending aorta up to the branching of the
brachiocephalic artery were collected from adult pigs at the local abattoir (Snow Creek
Meat Processing Center; Seneca, SC) and transported to the lab in ddH2O over ice. Aortic
roots were further dissected to include 6-8 cm of intact aorta, 5-10 mm long coronaries,
and about 3 cm of mitral valve leaflet and ventricular endocardium tissue with an intact
mitral-myocardial junction. The valve roots were cleaned of fat and other extraneous
tissues while maintaining a thin muscular shelf under the muscular cusp and a thin
muscular layer all around the valve 360° with a thickness matching that of the mitral
valve leaflet (about 1-3 mm). The coronaries were sutured shut and the valve roots were
rinsed with ddH2O.
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3.3.2 Valve Mounting
The process of assembling the valve-mounting device can be seen in Figure 3-7.
First, the tightening tool with short teeth is placed on the counter and the upper casing
ring, spring, and upper bracing ring are placed, upside down, onto the tightening tool.

Figure 3-7: Assembly and mounting of an aortic root in the quick-mount device
Components of valve mounting device including upper and lower casing rings, upper and lower bracing
rings, spring, distal root constrictor, and distal root stabilizer ring and stand (A). To assemble, support
“tower” (B) is placed on the counter and the upper casing ring (C) is placed on the support tower followed
by the spring and upper bracing ring (D). A fresh aortic root (E) is cleaned and the root is mounted inside
the support system (F), spread out and temporarily attached (G), and secured in place by the threaded
outside casing ring using a second tightening tower tool (H). The valve root is then adapted with a fitting
connector to the aorta (K).
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The height of the tightening tool allows the valve root to rest on the upper bracing ring
without touching the countertop below. A prepared valve root is then placed, upside down,
through the center hole of the upper bracing ring and the mitral valve leaflet and thinned
endocardium are spread around the surface of the upper bracing ring. The appropriate
vertical location is achieved by ensuring that the base of each cusp is about 2 mm beyond
the reach of the upper bracing ring. Any excess muscle or mitral valve that proceeds
radially to cover the external holes can be trimmed and the tissue pressed into the bumps
on the upper bracing ring, providing a temporary hold until the lower bracing ring is
placed onto the assembly. Following the lower bracing ring, the lower casing ring is
placed, the external holes are aligned, and a second tightening tool with long teeth is
placed onto the assembly, all while maintaining an exertion of force onto the assembly to
prevent slippage of the tissue. Following placement of all pieces, the tools can be picked
up or kept on the counter and used to twist the casing rings and engage the threading.
The threading should be tightened until the top of the upper casing ring is flush or below
the top of the lower casing ring. In cases where the tissue is extremely thick or alternative
bracing rings/devices are used, the upper casing ring can extend above the lower casing
ring, but should always have at least two full threads engaged. After this initial tightening,
the spring will provide a relatively constant force on the tissue during any subsequent
decellularization and processing.
3.3.3 Distal Aortic Root Stabilization
In preparation for decellularization, the distal ascending aorta is trimmed flat and
the outflow plug is inserted into the aorta and secured with cable ties. This plug has a
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groove near its base and when cable ties are secured around the external diameter of the
aorta, the tissue and cable ties are held in place within this groove (Figure 3-6A). This
plug is used to create a pressure differential between the interior and exterior of the valve
root during further processing.
When the valve is fully decellularized and any subsequently desired sterilization
and crosslinking is completed, the aorta can be cut just below the plug to remove any
unwanted tissue that was clamped. Alternatively, the plug can remain in place to allow
for more directed cell seeding to the interior of the heart valve during further processing.
Prior to bioreactor conditioning of the valve root, the two-piece aortic stand
(Figure 3-6B) is placed around the exterior of the aorta and secured to the tissue via
suturing or an internal retaining ring. This stand does not interfere with the valve and
will prevent the root from collapsing during the backpressure created from bioreactor
functioning.

3.4 Discussion of Integration into Valve Preparation Process
With the self-adjusting mounting device, a researcher can mount a fresh valve and
transfer the valve between processing stages all the way to implantation without
removing the valve from the mounting device or even touching the valve directly. One
benefit that is highly desired by clinicians is the “no-touch” aspect. In the operating room
and when dealing with living tissue, direct handling of the tissue can be damaging. By
using external tools and manipulating only the portions of the aortic root that are not
vital, inherent tissue integrity is not altered.
This device contains many pieces and performs multiple functions. However,
during any given stage of processing, it is possible to remove or disable the aspects that
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are either undesired or unneeded. At the same time, the valve is securely housed in one
piece of equipment that can be transferred between processing devices. Furthermore, the
features not currently in use do not interfere with the purpose or function of the
immediate device.
Use of this device has truly streamlined the development of tissue engineered
heart valves, especially in the context of transferring the valves between systems having
a distinct purpose and design. It is the key to fast transfers between systems and as well
as appropriate care of the living tissue. Although currently fabricated in stainless steel
and ABS-like material, it could easily be made of ceramics or other plastics to facilitate
magnetic imaging techniques, cost-effectiveness, or other desired properties to further
expand its uses in additional systems.
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CHAPTER 4: A

CYCLICAL

PERFUSION

DEVICE

FOR

DECELLULARIZING WHOLE AORTIC VALVE
ROOTS
4.1 Introduction to Need
Multiple methods of creating tissue engineered heart valves are foreseeable and
many are being thoroughly investigated and developed. Among the most researched and
advanced methods are those that utilize a decellularized xenographic aortic valve as a
scaffold.[20,68,81] Combining those easily accessible scaffolds with the patient’s own
stem cells before conditioning in a bioreactor and implanting would provide a
replacement that is fully functional from initial implantation while able to maintain matrix
homeostasis and reduce valve thrombogenicity for the lifetime of the patient.
While alternative ground up approaches have also been researched, a native
scaffold gives the best mechanical properties and structural functionality to withstand the
rigorous conditions of a replacement valve in the aortic position. Current progress of
xenographic valve preparation has been widely successful in decellularizing pulmonary
and aortic valve cusps.[82–87,117] Even attempts at decellularizing whole pulmonary
artery roots has been adequately demonstrated.[82] Our own investigations with
decellularizing aortic valve cusps has also been successful.[117]
However, if an entire aortic root is to be used as a tissue engineered heart valve
replacement, it is vital that the entire tissue be free of native cells to reduce or eliminate
chances of immune rejection and subsequent failure. The most severe example, wherein
all native porcine cells were not removed from implanted tissue, resulted in the death of
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three children due to severe inflammation, degeneration, and structural failure.[127] The
removal of all foreign cells from the cusps, sinuses, ascending aorta, and muscular regions
of an aortic root must be clearly demonstrated.
In some applications immersion decellularization techniques are frequently
replaced with perfusion techniques for tissues that are difficult to decellularize.[86,128]
When examining the properties of the aortic root tissues, it can be inferred that
procedures that are more rigorous will be necessary to decellularize those portions than
the procedures used to decellularize the cusps. However, the balance must be made to
retain the structural integrity of the cusps while providing conditions harsh enough to
decellularize the aortic wall. In this way, the entire aortic root would be prepared for
recellularization with patient cells without the fear of an immune response caused by
remnant xenogenic cells.
During perfusion decellularization, tissue is generally subjected to multiple
treatment regimens including various chemicals, detergents, enzymes, and pressure
profiles. What is needed in the art of
decellularizing whole aortic heart valve roots
is a system and method for decellularizing
tissue that can provide independent conditions
of immersion, pressure, and stretch to the
cusp, sinus, aorta, and muscular portions of the
aortic root. These areas are mapped visually in
Figure 4-1.

Figure 4-1: Mapping of tissues in the aortic root
Main anatomical coordinates of the aortic root
are displayed. Each component has different
physical characteristics and function.[105]
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4.2 Materials and Methods
Inadequate decellularization of entire aortic roots necessitated the creation of a
perfusion decellularization system for aortic valve roots. Decellularized tissue samples
from the cusp, sinus, aorta, and muscle were compared to fresh regions for DNA presence,
matrix stability, and mechanical properties.
4.2.1 Perfusion Device Components and Assembly
Cleaned and prepared aortic valve roots were mounted in custom mounting rings
as previously described (sections 3.3.1 and 3.3.2) and the distal portion stabilized with an
outflow plug as previously described (section 3.3.3). If less than five valve roots were
available for decellularization, acrylic cylinders having the outer dimensions of the lower
casing rings were used as space holders. Figure 4-2D shows the assembled perfusion
decellularization system. A brief overview of the process of assembly follows. All custom
components were manufactured from stainless steel, acrylic, or polycarbonate materials
by Clemson University Machining and Technical Services. Materials were chosen to
provide strength in thin areas or transparency for visualization of aortas and cusps.
Phase 1: Attaching Through-Wall Fittings
Custom through-wall fittings (Figure 4-2A) were designed and manufactured that
would protrude through the wall thickness while maintaining a seal, attaching to tubes,
and not slip from their placement. Depending on need fittings either act as plugs or have
barbed attachments on one or both ends. O-rings on either side of the fittings provide
stabilization and a seal across the wall. A shoulder on one side of the fittings prevents the
fitting from advancing through the wall in one direction while an external retaining ring
Page | 53

and groove prevents the fitting from reversing back through the wall. All fittings are
pushed from the interior areas of the device through the wall and the retaining ring is
attached on the portion of the fitting advancing on the outer portion of the wall. Fittings
are attached to the lids for inflow and outflow and to appropriate areas in each other layer
to provide the necessary circulation of fluid through the system

Figure 4-2: Perfusion decellularization system for heart valves
The flow diagram (C) illustrates the main system components comprising a valve (v), peristaltic pump, pulse
dampener (d), valves (c) and pressure transducers (p). The working setup is shown in (D). Direction of flow,
indicated by arrows is as follows: from the pump through the dampener (D) enters the bottom of the system
and pushes fluid through the valves. Fluid then collects via a manifold (white arrows) into a single line which
feeds the system again and bathes the valves from the outside.
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Phase 2: Valve Clamping
The next step of device assembly is to clamp the self-adjusting, no-touch valve
holders in place between the three layers of the device that create a common solution
chamber (between layers 1 and 2) and do the holding of the valves in the holders (between
layers 2 and 3). The valves are placed in the circular grooves of plate 3 before plate 2 is
lowered around them and plate 1 above that. The three layers are bolted together to
create a seal that forces fluid from the solution chamber into the inflow side of the valve
lumens.
Phase 3: Chamber Assembly
After the valve holders are clamped between the three plates, the next layer is
placed onto the root side of the plate assembly to create the main chamber. The outflow
plugs of each valve root are connected to the through-wall fittings of the main chamber
and the final layer, the outflow lid, is placed on top of the main chamber. Layers, 3, 4, and
5 are then bolted together to create a sealed chamber around the valves.
Phase 4: Flow Loop Assembly
A five-port luer manifold with on/off valves is used to direct flow between the
interior of the valves and the main chamber, where the solution bathes the tissues before
exiting the system. This manifold and main chamber contain pressure transducers and a
constriction valve between them to measure and control the pressure differential between
the interior and exterior of the aortic roots. 500 mL bottles with glass-blown barbed
attachments are used as reservoirs and pulse dampeners between the system and a
peristaltic pump to create pressures and flow through the system.
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Phase 5: Device Filling, Description of Flow, and Emptying
Four liters of solution are used to fill the system. The pressures during filling
should never exceed the running pressures of the desired protocol (described below) and
after filling, any air bubbles are removed component by component in the direction of
fluid travel. Once full, the system can be subjected to the desired protocol. Pressures are
monitored with the transducers and a custom LabView program (Figure 4-3) the proper
flow protocol is set in the menu of the peristaltic pump. Pressure and flow are controlled
by adjusting the speed of the peristaltic pump and the constricting valve coming from the
outflow of the manifold.
4.2.2 Decellularization by Immersion
Aortic roots were cleaned and
prepared as previously described (section
3.3.1), then decellularized in containers on
an orbital shaker (immersion technique) at
a ratio of 500 mL solution for 5 aortic
roots. Decellularization steps consisted of
hypotonic shock (ddH2O, 24 h, 4°C),
loosening of extracellular matrix and
initialization of cell removal (0.1 M NaOH,
2 h, 22°C), decellularization solution (1% Figure 4-3: Monitoring of decellularization system

(A) The main decellularization system is comprised of
Sodium Dodecyl Sulfate, 1% Triton X-100, 5 layers which help direct flow through, then around
the aortic roots. (B) The LabView software reads
direct pressure inside and outside of the aortic roots,
1% Na-Deoxycholate, and 0.2% EDTA conditions it to achieve steady values, then gives a
direct output of the differential of pressure.
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acid in 50 mM TRIS, pH 7.5, 8 days with fresh solution every 2 days, 22°C), and removal
of nucleic acid remnants (720 mU/mL deoxyribonuclease & 720 mU/mL ribonuclease in
5mM Magnesium Chloride in 1xDPBS, 24 hours, 37°C). To reduce bio-burden, each
extraction step was preceded by a 15-minute 70% ethanol treatment and appropriate
rinsing. The roots were incubated in 70% ethanol (24 hours, 22°C) and sterilized[129] in
0.1% peracetic acid (2 hours, 22°C).
4.2.3 Decellularization by Perfusion
Aortic roots were assembled into the perfusion system as described above for
decellularization. Perfusion decellularization steps were performed with a cyclic
transmural pressure gradient of about 52±2 mmHg and mechanical stretching for 3
minutes on and 30 seconds off. Cyclical pressure steps were followed by rinsing with
water, ethanol, or 1xDPBS as appropriate and consisted of hypotonic shock (ddH2O, 24
hours, 22°C), loosening of the extracellular matrix and initialization of cell removal (0.1M
NaOH, 2 hours, 22°C), detergent decellularization (1% sodium dodecyl sulfate, 1% Triton
X-100, 1% sodium deoxycholate, and 0.2% EDTA in 50mM TRIS, pH 7.5, 16 days with
fresh solution every 4 days, 22°C), enzymatic removal of nucleic acids (720 mU/mL
deoxyribonuclease & 720 mU/mL ribonuclease in 5mM Magnesium Chloride in 1xDPBS,
4 days with fresh solution every 2 days, 37°C), and initial sterilization (0.1% peracetic
acid, 1 hour, 22°C). Immediately following, the distal root outflow constrictors were
removed with sterile tools and the mounted valve roots were transferred to individual
300 mL wide mouth glass containers with silicone membrane sealing lids on an orbital
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shaker instead of the perfusion system for final sterilization (0.1% peracetic acid, 1 hour,
22°C).
Additionally, one group of aortic roots underwent the above protocol, but for 8
days instead of 16 days in the detergent decellularization step. Another group underwent
16 days of detergent decellularization, but was stopped immediately prior to enzymatic
removal of nucleic acids.
4.2.4 PGG Crosslinking Treatment
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl glucose,
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
(www.omnichem.be). Acellular valve scaffolds were rinsed in sterile PBS and then treated
with sterile 0.15% PGG in 50 mM dibasic sodium phosphate buffer in saline containing
20% isopropanol, pH 5.5. Treatment occurred at 22°C on an orbital shaker for 21±1 hours.
At the onset of fixation, cusps were lightly stuffed with sterile cotton balls pre-soaked in
PGG solution to preserve the valve conformation in ‘‘closed’’ position. After treatment,
the cotton balls were removed and the scaffolds were rinsed then stored in sterile 1xDPBS
solution at 4°C.
4.2.5 RapidGlut Crosslinking Treatment
Valves were treated with 0.7% Glutaraldehyde (Polysciences, Inc) at 22°C on an
orbital shaker for 15 minutes. Valves were rinsed with sterile 1xDPBS for 15 minutes
then incubated in two rounds of 1% Glycine (Fisher Scientific) solution for 15 minutes
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each. After overnight rinsing in 1xDPBS, valve scaffolds were stored in sterile 1xDPBS
solution at 4°C.
4.2.6 DNA Analysis
DNA was extracted from aorta, sinus, cusp and muscle tissue samples (n=4) and
purified with the DNeasy Blood & Tissue Kit (Qiagen), then analyzed by Ethidium
Bromide agarose gel electrophoresis. Samples were also quantified by reading absorbance
at 260nm on a NanoDrop 2000c (Thermo Scientific). Quantities of DNA were normalized
to dry tissue weight and expressed as ng/mg dry tissue.
4.2.7 Histology and Immunohistochemistry
For histology studies, samples collected from the aortic wall, sinus, cusp and
muscle were fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm (3 µm for the
aorta), and stained with DAPI for nuclei, Hematoxylin & Eosin (H&E), and Movat’s
Pentachrome.
Immunohistochemistry (IHC) was performed to detect remaining components
after decellularization. Biotinylated Griffonia simplicifolia (GS) lectin was used to detect
Gala1–3Gal (a-Gal), the main porcine antigen responsible for acute rejection of
xenotransplants. IHC for laminin, and type IV collagen was also performed. Tissue
samples were rinsed with 1X PBS fixed at room temperature in 4% formaldehyde (BDH
Chemicals). Following rinsing samples were blocked using 5% Bovine Serum Albumin
(Rockland Immunochemicals, Gilbertsville, PA) with 0.05% Triton (BDH Chemicals) in
1X PBS for 2 hours at room temperature. The blocking solution was removed and 250
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μL primary CD-31/PECAM1 Antibody (VM64) (NBP1-42152; Novus Biologicals,
Littleton, CO) in blocking solution (1:2 dilution) was added for 1.5 hours at room
temperature. The primary antibody was removed before rinsing 4 times with 1X PBS.
The secondary antibody, Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand
Island, NY) diluted in blocking solution (1:2 dilution) was added for 1 hour at room
temperature in the dark followed by 4 rinses with 1X PBS. Finally, 500 μL DAPI stain

(Sigma-Aldrich) was added to each slide for 5 minutes at room temperature in the dark
before fluorescent imaging. Primary antibody was omitted for staining negative controls.
4.2.8 Biaxial Mechanical Testing
Samples were prepared from native (fresh) aortic valve leaflets and the PGG
treated decellularized aortic valve leaflets (N = 6 for each group) using the methodology
previously reported.[87,103] Square-shaped samples (~ 12 mm × 12 mm) were dissected
from the belly region of the aortic valve leaflet, with one edge aligned with the leaflet
circumferential direction and the other edge aligned with the leaflet radial direction.
Thickness of each sample was measured in triplicate using digital calipers. Four dark
markers were placed in the center region of the square sample (pasted on the ventricularis
side of the leaflet). Samples were mounted onto the biaxial testing system via stainless
steel hooks attached to 8 loops of 000 polyester suture of equal length (2 suture loops per
sample edge). Membrane tensions (force/unit length) were applied to the circumferential
direction and radial direction of the leaflet sample. A pre-load of 0.5 N/m was used during
the biaxial mechanical testing. After 10 cycle preconditioning, the leaflet sample was
loaded to an equbiaxial tension of 60 N/m. The leaflet extensibility was characterized by
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the maximum stretch ratio along the circumferential direction (λcirc) and the maximum
stretch ratio along the radial direction (λrad). Biaxial testing was carried out with the
samples submerged in in PBS bath (pH 7.4) at 37˚C.
4.2.9 Bending Mechanical Testing
Bending tests were performed by following a previously reported protocol.[87]
The bending tests were carried out in a bath chamber with PBS. Aortic valve samples,
both native and PGG treated decellularized valve groups, were dissected out of the belly
region of the valve leaflet (N = 5 each group). These samples were further trimmed to
tissue strips (~8 mm long by ~4 mm wide) in both the circumferential and radial
directions. Two hollow posts (~4mm) were attached to each end of the tissue strip for
mounting purpose. One end of the tissue strips were attached to a post that was fixed on
the inside wall of the bath chamber and the other end was mounted onto the bending bar.
Each strip was mounted and subjected to simple bending testing with the ventricularis
side up and the fibrosa side down. Five dark contrast markers used for tracking the leaflet
strip curvature, i.e., marker 1 was pasted on the fixed post, marker 2 to 4 pasted along the
edge of the tissue strip, and marker 5 pasted on the end of the bending bar (Figure 4-8D).
The bending movement was tracked using a Firewire camera (DMK21AF04 model, The
Imaging Source).
Due to the previously reported variation in material stiffness between the native
and PGG treated samples,[130] two different sizes of Titanium bending bars (grade 23,
Small Parts Inc.), one with a diameter of 0.38 mm and the other with a diameter of 0.71
mm, were used for testing the native leaflets and the PGG treated leaflets, respectively.
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Both bending bars a length of 14 cm. The bending movement in the tissue strip was
produced by moving the bath chamber toward the bending bar by a linear positioner
controlled by a Velmex stepper motor (Velmex Inc., Bloomfield, NY). The corresponding
change in bending bar deflection was recorded by tracking marker pasted on the end of
the bending bar, and the force was calculated by reference to the bending bar calibration
curve. Both the Velmex motor and Firewire camera were controlled by a custom written
Labview program (version 2000, National Instruments).
In addition to circumferential and radial directions, each leaflet strip was tested
by flexing the strip with the natural curvature (WC) and against the natural curvature
(AC). The WC tests result in the ventricularis layer being in tension and the fibrosa layer
being in compression, while the AC tests result in the ventricularis layer being in
compression and the fibrosa layer being in tension.
4.2.10 Statistical Analysis
Results are represented as means ± standard deviation. Statistical analysis was
performed with one way analysis of variances (ANOVA) and results were considered
significantly different at p<0.05.

4.3 Results
4.3.1 Cyclical Perfusion Decellularization Device
The novel device for decellularizing a whole aortic root can fully decellularize up
to five aortic roots by circulating 4 liters of solutions through the system under a cyclical
pressure regime that creates a transmural pressure gradient of about 52 mmHg. Utilizing
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a peristaltic pump to create flow, the system (Figure 4-2D) incorporates a pulse dampener,
reservoir, constrictor valve to build pressure, and a series of plates and chambers to
appropriately direct flow through and around an aortic root. A simplified cross section of
the fluid flow path is shown in Figure 4-2C. Fluid flows from the pump and through the
dampener into the lower level of the chambers. It is directed into each of the valves
mounted in the system where it can build pressure due to the downstream constriction
created by the manifold and outflow constricting valve. From the manifold, it circulates
back into the system to bathe the outside of the tissue in solution at a low pressure. From
there, the fluid freely flows out of the chamber and into a reservoir for recirculation.
Pressure is measured in lines communicating with the outside as well as the inside of the
aortic roots by transducers controlled by custom LabView software, which displays inner,
outer, and differential pressures (Figure 4-3B).
4.3.2 DNA and Cellular Content
Figure 4-1 and Figure 4-5 show a mapping of each portion of tissue in the aortic
root. While it is clear that the aorta, muscle, and cusp are different tissues, it should also
be noted that the sinus is a different tissue than the aorta, with a different structure and
function.
H&E and DAPI analysis for the 8-day immersion-decellularized valves revealed
complete cellular removal from valve cusps (Figure 4-4A&B), which was confirmed with
Nanodrop data (not shown). However, the sinus, aorta, and muscle were not completely
decellularized using this immersion technique (Figure 4-4D).
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While

8

days

of

perfusion

treatment was sufficient to remove cells
from the muscle and sinus as well as the
cusp (Figure 4-5), a longer time was
needed to decellularize the full thickness of
the aorta. In unsuccessful attempts, cells
remained in the central layers of the aorta,
but were removed near the media and
adventitia. Agarose gel imaging (Figure
4-5A), Nanodrop (Figure 4-5B), H&E Figure 4-4: Immersion decellularization is

incomplete for all valve root areas
(Figure 4-7), and DAPI (Figure 4-5) show Fresh (left) and immersion decellularized (right) H&E
staining of the cusp (A&B) and H&E and DAPI staining
of the aorta (C&D) with elastin autofluorescence.

that 16 days of decellularization treatment

was adequate to remove sufficient amounts of DNA from all aortic root areas. Notably,
the use of DNase and RNase enzymes were vitally necessary to remove cellular content
from the aorta after 16 days as well as from the sinus at the 8 day time point as seen in
the agarose gel images (Figure 4-6). Nanodrop analysis (Figure 4-6) confirmed the drastic
reduction in DNA content after the full 16 day perfusion decellularization protocol.
4.3.3 Extracellular Matrix Components
Examination of the H&E and Movat’s Pentachrome staining, as in Figure 4-7,
revealed an intact matrix primarily comprised of collagen and elastin. As expected,
glycosaminoglycans were not seen after any decellularization steps.
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Figure 4-5: Decellularization results of immersion and perfusion methods
(A) Representative histology images of fresh aortic root sections stained for nuclei with DAPI (blue) before
(Fresh) and after immersion decellularization (Decell). Arrow points to DAPI stained cell remnants after
immersion decellularization. (B) Representative DAPI stained sections of aortic valve root areas after 8 and
16 days of perfusion decellularization. Arrow points to DAPI stained cell remnants. (C) Macroscopic images
showing a fresh intact aortic root (1) and a root cut open with one cusp removed to reveal the main
anatomical coordinates (2). A fully decellularized aortic root is shown in top view (3) and cut open (4).
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4.3.4 Cusp Mechanical Testing
Biaxial
The biaxial data obtained (Figure 4-8A) for both groups (native leaflets and PGGtreated leaflets) showed that the PGG-treated leaflets preserved the anisotropy of aortic
valve leaflet tissue, i.e., a
stiffer

circumferential

direction

and

more

extensible radial direction.
Moreover,

the

PGG-treatment
generated
with

current
protocol

leaflet

extensibility

tissue
very

close to the native leaflets.
We found that λcirc and λrad of
the native leaflets were
1.0193 ± 0.0108 and 1.2110
± 0.0504, respectively; and
λcirc and λrad of the PGGtreated leaflets were 1.0245 Figure 4-6: DNA analysis by agarose gel electrophoresis and
± 0.01507 and 1.2191 ±
0.0509,

respectively.

However, we noticed that
the tension-stretch curve of

nanodrop UV spectrophotometery
(A) Ethidium bromide agarose gel electrophoresis of genomic DNA
extracted from fresh aortic root tissues (F) and tissues collected after 8
days (D8) and 16 days (D16) of perfusion decellularization. Samples
were also collected before the nuclease treatment step from the 16
days groups (D16 -). S = DNA standards consisting of whole genomic
DNA (*) and DNA ladder (#). (B) Nanodrop UV analysis of DNA extracted
from fresh aortic root tissues and tissues collected after 16 days of
perfusion decellularization (Decell).
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the PGG-treated leaflets showed a much stiffer toe region in the radial direction when
compared with the native leaflets.
Bending
The native aortic valve leaflets followed a similar trend as we observed in our
previous study.[87] The moment-curvature curves (Figure 4-8B) showed that AC
bending was stiffer than the WC bending, and the circumferential direction bending is
stiffer than radial direction. After PGG treatment, the aortic valve leaflets showed a large
increase in overall bending stiffness. In PGG-treated leaflets, we still observed that AC
bending is stiffer than WC bending, and circumferential is stiffer than radial. Moreover,
the degree of nonlinearity increases after PGG treatment, exhibiting a very stiff response
when the bending curvature is small, but the increasing trend of the moment-curvature
curve greatly slowed down after the bending curvature passed ~0.04 mm-1.

4.4 Discussion
4.4.1 Perfusion Decellularization Device
Although widely used because of its simplicity to operate, immersion
decellularization techniques are inadequate for decellularizing whole aortic roots. We see
their successful utilization for tissues that are thin or relatively more porous than the
aorta, which contains hundreds of layers of elastin that are difficult for solutions to
penetrate. When considering the function of the aorta, to contain the pressurized blood
within, it becomes apparent that simple immersion will not be adequate for solutions to
reach all layers of this remarkable structure. Even the pulmonary artery is thinner and
more porous than the aorta, resulting it its relative ease to decellularize.
Page | 67

Figure 4-7: Histology of decellularized root tissues
Representative images of H&E stained (A) and Movat’s pentachrome stained (B) sections showing fresh
aortic root tissues before (Fresh) and after 8 and 16 days of perfusion decellularization. Arrows point to
stained cell remnants. H&E stain shows nuclei in blue and cytoplasm and matrix in pink. Movat’s
pentachrome stain reveals collagen (yellow), elastin (dark brown) and muscle cells (red).
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A device and method of use was created for decellularizing the thick portions of
the aortic root as well as the more fragile cusp portions. The cusps were subjected only
to immersion conditions, the aorta and sinus were subjected to a cyclical transmural
pressure gradient and resultant stretch, and the muscular regions were subjected to a
transmural pressure gradient and increased perfusion. This combination of isolated
conditions resulted in an aortic root that was overall, decellularized, yet maintained
structural integrity in the most fragile and vital areas.
4.4.2 Decellularized Aortic Root
Upon initial evaluation of an immersion-decellularized aortic root, it was quickly
apparent that the aorta regions of the root were not fully decellularized using our
detergent and immersion method of decellularizing valve cusps. Further examination of
the literature revealed a lack of evidence supporting full decellularization of the aortic
roots. If an entire aortic root is to be used as a tissue engineered heart valve replacement,
it is vital that the entire tissue be free of native cells to reduce or eliminate chances of
immune rejection and subsequent failure.[127] The removal of all foreign cells from the
cusps, sinuses, ascending aorta, and even muscular regions of an aortic root must be
clearly and satisfactorily demonstrated and the aforementioned reports of decellularized
aortic roots are inadequate in their descriptions.
Our own experience indicates that cell removal must be evaluated by a variety of
methods rather than one sole method of analysis. It can sometimes be difficult to classify
an object as a cell or not in histological images. NanoDrop analysis is not as accurate at
near-zero levels of dna, as evidenced by numerous negative readings, despite routine and
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normal reads of our blanking solution. Perhaps the most identifying single analysis is the
agarose gel. However, even that analysis is subject to human interpretation. Our
demonstration of the necessity to utilize a perfusion system for decellularizing aortic
roots reveals that many previously published methods should verify the cellular content
of all areas of tissue to be used for implantation. Furthermore, the innermost portions of
the aortic tissues should be verified to be free of cells and shown in publications. For the
reasons stated above, multiple methods of analysis should be shown to demonstrate
complete removal of cellular content.
4.4.3 Mechanical Analysis
The current protocol includes the step of leaflet decellularization followed by
PGG treatment. It is well known that for most decellularization protocols, the aortic
valve leaflets experience an increase in overall tissue extensibility due to the
microstructural disruptions (e.g., disruption of collagen network and elastin fibers).[87]
On the other hand, PGG treatment generates crosslinking at molecular level, which has
a stiffening effects on collagenous tissues.[78,103,131] The treatment of PGG on the
decellularized leaflets causes tissue crosslinking and stiffening, and hence the extensibility
of the decellularized leaflets could be reduced accordingly. Interestingly, we found that
the current protocol generated PGG-treated leaflets with an overall tissue extensibility
comparable to the native leaflets. However, as we pointed out, the biaxial behavior of the
PGG treated leaflets was not exactly the same as the native leaflets. The tension-stretch
curves showed that the toe region of the radial direction is much stiffer than that of the
native leaflets. The loss of a relatively flat toe region after PGG-treatment demonstrated
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that the PGG-treated leaflet picked up mechanical load much quicker in the deformation
initiation region.
We found that the PGG treated aortic valve leaflets had a much stiffer bending
moment-curvature relationship than the native aortic leaflets. This reflected the fact that
the crosslinking took place at the molecular level after PGG treatment. Tissue bending
stiffness seemed to be more sensitive to this molecular level crosslinking, and the order
of change we observed is very high (Figure 4-8). Interestingly, the subtle variations of
leaflet flexure, in terms of AC vs. WC bending and circumferential vs. radial bending,
were all preserved after PGG treatment. This observation implied that the PGG
treatment still preserved the ultrastructural level subtlety while in overall increasing the
tissue bending stiffness. The increase of the degree of nonlinearity after PGG treatment
is another interesting finding. As we notice, the stiffening effect was more in the range of
small bending curvature, and this observation echoed with the biaxial testing, which
showed the toe region of the radial direction curve turned into much stiffer after PGG
treatment. All the biomechanical observations seemly hinted that the mechanical effect of
PGG treatment on tissue behavior was more noticeable in the deformation initiation
range.
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Figure 4-8: Mechanical properties of decellularized cusps
(A) Biaxial stress-strain analysis of fresh cusps and cusps which underwent decellularization and PGG
stabilization, tested in both circumferential and radial directions. (B) Bending test results for fresh and PGGtreated decellularized cusps tested with curvature and against curvature.
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CHAPTER 5: TECHNIQUES AND DEVICES FOR CELL SEEDING
OF HEART VALVES
5.1 Introduction to Need
Cell seeding plays an integral role in the production of a tissue-engineered implant.
Regardless of the target tissue, the idea of adding cells to a scaffold is a fundamental part
of tissue engineering. Literature demonstrated numerous methods of adding cells to a
scaffold, but no method has been deemed to work far better than any other does.
Optimization of this process is considered to be an important aspect in the paradigm of
tissue engineering.[65] Overall, seeding techniques can be categorized into three areas:
static, dynamic, and perfusion.[65,132]
Static seeding methods (Figure 5-1A) usually involve manually pipetting a cellular
suspension directly on the scaffold and re-pipetting the solution back onto the scaffold as
necessary. After a specified amount of time of pipetting, the scaffolds are kept static to
allow for strong attachment of cells. This is by far the simplest and most widely used
method of seeding, but complex geometries of scaffolds often make uniform and
repeatable results impossible.[133] Additionally, this method often results in low seeding
efficiencies.
Dynamic seeding methods (Figure 5-1B) utilize fluid motion to maintain cells in
a state of constant suspension around a tissue so they can contact many portions of the
tissue evenly as they move. An example of this type of seeding is a commonly used spinner
flask whereby the scaffold is placed inside the flask and the stir bar agitates the liquid to
maintain cellular suspension. Although this constant mixing will provide cell contact to
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many areas of the tissue, it can also cause the cells to detach and even cause cell death if
shear forces are too high.[132,134] Another approach to dynamic seeding involves
creating

random

fluid

motions

by

randomly rotating a sealed container with
the scaffold housed within.[65,135,136]
This random cell movement increases the
probability of cells attaching to multiple
surfaces, but can sometimes require a more
difficult method of mounting the scaffold.
However, these methods can combine
gravitational force to cause cells to fall and
attach to specific portions of tissue when
rotations are paused for a limited amount
of time.
Perfusion seeding methods (Figure
5-1C)

rely

on

hydrostatic

pressure,

magnetism, or electrostatic forces to move
cells onto or into scaffolds.[132,137–139]
Hydrostatic pressure utilizes a pressure
Figure 5-1: General methods of cell seeding

gradient to force seeding solutions into a Static (A), dynamic (B), and perfusion (C) methods of
seeding cells on a scaffold.Static methods rely on re-

scaffold by increasing internal pressures or pipeting the cell suspension over the tissue. Dynamic

methods use fluid movement to keep cells in

pulling an external vacuum. Magnetic suspension so they can contact and attach to many
areas of the tissue. Perfusion methods use forces to

nanoparticles bound to cell surfaces can drive cells deep into the tissue rather than relying on
cellular migration alone.[65]
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allow the cells to be manipulated through precise use of magnets to direct cells onto
specific surfaces of a scaffold. Electrostatic force methods involve inducing a positive
surface charge on a scaffold to attract the negatively charged cells onto the scaffold. These
methods are usually utilized in flat or tubular structures and could be difficult to apply to
the complex geometry of a heart valve root. Additionally, they often involve complex
equipment that makes maintaining sterility difficult.
The methods developed here serve to combine the advantages of multiple methods
of seeding to achieve optimal results for heart valve and aortic root scaffolds. They utilize
other devices created in the lab that eliminate some of the difficulties previously
mentioned. They also seek to take into consideration the complex geometry of the
scaffolds and do not rely on cellular migration, which has been shown to be extremely
slow and not far enough into the tissue in our previous work.

5.2 Materials & Methods
Cell seeding methods were developed in close collaboration with other students
and improved or modified as needed. Notably, internal cellular seeding protocols were
initially developed by Jordan Maivelett and improved in collaboration with Allison
Kennamer.[140] External seeding devices and protocols were developed by Richard
Pascal[126] and underwent design improvements described herein.
5.2.1 Valve Scaffold Preparation
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described
in section 3.3.1. Aortic roots were decellularized by either the immersion (section 4.2.2)
then mounted in the valve mounting rings as in section 3.3.1 or decellularized by 16-day
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perfusion (section 4.2.3) techniques. Following decellularization, roots were crosslinked
with PGG as in section 4.2.4 and neutralized for 18-24 hours in DMEM with 50% FBS
and 1% Antibiotics/Antimycotics at 37°C.
5.2.2 Stem Cell Culturing
Human adipose-derived stem cells (hADSC; Invitrogen, Eugene, Oregon) were
cultured on cell-culture flasks at initial densities of 5000 cells per cm2. Cell culturing
media consisted of Complete MesenPRO RSTM Medium (Invitrogen, Eugene, Oregon)
with 1% Antibiotic/Antimycotic (Mediatech, Manassas, VA), and 0.36 g/L of LGlutamine (Fisher Scientific). Passaging occurred at 75-85% confluence and, unless
otherwise noted, hADSCs were not used beyond passage 6.
5.2.3 Rotational Seeding Device Design, Components, and Assembly
A LabView-controlled dynamic seeding device (Figure 5-2) was developed using
SolidWorks software and engineering design techniques and manufactured out of acrylic
and aluminum. The device was designed around the aortic root characteristics and with
the intention of easily integrating into the overall valve preparation process. A
combination of static and rotational seeding methods were deemed the best fit for this
tissue and integration into the valve preparation process.
Initial methods of holding the aortic root involved previously used bracing rings
described in section 3.2.2. These bracing rings contain holes around the outside of the
center hole to allow a cell suspension to flow around the external surfaces of the valve
roots and through the valves during rotation of the seeding chamber. Further
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Figure 5-2: External seeding device
Six chambers (B) can be held in the frame connected to the shaker plate (A) for cell seeding with agitation
and pause cycles. The valve quick mount fits inside the chamber and allows flow to pass around the valve
(C). The chambers are assembled and set into the chamber holder plates according to specific protocols
that maintain consistency and ability to track valves (D). During rotation, cells are resuspended and during
pausing at each angle, cells are allowed to fall to a valve surface and attach (E). During chamber assembly
and placement into the chamber holder plates, the thumbscrews, degree marks, and ports must be
alighned with specific characteristics in relation to each other and the set line or axial chamber holder plate.

developments led to the improved method of mounting the aortic roots described in
section 3.2.4. Utilizing these self-adjusting, no-touch valve mounting devices allowed an
easier transition between devices and improved the retention of structural integrity of the
tissue since no further handling was necessary. The improved valve mounting devices
contain the same holes to allow fluid movement around the valve and fit well into the rest
of the seeding device (Figure 5-2C) and methods.
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The chambers (Figure 5-2B&C) to hold the valves were designed to use as little
seeding solution as possible and reduce violent flow patterns that could cause cell removal
from the scaffold or cell death. Rounded edges that fit closely to the outline of the aortic
root were designed with dimensions that would cause the fluid to flow smoothly through
the slits in the mounting device as well as the valve itself. The lid of the chamber contains
two ports (Figure 5-2D) to allow pressure equalization and media or gas exchange as
necessary. During end-over-end rotation, needleless ports can be added to the luer ports,
but during axial rotation, luer plugs must be used for three chambers to fit into one
chamber holder plate. It utilizes an o-ring seal to maintain sterility and slides into the
outer chamber, thereby clamping the mounting device and holding it in place. The
pressure of the o-ring seal provides temporary closure until the seeding chamber is
mounted to the chamber holders described below. The chamber and lid was manufactured
from acrylic material to allow visualization of flow and sterilization via ethylene oxidegas treatment.
After or during attachment of the lids, each set of three lids should be lined up in
relation to the chamber body so that each degree mark (0, 120, and 240) is each 1) aligned
with both luer ports and 2) between two bolts. For example, on the first chamber, the 0°
mark should be in line with both luer ports and also between two bolts; on the second
chamber, the 120° mark should be in line with both luer ports and also between two bolts;
and on the third chamber, the 240° mark should be in line with both luer ports and also
between two bolts. This can be achieved by rotating the lid in relation to the chamber
body and will be important when using the axially rotating chamber holder plate.
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Up to three seeding chambers are mounted into aluminum chamber-holder plates
by hand-tightened bolts between the lid and threaded portions of the chamber holder.
These holders are mounted onto a frame containing a stepper-motor controlled by custom
LabView software that provides rotation of the holders. The upgraded frame can hold
two chamber-holder plates, resulting in the processing of up to six heart valves at one
time. The frame can be mounted onto an orbital shaker that provides and additional
direction of motion to help maintain suspension of the cells and create random fluid
movement within the chamber (Figure 5-2A). The entire assembly of chambers, holders,
frames, motors, and orbital shaker can fit into a standard cell culture incubator or heating
oven to provide physiological temperature during seeding.
Two versions of chamber holder plates were designed that can be exchanged with
by loosening set screws on either end of the plates. One chamber holder holds the seeding
chambers so they rotate in an end-over-end fashion around the point directly in the center
of each heart valve (Figure 5-2 – upper plate) while the second chamber holder holds the
seeding chambers so they rotate around their natural axis (Figure 5-2A – lower plate).
The end-over-end rotation and pauses at specific orientations will ensure that cells flow
through the valve scaffold and contact multiple areas of the valve when they fall due to
gravitational forces during the static phases. The axially rotating chamber holder will
ensure cell contact with all interior surfaces of the valve root and may provide additional
coverage over the alternative chamber holder.
Several marking systems (Figure 5-2D) were used to ensure uniform conditions
between valve root samples and track areas already seeded with cells when performing
multiple seeding steps. Each seeding chamber and lid set was labeled with a unique
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number from 1 to 6 to identify and track each valve. The seeding chambers were also
marked between each bolt with the degree marks of 0, 120, and 240. With three bolts,
three degree marks, and by ensuring the non-coronary sinus was aligned with the 0° mark,
we could ensure all three cusps and sinuses were treated equally as long as we performed
three repetitions with 1/3 rotation between each repetition. A simple dash mark was made
on the end-over-end rotating chamber holder that would align with one of the three
degree markings on the seeding chamber. When using the axially rotating chamber
holder, the degree markings would be referenced to the location between the two bolts
that hold the chamber to the chamber holder.
The LabView software allows the chamber holders to be programed and rotated
automatically. The hardware interfaces included the National Instruments cDAQ-9171
chassis and cDAQ-9401 module. Controllable parameters include rotation direction,
rotation time, rotation pause time, orbital shaking speed, orbital shaking time, orbital
shaking pause time, and number of repetitions. By using a finely-controlled stepper motor
and calculating rotations per minute by time rotated, the final resting degree of rotation
can also be controlled.
5.2.4 Changing Media and Gas Exchange in the Seeding Chambers
The needleless ports attached to the lid of the seeding chambers can be used for
changing media, adding cells, cycling the gas content, or any other access necessary. To
change media, the seeding chamber is removed from the A-frame and transferred to the
cell culture hood. The chamber is drained by vacuum through a needleless port with an
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empty 50 mL syringe attached to
the other port to allow sterile air
into the system (Figure 5-3).
Following removal of all liquid,
media is added to the chamber
through the 50 mL syringe until
the media just covered the stainless
steel mounting rings (about 120 Figure 5-3: Media and gas exchange in seeding chambers

(A) Media can be changed without opeing the lid by aspirating
mL). The attached vacuum will pull through needleless ports. (B) If necessary, CO2-rich gas can be
cycled through the chambers via sterile filters and vacuum
the media from the syringe into the pressure.[140]

chamber, but is not necessary for the chamber to fill. If additional gas exchange is
necessary, sterile filters can be attached to each needleless port and vacuum applied to
one port. This will draw CO2 rich air into the seeding chamber. It should be noted that
compressed CO2-rich air can be used, but only when chambers are securely latched to the
holding plate. If the lid is not attached, the pressurized air will force the lid out of the
system.
5.2.5 Internal Cellular Seeding via Injection
Valve scaffolds were prepared as above and seeded with cells as in Figure 5-4.[140]
Following neutralization, the base and free edge of all cusps in the valve were inflated
with sterile compressed air (15-20 psi) attached to a sterile 33G x 1.25 inch needle. A
sterile pipet was used to stabilize the tissue and the needle was inserted into the middle
layer of the cusp, causing the fibrosa and ventricularis layers of the cusps to delaminate.
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Immediately after mixing, 4 million hADSCs in 1 mL were loaded into a 1mL syringe
and manually injected into the free edges of the cusps in multiple areas and in the base of
the cusp through a 33G x 1.25 inch needle. Injection was repeated for each cusp for a total
of 12 million cells into the interstitial cusp area of each valve.
Valves were then placed into a seeding chamber with the non-coronary sinus
aligning with the 0° mark on the chamber. The chamber was filled with enough cell
culture media (DMEM with 10% FBS, 1% Antibiotic/Antimycotic) to cover the stainless
steel mounting rings (about 120 mL). The chamber was closed as described above and

Figure 5-4: Internal cell seeding of valve cusps
(A) Internal cell seeding was performed after mounting into the valve quick mount to assist in stabilization.
(B) The bulb of a sterile pipet was inserted into the valve root to (C) hold the cusp in place. Compressed air
(15-20 psi) was (D) pushed through a filter to sterilized the air before (E) injecting the base and free edges
of the cusps with air. (F) After air injection, cusp layers delaminated and usually maintained pocket of air
after needle removal. (G) Cell culture media was drawn into a syringe prior to (H) attaching a needle to the
syringe. (I) Cells were injected into the previously delaminated cusps at the base and free edge.[140]
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placed into the end-over-end chamber holder on the A-frame with the 0° chamber mark
aligning to the corresponding mark on the end-over-end chamber holder.
After placing all the valves into the chamber holder, the shaker was set to speed
20%. The LabView program was set with the rotator at 5.0 RPM with a rotating time of
300 seconds and pause time of 300 seconds. Rotations alternated direction each time and
the seeding chambers were rotated for 18-24 hours at 37°C at those conditions to improve
cell attachment to the valve scaffolds.
5.2.6 External Cell Seeding via Rotational Device
One day prior to internal seeding (the same night as the neutralization step), the
seeding chambers were assembled and filled with sterile 5% BSA in 1xDPBS to block
attachment to the container and localize the future fibronectin/pronectin attachment to
the valve. The next night, the freshly internally injected valve scaffolds were coated with
4 µg/cm2 (approximately 4 µg/mL in this application) fibronectin (Sigma) or pronectin
(Sigma) by adding the correct volume of fibronectin/pronectin to the culture media.
Following interstitial cell seeding and coating with 4µg/cm2 fibronectin or pronectin, the
exterior surfaces of the valves were seeded by one or a combination of the methods
described below.
External Seeding Method 1
In the first method, 16-24 million hADSCs were seeded in one night using endover-end rotation of the valves. For this method, the seeding chamber was removed from
the A-frame and drained as described in section 5.2.4. 16-24 million hADSCs (as

Page | 83

Table 5-1: External seeding method 1 dynamic regimen
In one trial, the root was positioned down for only 5 minutes.

Rotator
Position A
Position B
Time
Shaker
Speed
(holder orientation)
(rotation in holder)
(min)
Speed
(RPM)
Rotating
0° on set mark
30 30%
5.00
Root Up
0° on set mark
200 Off
Rotating
120° on set mark
20 20%
0.75
Root Up + 180 degrees
120° on set mark
90 or 5 Off
Rotating
240° on set mark
20 20%
0.75
Root Up + 30 degrees
240° on set mark
90 Off
0
Rotating
240° on set mark
1000 Off
0.01
Run the above until next seeding day. Can leave shaker off if needed.

Rotating
Time
(seconds)
30

Pause
Time
(seconds)
0

60

0

60

0

1800

7200

determined by the experiment trial) were resuspended in 35 mL cell culture medium and
added to the seeding chamber through the syringe, followed by about 90 mL of additional
cell culture media to fill the chamber.
The chamber was placed into the end-over-end holder on the A-frame with the 0°
chamber mark aligning to the corresponding mark on the end-over-end chamber holder
(position B in Table 5-1) and the rotational regimen in Table 5-1 was followed overnight.
External Seeding Method 2
For the second method, 30 million hADSCs were seeded over the course of three
nights using end-over-end rotation of the valves. For this method, the seeding chamber
was removed from the A-frame and drained as described in section 5.2.4. 10 million
hADSCs were resuspended in 35 mL cell culture medium and added to the seeding
chamber through the syringe, followed by about 90 mL of additional cell culture media
to fill the chamber.
The chamber was placed into the end-over-end holder on the A-frame with the 0°
chamber mark aligning to the corresponding mark on the end-over-end chamber holder
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Table 5-2: External seeding method 2 dynamic regimen
Position B
Position A
(rotation in
Time
Shaker
(holder orientation)
holder)
(min)
Speed
Pre-Setting: Root Up
0° on set mark 00.13
Off

Rotator
Speed
5.00

Rotating
Time
(seconds)
11

Pause
Time
(seconds)
300

Cycles
1

5400

1

5400

1

6300

100

Run for 12-15 seconds, then hit circular stop button during the first pause time.
Rotating
0° on set mark 30.05
20%
Root Up + 30 degrees 0° on set mark 90.00
Off
2.00
1805
Rotating
0° on set mark 30.05
20%
Root Up + 330 degrees 0° on set mark 90.00
Off
Run the above for 1 cycle = 4 hours. Be sure to turn shaker off/on as appropriate.
Second pre-Setting
0° on set mark 00.03
Off
5.00
1
Run for 2-5 seconds, then hit circular stop button during the first pause time.
Rotating
0° on set mark 15.30
20%
Root Up + 180 degrees 0° on set mark 105.00 Off
1.00
930
Rotating
0° on set mark 15.30
20%
Root Up
0° on set mark 105.00 Off
Run the above until next seeding day. Can leave shaker off if needed.

(position B in Table 5-2). The chamber holder was positioned with the root up (position
A in Table 5-2) and the rotational regimen in Table 5-2 was followed overnight.
On the second day of seeding, the media was aspirated and another 10 million
hADSCs were added to the chamber in 120 mL media through the needleless ports as
described above. The seeding chamber was then placed back into the end-over-end holder
on the A-frame with the 120° chamber mark aligning to the corresponding mark on the
end-over-end chamber holder (position B). The chamber holder was positioned with the
root up (position A) and the rotational regimen in Table 5-2 was followed overnight with
the only change being position B was at 120° on the set mark.
On the third day of seeding, the media was aspirated and another 10 million
hADSCs were added to the chamber in 120 mL media through the needleless ports as
described above. The seeding chamber was then placed back into the end-over-end holder
on the A-frame with the 240° chamber mark aligning to the corresponding mark on the
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end-over-end chamber holder (position B). The chamber holder was positioned with the
root up (position A) and the rotational regimen in Table 5-2 was followed overnight with
the only change being position B was at 240° on the set mark.
External Seeding Method 3
For the third method, 30 million hADSCs were seeded over the course of three
nights using axial rotation of the valves. After removing the seeding chambers from the
A-frame, the end-over-end chamber holder was replaced with the axial chamber holder
on the A-frame. For this method, needleless ports were replaced with luer plugs before
the first media aspiration to allow three chambers to fit into the axial chamber holder.
The seeding chamber was drained as described in section 5.2.4.. 10 million hADSCs were
resuspended in 35 mL cell culture medium and added to the seeding chamber through the
syringe, followed by about 90 mL of additional cell culture media to fill the chamber..
Following the additional media, luer plug caps were place onto the luer fittings.
The chamber was placed into the axial holder on the A-frame with the 0° chamber
mark being set between the bolts holding the seeding chamber to the chamber holder
(position B in Table 5-3). The chamber holder was positioned with the bolts up (position
A in Table 5-3) and the rotational regimen in Table 5-3 was followed overnight.
On the second day of seeding, the media was aspirated and another 10 million
hADSCs were added to the chamber in 120 mL media through the luer ports as described
above. The seeding chamber was then placed back into the axial holder on the A-frame
with the 120° chamber being set between the bolts holding the seeding chamber to the
chamber holder (position B). The chamber holder was positioned with the bolts up
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Table 5-3: External seeding method 3 dynamic regimen
Position A
Position B
Rotating
(holder
(rotation in
Time
Shaker Rotator
Time
orientation)
holder)
(min)
Speed
Speed (seconds)
Pre-Setting:
Bolts Up
0° between bolts
Rotating
0° between bolts
30.15
20%
Bolts Down
0° between bolts
90.00
Off
2.00
1815
Rotating
0° between bolts
30.15
20%
Bolts Up
0° between bolts
90.00
Off
Run the above for 1 cycle = 4 hours. Be sure to turn shaker off/on as appropriate.
Rotating
0° between bolts
15.30
20%
Bolts Down
0° between bolts
105.00 Off
1.00
930
Rotating
0° between bolts
15.30
20%
Bolts Up
0° between bolts
105.00 Off
Run the above until next seeding day. Can leave shaker off if needed.

Pause
Time
(seconds)

Cycles

5400

1

6300

100

(position A) and the rotational regimen in Table 5-3 was followed overnight with the only
change being position B was at 120° between the bolts.
On the third day of seeding, the media was aspirated and another 10 million
hADSCs were added to the chamber in 120 mL media through the luer ports as described
above. The seeding chamber was then placed back into the axial holder on the A-frame
with the 240° chamber being set between the bolts holding the seeding chamber to the
chamber holder (position B). The chamber holder was positioned with the bolts up
(position A) and the rotational regimen in Table 5-3 was followed overnight with the only
change being position B was at 240° between the bolts.
5.2.7 Live/DEAD® Imaging
Presence of live cells on tissue surfaces was analyzed using Live/DEAD® stain
(Invitrogen, Eugene, Oregon) according to manufacturers’ directions, using 20 µL of
EthD-1 and 5 µL of Calcein-AM in 10 mL of 1X PBS. The Live/DEAD® solution was
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added to cover each sample and covered with foil at 37°C for 20 minutes before fluorescent
imaging with an inverted microscope.
5.2.8 SEM Analysis
Scanning electron microscopy (SEM) was used to visualize the 3-D morphology
of cells on the cusp surfaces. After rinsing in 1xDPBS, the cusps were fixed in Karnovsky’s
fixative (2.5% glutaraldehyde, 2% formaldehyde in 0.1 M cacodylate buffer, pH 7.4) for at
least 24 h. Samples were dehydrated in increasing ethanol concentrations until absolute
alcohol was reached, then stored in 100% ethanol for up to 12 hours. Following immersion
in hexamethyldisilazane (Polysciences, Inc., Warrington, PA) for 15 min, samples were
left to air dry. Samples were then coated with platinum for 2 min (Hummer 6.2, Anatech
LTD, Union City, CA) before imaging with a Hitachi S4800 or TM3000 Tabletop
scanning electron microscope (Clemson University Electron Microscope Facility,
Anderson, SC).
5.2.9 Histology
For histology studies, samples collected from the cusp were fixed in 10% formalin,
embedded in paraffin, sectioned at 5 µm and stained with DAPI for nuclei and
Hematoxylin & Eosin (H&E).

5.3 Results and Discussion
5.3.1 Injection Seeding
Several trials of injecting cells into the cusps were used to determine the best sizes
of needles and other tools to use during inflation and injection. Initial trials using carbon
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particles were helpful in tracking
where the injected media traveled,
but did not travel in the same
manner as the cell suspension.
Figure 5-5B shows the route of
needle injection into the central
layer of the cusp where a bolus of
localized carbon particles can be Figure 5-5: Mapping and repopulation after injection

(A) Carbon particles (black) were injected into the base and
free edge of the cusps. (B) Area of carbon injection in the free
edge of a cusp immediately after injection. Pre-inflation areas
Initial placement of cells by (C) and direct-inject areas (D) near the free edges are both
repopulated with cells after injection. The air pockets created
injection yielded similar boluses of by inflation can be seen clearly in the base as shown in the left
image. The blue line indicates where the cusp was cut from the
cells in the free edges of the cusps valve root.[140]

seen in black.

(Figure 5-5D). The base of the cusp (Figure 5-5C) yielded the most complete air inflation.
This allowed the injected cells to spread through the tissue more than in the free edges
of the cusps. Overall, our method of injecting cells into the central layers of aortic cusps
yields an initial distribution of cells that is concentrated in boluses in various locations of
the cusp. We will rely on cell migration and dynamic forces to cause these cells to spread
throughout the tissue during culture.
Other trials using static seeding and relying on cellular migration to repopulate
the scaffolds are clearly inadequate up to six weeks when using hADSCs (Figure 5-6).
Briefly, hADSCs were seeded onto 1 cm2 scaffolds with dropwise methods in 12-well
plates and kept in static conditions for 6 weeks with media changes every 2-3 days. We
saw complete cell coverage by the 2-week time point with apparent proliferation beyond
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that, but extremely few cells penetrated the surface of the scaffolds. Although not ideal,
the injection method of recellularizing the internal layers of the valve cusps holds promise.
While other methods of achieving a uniform repopulation of the cusp layers are being
developed, this method is substantially faster and more effective than current methods
available.
5.3.2 Rotational Seeding
Following rotational seeding with method 1, valves were analyzed immediately
for cellular attachment, spreading, and alignment in comparison to fresh valve cusps
(Figure 5-7). Analysis using Live/DEAD® imaging and scanning electron microscopy for
the cusps revealed substantial recellularization. Many surfaces appeared to have as many
cells present as the native cusps. The exception to this is seen in Figure 5-7K, where fewer
cells are covering the ventricularis side of the cusp. However, during this trial of cell
seeding, the rotational regimen was varied and the valve rested in the “root down”
position for 5 minutes instead of 90. Since this is the position in which the ventricularis
would have been seeded, this is likely the cause for less coverage here.
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Figure 5-6: hADSC migration into valve root scaffolds
hADSCs seeded onto the surfaces (Live/DEAD images) of each type of scaffold proliferated, but did not
penetrate the surface except in a few instances (C,G,H). The brightness/contrast settings in the DAPI images
have been artificially increased to enable visualization.
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Overall, initial cell repopulation was very successful with this method. However,
the aortic wall and sinus are not as well covered as the cusp (data not shown). Data is not
available for initial seeding using methods 2 and 3, but analysis of the surfaces after
further conditioning suggests that these methods are equally or more effective at
recellularizing the sinus and aorta portions of the valve root than method 1 (see Chapter
8: for details). One drawback to these methods is the large number of cells to be used at
one time. For example, a study recellularizing five heart valves by injection and a
combination of methods 2 and 3 for full surface revitalization would use over 360 million
cells. As demonstrated in Figure 5-7, fewer cells can achieve excellent results, but
modifications to the rotational protocol and alternative chamber holders may be
necessary to accomplish similar seeding densities on the sinus and aorta luminal surfaces.

Figure 5-7: Initial cell coverage of valve cusps
Fresh cusp surfaces (A-D) are compared with recellularized surfaces (E-L). External seeding method 1 was
used for these valves. I-L show external seeding method 1 with very limited time resting in the root down
position, resulting in fewer cells attached to the ventricularis surface.

Page | 92

5.3.3 Rotational Device
Improvements to the previously developed seeding device allow for a semiautomated process. Minimal user intervention is necessary, but observation during active
phases of seeding is recommended to prevent unintended scenarios of rotation until the
software and hardware can be further developed. By calculating the speed and time in
relation to the physical parameters of the stepper motor, a stopping angle can be
determined and set by the software and timing. Software and hardware is being developed
that can control the speed of the shaker plate.
The additional seeding chamber holding plate to provide an axis of rotation along
the axis of the valve root was important in achieving full recellularization of all surfaces
of the valve root. Furthermore, capabilities to seed up to six valves on the same system
will improve future experiments by allowing for higher sample size. Overall, the
rotational seeder works very well for creating an initially recellularized valve surface.
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CHAPTER 6: A PLATFORM HEART VALVE BIOREACTOR
6.1 Introduction and Background
Bioreactors have many applications from the bioreactors used for microbial
expansion to those intended to prepare a tissue for implantation. In the realm of tissue
engineered heart valves, they have two main purposes: 1) to elucidate the mechanisms
that influence interactions between cell types or cells and scaffolds and 2) to prepare a
tissue engineered construct for implantation into a living animal.[118] However, even
within the application of preparing or testing valve constructs, many various functions
are performed by bioreactors. From seeding cells, to testing cell retention, to developing
new extracellular matrix, bioreactors fulfill many purposes that are otherwise unavailable
with conventional 2D or even some 3D methods.
6.1.1 Previous Bioreactor Systems
Many bioreactors focus on subjecting valves, cusps, or cells to stretch, flexure,
flow, or a combination therof. Commercial systems such as Flexcell (Flexcell
International, Hillsborough, NC) and other noncommercial systems[141,142] can
subject cells or small pieces of tissue to various physiological levels of stretch. Flexure
bioreactors have been created[143] to test the effects of bending on isolated segments of
scaffolds with or without cells. Flow systems[144,145] have frequently been used in
many applications to explore the effects of sheer stress on cellular function. Furthermore,
many systems have been created[146–148] to combine the effects of various conditions
for the purpose of studying independent vs synergistic effects of those conditions.
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Despite the wide array of bioreactors present, relatively few are capable of
preparing a tissue engineered construct for implantation. However, it is in this final area,
that the most complicated of systems are necessary. They must be capable of subjecting
the replacement to a gradually increasing set of physiological conditions until the final
conditions that represent or exceed those seen in the body are reached. Furthermore,
these types of bioreactor systems must keep the environment sterile and allow for other
complications seen in the laboratory environment such as limited space, assembly
techniques, and general lack of ready to use equipment for such purposes.
The requirements for a heart valve bioreactor system have been discussed in
previous sections. Although not the most sophisticated system in the literature,
understanding the function of our previously published version will provide the
foundational exposure necessary to see the further advances described herein.
6.1.2 Previous Clemson Heart Valve Bioreactor
The first edition Clemson heart valve bioreactor was developed to test and
condition all types of tissue engineered, replacement, and native aortic and pulmonary
heart valves under adjustable physical stimuli similar to those experienced in
vivo.[117,149] It was designed with the following 10 important considerations:
1) To allow mounting of various sizes and shapes of free-standing (“stentless”)
and stented valve designs into the bioreactor.
2) To ensure that the valve opens and closes cyclically due to measurable
changes in trans-valvular pressure.
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3) To maintain the desired concentration of gases and nutrients and waste
removal in/from the culture medium.
4) To expose cell-seeded tissue engineered scaffolds to physical stimuli
similar to in vivo, including trans-valvular pressures, pulsatile forces, flow
rate, frequency, stroke rate, stroke volume and sheer stresses on the valve
surfaces.
5) To allow full control over parameters and to allow for implementation of
progressive adaptation protocols.
6) To ensure maximum visibility and the ability to continuously and remotely
monitor and record valve function.
7) To use materials which are non-toxic, non-degradable, and easy to sterilize,
8) To ensure reasonable durability, easy setup, and compact size to fit in
standard cell culture incubators.
8) To maintain the system at 37oC, 5% CO2, and 95% humidity in sterile
conditions.
9) To yield repeatable results while fulfilling all of the above conditions.
The valve bioreactor is based on a functional principle proposed by Hoerstrup et
al[111] with numerous modifications. The pneumatic-driven conditioning system
(Figure 6-1C) consists of a three-chambered heart valve bioreactor (1), an optional
pressurized compliance tank (2), a res ervoir tank (3) with sterile filter (4) for gas
exchange, one-way valves (5), resistance valves (6), pressure transducers, a webcam (7),
and a ventilator pump routinely used in clinics for intensive care and anesthesia (Siemens
900E, Soma Technology, Bloomfield, CT). The entire system (except ventilator) can be
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sterilized using conventional methods (ethylene oxide gas for the acrylic and high-density
polyethylene components and autoclave for the silicone, PVDF, and stainless steel
components) and accommodates all clinically relevant sizes of stented or stentless
biological, mechanical, or tissue engineered valve substitutes. The valve bioreactor is
made of acrylic, composed of three compartments and measures 6 inches in diameter and
8.5 inches in height and is completely transparent (Figure 6-1A). The three parts of the
bioreactor are held together by stainless steel screws.
The air chamber is connected to the external pump and is the only chamber not
filled with culture medium. It is separated from the ventricular chamber by a clear silicone
rubber membrane. During the inspiration phase of the ventilator (ventilator causing the
patient to breath air in), air is pushed from the ventilator into the air chamber, the
membrane bulges into the ventricular chamber, and the residing media is pushed through
the heart valve into the aortic chamber, opening the valve. Once completed, the exhalation
phase of the ventilator begins (ventilator relaxes pressure to allow the natural patient
exhalation) and the ventilator releases pressure in the air chamber, allowing the
hydrostatic pressure of the remaining fluid in the ventricular chamber to push down on
the silicone membrane, creating vacuum pressure inside the ventricular chamber. The
resultant pressure gradient between the ventricular chamber and the reservoir causes
culture medium to flow from the reservoir tank, through the one-way valves, and into the
ventricular chamber in preparation for the next cycle (Figure 6-1B).
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Figure 6-1: First edition heart valve bioreactor and conditioning system
a) CAD designs (left) and manufactured heart valve bioreactor (right) showing the four main components.
A transparent silicone membrane diaphragm is mounted between the air chamber and the ventricular
chamber. b) Air and media flow through the system during systole (left) and diastole (right). Color coding
aids identification of the components and black arrows indicate direction of air and media flow. c)
Schematic overview of the entire conditioning system: a three-chambered heart valve bioreactor (1), an
optional pressurized compliance chamber (2), a reservoir tank (3) with sterile filter (4) for gas exchange,
one-way valve (5), pressure-retaining valve (6), a webcam (7), and a ventilator pump (air pump). The entire
setup fits within a standard cell culture incubator. d) Two identical bioreactor systems (Br 1 and Br 2) with
endothelial cell-seeded, functioning valves inside an incubator; the bioreactors are in the front row while
their corresponding reservoirs are in the back row. The webcams normally mounted onto the top viewing
windows of the aortic chamber have been removed to reveal bioreactor details.[117]
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During the pumping phase, the curvature of the ventricular chamber and angle of
media inlets contributes to the circulation of culture medium throughout the chamber.
Once through the valve, the medium enters the aortic chamber then flows through a
compliance chamber and into the reservoir. Both the aortic and ventricular chambers have
multiple ports for easy access of pressure transducers, as inlets and outlets for media
change, or for other probes.
Figure 6-1D shows two bioreactors set up in one standard size incubator. The
clear, flat top of the aortic chamber facilitates the viewing of the functioning of the heart
valve via the webcam. A permanent fluorescent lamp mounted inside the incubator
provides lighting. Using websites such as www.livestream.com and others, continuous
broadcast of the bioreactor and valve performance is possible over the internet, allowing
the investigators remote viewing of valve performance from any computer and sharing of
information with collaborators.
6.1.3 System Limitations and the Need for Further Development
The manufactured and tested first edition bioreactor system fulfills most of the
original conditions, including mounting of various types of valves and excellent valve
opening and closing characteristics. The system ensured good cell and valve viability
under sterile conditions for extended periods of time and excellent reproducibility. It also
allowed for implementation of progressive adaptation protocols, ensured perfect visibility
and the ability to continuously and remotely monitor and record valve function. Many
successful experiments have been conducted using that edition including cell seeding of
valves and testing under flow conditions as highlighted in Figure 6-2.
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Most heart valve
bioreactors in the literature
are designed for use with
only

the

valve

type

in

that

investigated

laboratory. Many facilitate
testing

of

decellularized

valves[84,115]

or

laboratory-manufactured
polymer
However,

valves.[150]
the

Clemson

heart valve bioreactor is
able to test all clinically
relevant

sizes

and

variations of stented or
stentless
mechanical,

biological,
or

engineered

tissue Figure 6-2: Cell analysis of endothelial cell-seeded valvular scaffolds
after functioning in the first edition bioreactor

valve Representative SEM images showing native cusp surfaces (a, b), at time

zero (T=0d), i.e. immediately after seeding (c, d) and after 17 days

substitutes with multiple (T=17d) in the conditioning system (e-h).

mounting methods allowing for variations in tissue thickness, engineered material, valve
diameter, amount of excess tissue, and presence or absence of aortic sinuses. Our
bioreactor’s mounting design easily facilitates many different valves in a variety of nonrestrictive options.
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Incremental stroke volumes from 4.7 to 22.3 mL were achieved. For the lowest
stroke volume, the valve was only slightly opening. Under no added pressurization,
systolic and diastolic pressures had an average value of 40/15 mmHg, respectively. After
pressurization, these values increased to a stable 80/70 mmHg. Higher pressures could
be attained, but this halted circulatory flow and the pressures were not stable. The
pressure limitations were the result of an inability of the system to circulate fluid
effectively. A very high level of pressure could be reached if the pumping mechanism could
match and overcome that pressure. By using an alternative pumping mechanism that
would preserve energy by reducing air compression, modifications could be made to
increase the flow to match and surpass even high physiological values. The stroke volume
and pressure of our first edition bioreactor do not yet meet aortic physiological levels and
as the tissue engineering technology improves and valves get closer to implantation
stages, we will need to be able to reach those higher values.
Our heart valve bioreactor system’s primary function is to prepare tissue
engineered heart valves for animal implantation. Thus, representing the whole spectrum
of physiological conditions as well as those leading to those conditions and sometimes
exceeding them is necessary. Although the current system is capable of meeting some of
those needs independently, improvements were necessary to reach the desired outputs
and capabilities of the system. Thus, one goal of this research was to modify the heart
valve bioreactor system to achieve simultaneous physiological levels of flow, pressure,
and shear stresses while maintaining the independent adjustment of each.
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6.2 Materials, Methods, and Description
Incremental improvements have been made to the bioreactor system to reach the
current capabilities. Each increment (Figure 6-4) added specific value that should not be
veiled by the consummated design.
6.2.1 Second Edition Heart Valve Bioreactor
Aside from the technical capabilities, the largest pitfall of the first edition
bioreactor was its susceptibility for contamination and cracking of the acrylic material
around the threaded ports. Not only did this consume a tremendous amount of resources
to repeat contaminated experiments, it was also very time consuming to assemble in a
sterile hood. A method of connecting the multiple chambers that did not utilize threaded
fittings was investigated. A quick connect fitting similar to those available from Colder
Products Company (Figure 6-3A) was desired, with the only difference being that the
male end plugged into a bulkhead (the side
wall of the acrylic chamber) instead of
another fitting. If the second fitting was
used, the same problem of connecting that
fitting to the acrylic chamber would occur.
After

exhausting

all

known

distributors and suppliers as well as
inquiring about custom fittings, a novel
quick-connect fitting (Figure 6-3B) was Figure 6-3: Quick connect fittings

Commercially available (A) quick-connect fittings did

developed and patented[151] that would not resolve existing issues, so new fitings (B) were
designed to plug into a tank like the bioreactor.[151]
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maintain a sterile seal and be quick to install without utilizing Teflon tape, threading, or
difficult to sterilize materials. This quick connect fitting is a male fitting with an actuating
member that engages with a groove in the wall of the bioreactor to lock it in place. It
utilizes a reliable o-ring seal to maintain sterility and allow for a quick-connection.
Additionally, it can be manufactured out of materials that can be cleaned and sterilized
multiple times or 3-D printed and autoclaved for single uses.
Although the hospital ventilator was able to fulfill the role of pumping media, the
controls of this ventilator
did not provide adequate
tuning of the conditions
desired

and

are

often

difficult and expensive to
acquire. A custom LabView
program was written to
control and monitor custom
equipment (Figure 6-4B)
for

setting

the

stroke

volume, stroke rate, duty
cycle,

trans-valvular

pressures, and overall flow Figure 6-4: Editions of the heart valve bioreactor
rate.

Figure

The conditioning system (A) consists of a three-chambered heart valve

6-5B bioreactor (1), an optional pressurized compliance tank (2), a reservoir
tank (3) with sterile filter (4) for gas exchange, one-way valves (5),

demonstrates the second resistance valves (6), pressure transducers (7), a flow meter, a webcam
edition

(8), and an air supply. External LabView software and custom hardware

bioreactor’s (B) monitor and control the system. The bioreactor has come through
three iterations (C) with the current design shown here (D).
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attainable pulmonic and aortic
levels of pressure at 75 beats per
minute, which is adjustable for all
relevant values. The new system
for

providing

the

pumping

mechanism was powered by a
standard air compressor instead of
a hospital ventilator. Bioreactor

Figure 6-5: Third edition ioreactor function and capabilities
Mechanical and bioprosthetic (A) replacement valves in their
pressures are easily adjusted by open and closed positions. Screenshot of LabView program (B)
showing pulmonic and aortic pressures.

controlling input air pressure and

can currently reach any desired level. Maximum stroke volume levels achieved under
sterile conditions with the second edition bioreactor are roughly 30 mL (70 mL is normal
average).
An additional upgrade in this edition was utilizing custom glass-blown bottles as
compliance chambers and reservoirs. By using standard media bottles with barbed
attachments, we were able to replace multiple assembly steps. Together, the new bottles
and fittings were able to drastically reduce system setup time and connection points and
therefore reduce the opportunity for contamination of the system during initial setup.
While the first edition took 4-6 hours to set up depending on user skill, the second edition
took less than 2 hours. More improvements in the third edition bioreactor system would
further reduce that time to about 30-45 minutes for an experienced user.
User-friendliness was drastically improved with the second edition bioreactor. As
a result, it was able to support more valve testing experiments than previously possible,
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but at sub-physiological flow rates. Shear stress on the tissue was also low because the
viscosity of the fluid in the system was much lower than that of blood. As the main
objective of developing a tissue engineered heart valve progressed, additional
improvements were desired to reach full physiological conditions, decrease complexity of
the system, and allow for seamless integration into the entire valve preparation process.
6.2.2 Third Edition Heart Valve Bioreactor
The next edition of the heart valve bioreactor had slight modifications to its main
chambers. It eliminated unnecessary ports; added custom threaded nuts to reduce the
number of bolts used and eliminate any threading in the acrylic components; and utilized
a re-designed method of holding the heart valve tissue. This tissue holder (described in
Chapter 3:) is installed around a fresh heart valve and is used to hold, transport, and seal
the valve in the various treatments of decellularization, fixation, cell seeding, condition,
and final preparations for implantation. It provides a no-touch approach to handling the
valves and fully integrates the entire valve preparation process. Utilizing this valve holder
significantly reduced the time to install a valve into the bioreactor, which not only
decreased overall assembly time, but also increased cell viability because of the decreased
amount of time the cell-seeded valves were outside of culturing media.
3-D printing technology provided by Clemson University Machining and
Technical Services (both Printer companies, places) was utilized to reduce the footprint
and number of bioreactor components and subsequently, those connections. It allowed
the quick connect fittings to be directly attached to custom-shaped reservoirs and
compliance chambers. By printing the external modules of the bioreactor in a material
Page | 105

that could be autoclaved once, we were able to pre-assemble a majority of the components
outside of the hood, saving time and decreasing the difficulty of assembling a majority of
the system in a laminar flow hood.
The new components and custom shapes also allowed for reduced overall footprint,
lower media volumes used, and an alternative air filter for gas exchange. Very few filters
were found that could provide the volume transfer over the low pressure drop provided
by the bioreactor system. Although two options remained, the large flow filter was
utilized.
One of the requirements of this edition of the bioreactor was to reduce complexity
by utilizing disposable or autoclavable components that could be pre-assembled. Recently
developed turbine flowmeters (EquFlow, Netherlands) were acquired that could be
autoclaved, but were also relatively inexpensive and could be discarded if necessary. They
also acted as a partial constriction valve by their inherent functional properties.
Alternative disposable pressure transducers were utilized that would connect directly to
ports on the 3-D printed fittings. Normally utilized for invasive blood pressure
monitoring, these transducers are very precise.
Utilization of the new flowmeters and pressure transducers also required an
upgrade to the hardware and software of our controls devices. A chassis system with
interchangeable modules (National Instruments) that could support the new systems
components was utilized. This chassis system allowed for numerous counters for the
flowmeters and data conditioning required by the pressure transducers. This chassis
system was also beneficial for use in controlling the other components and devices utilized
in the valve preparation process.
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6.2.3 Achieving Physiological Pressure, Flow, and Viscosity with the Third Edition
Heart Valve Bioreactor (Fourth Edition Bioreactor)
Although the changes made for the third edition bioreactor enable normal and
pathological conditions of pressure, flow, and shear stress, further modifications were
necessary to provide those conditions in a sterile environment and control them
independently. To modify fluid viscosity, 2.5% dextran (Sigma Aldrich) was added to the
media to thicken the media.
As previously described, all normal and pathological levels of pressure can be
achieved by adjusting the input air pressure pumping the system. By increasing the
pressure, the flow will also increase. However, the physical components of the previous
versions have limited the flow to about 30 mL per stroke (normal stroke volume is 70 mL
per stroke) at physiological pressures and 75 beats per minute (bpm). As a result, larger
flow paths and different compliance chambers were developed with the goal of achieving
up to 100 mL per stroke at 75 bpm with physiological pulmonic and aortic pressures.
After increasing all fluid lines to at least 0.9 inches in diameter, we determined
that initial air volumes of 8 and 1.5 liters would be necessary for pulmonic and aortic
conditions, respectively to provide adequate flow. This can be calculated from the
compression ratio of air from 10 to 25 mmHg and 80 to 120 mmHg for pulmonic and
aortic pressures, respectively. However, it is also dependent upon having enough time
and low enough resistance to move the fluid by that amount under those relatively small
pressure changes
Since 10 liters is too large of a volume to fit multiple systems into one incubator,
we investigated alternative methods of creating such a compliance chamber. The
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Figure 6-6: Fourth edition bioreactor CAD and photographs
Pulmonary (A) and aortic (B) modules are shown. CAD renderings and photographs demonstrate the path
from design to manufacturing

approach of using a liquid head of pressure for pulmonic conditions was investigated.
Since 30 mmHg is equivalent to roughly 40 cm H2O, we determined that a cylinder that
extended at least 40 cm above the valve would be adequate to create pulmonic pressures.
Additionally, this configuration would fit inside a standard sized incubator. The final
approach was to attach a 3-D printed cylinder with specific variances in diameter to the
fluid circulatory line of the system (Figure 6-6A) to create the appropriate pressure head
on the valve. During diastole, as the fluid continued to flow out of the compliance chamber
cylinder and into the reservoir, the fluid level would lower and the pressure would
decrease. By changing the diameter of the cylinder and varying it along the length, we
could adjust how fast the fluid dropped, which affected the stroke volume and the diastolic
pressure. This rapid change in air volume in the system was only possible by allowing
airflow into and out of the compliance chamber. To accommodate, an air filter was
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attached to this chamber as well as the reservoir that had a large enough surface area to
accommodate the rapid change in air over the relatively low pressure changes.
A two-liter custom glass-blown bottle (Figure 6-6B) was used as a compliance
chamber for the aortic conditions. This size bottle allowed all ranges of stroke volumes,
depending on how much air was initially in the system at 80 mmHg. By altering the
amount of fluid in the bottle (and subsequently, how much air) we could control stroke
volume of the system independently from pressures. Designs have been made to adjust
the volume via an external source of fluid while maintaining system sterility. This would
require the least amount of culture media inside the flow loop to reduce supplies. In
addition, this bottle has a port through which an initial air pressure can be supplied to
ensure low media usage.
Incremental improvements in the bioreactor design have allowed us to control the
compliance tank size, compliance tank shape, pumping air pressure, media viscosity,
pumping rate, resistance, and duty cycle. Variations of certain combinations of these
factors allow for the independent control flow, pressure, and shear stresses applied to the
valves. Furthermore, each can be controlled while maintaining sterile testing conditions.
While the current system meets all the research needs, further improvements are
recommended to aid during assembly by novice users. These can be found in Error!
Reference source not found.: Error! Reference source not found..
6.2.4 Validation of Function Testing
St. Jude mechanical heart valves used for validation of functions. Viscosity
adjustments were made in accordance with published results.[152] Performance testing
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was performed on the benchtop to aid in fluid visualization, but closed systems as those
seen in sterile experiments were maintained. A custom LabView program was used to
control pumping and monitor flow and pressure during operation. This software utilized
a National Instruments cDAQ-9178 chassis and appropriate modules. Bioreactor
pumping utilized module 9472.
Flow between the compliance chamber and reservoir was measured by an EquFlo
turbine flowmeter. In this position, continuous flow occurred with cyclical increases in
flow rate during systole. All fluid passes through this one constriction point, but it should
be noted that if any regurgitation occurred, this volume of fluid would not be accounted
for in the flow calculations. Flow is measured in a turbine by counting the pulses sensed
from an infrared sensor placed in line with the turbine spokes. As the spokes pass, the
sensor is blocked and a pulse is generated. A National Instruments cDAQ-9401 module
was used to count pulses and calculations were made dependent upon each individual
flowmeter’s pulse/liter rating.
Pressure was measured by DTX Plus pressure transducers. A National
Instruments cDAQ-9237 module was used to measure and condition the incoming signals.
Transducers were located at the level of the valve or the baseline adjusted appropriately.
Each transducer was zeroed to atmospheric pressure in the software before initial use.

6.3 Results and Validation of Function
Overall, the bioreactor system has come through four iterations of design.
Alternative components (compliance chambers, reservoirs, restrictor valves, etc) were
developed or acquired to allow for physiological levels of flow at pulmonic and aortic
pressure conditions while maintaining sterility. The controlling hardware and software
Page | 110

was upgraded to allow simultaneous and independent operation of multiple bioreactors
and accurate monitoring of the flow and pressure conditions.
Shear stresses were increased by adding dextran to the culture media. Other
researchers had determined that a concentration of 2.5% Dextran (2x106 MW) in DMEM
with 10% FBS would result in a fluid viscosity to match that of blood. Their previous
experimentation to measure fluid viscosity was deemed unnecessary to repeat.
6.3.1 Pulmonary and Aortic Conditions
Although stroke rate and duty cycle can be adjusted to all reasonable levels,
testing was performed at 75 bpm with a systole time of 0.3 seconds and a diastole time of
0.5 seconds. Dextran can be easily added to thicken the media to the appropriate viscosity.
Full physiological conditions were met for pulmonic position testing. These included flow
rates exceeding 75 mL per stroke, and pressures up to 35/20 including the normotensive
pressure of 25/10 in that position. Figure 6-7 demonstrates a valve in the open and closed
position being tested in the bioreactor at those pulmonic conditions. Full physiological
conditions have been met for aortic position testing using non-sterile conditions only.
The newest updates will allow those conditions to be met while maintaining sterility, but
the

final

details

to

accommodate are not yet in
place. However, using the
aortic

module

on

the

benchtop, flow rates can

Figure 6-7: Valve in the functioning bioreactor at pulmonic
reach nearly 100 mL per conditions
Valves open and close well at both pulmonic and aortic conditions of
pressure and flow.
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stroke and pressures can rise well beyond 300 mmHg. Normotensive pressures of 120/80
mmHg and average flow rates of 70 mL per stoke are also reachable in this configuration.
However, until final device details are in place, increased amounts of media are necessary
to reach those conditions.

6.4 Discussion of Further Potential Uses
The most recent platform bioreactor system developed has numerous applications
for tissue engineering, mechanical testing, and pharmacological development. The
resulting small footprint, ease of assembly, modularity, and means of sterile media
exchange have led to a truly platform system that can be utilized in many fields. While
many systems described in the literature or that are commercially available can perform
a single function well, this system performs multiple functions well with a simple change
of module when necessary. For instance, it can:
1) Provide a variety of physiological pulmonary and aortic conditions.
2) Provide a flow loop condition for the mitral valve.
3) Maintain a sterile environment or be used on the benchtop.
4) Precondition a tissue engineered valve.
5) Mechanically test the opening of a valve.
6) Allow visualization and capture of cusp movement.
7) Test the placement and perivalvular leakage of transcatheter-deployment.
8) Assist in the training of transcather deployment of replacement valves.
9) Create normal or pathological conditions for use in disease modeling.
10) Independently control up to four systems inside one cell culture incubator.
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In all, nearly 100 experiments have been performed with these systems and
improvements have been made with each through the knowledge learned about the
system. With the knowledge gained from these experiments, we see an expansive field of
use for this and future editions of the Clemson heart valve bioreactor.
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PART 3: RESEARCH AND CLINICAL APPLICATIONS
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CHAPTER 7: BIOREACTOR VALIDATION CASE STUDIES
7.1 Introduction to Multiple Uses of the Heart Valve Bioreactor
Bioreactors have many applications from the bioreactors used for microbial
expansion to those intended to prepare a tissue for implantation. In the realm of tissue
engineered heart valves, they have two main purposes: 1) to elucidate the mechanisms
that influence interactions between cell types or cells and scaffolds and 2) to prepare a
tissue engineered construct for implantation into a living animal.[118] However, even
within the application of preparing or testing valve constructs, many various functions
are performed by bioreactors. From seeding cells, to testing cell retention, to developing
new extracellular matrix, bioreactors fulfill many purposes that are otherwise unavailable
with conventional 2D or even some 3D methods.
Our heart valve bioreactor system’s primary function is to prepare tissue
engineered heart valves for animal implantation. Thus, representing the whole spectrum
of physiological conditions as well as those leading to those conditions and sometime
exceeding them is necessary. However, at other times, our system has been utilized for
other purposes. Projects from undergraduates, other subprojects, and even other main
graduate student projects have, at various times, made use of the bioreactor systems
herein described. Disclosed here are other applications of our platform bioreactor system
that serve to demonstrate its versatility of uses including testing valve designs, creating
a diseased condition to evaluate drug treatment regimens, and even differentiating stem
cells into valvular interstitial cells[78]. It should be noted that with a simple switch of
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modules, the aortic/pulmonic bioreactor has been adjusted to become a mitral valve
bioreactor. As this is the focus of another student’s ongoing project, details are withheld.

7.2 Gelatin-Coated Resorbable Polymer Mesh as a Novel Scaffold for
Heart Valve Tissue Engineering
7.2.1 Abstract
A gelatin coated resorbable polymer scaffold was used to create tissue engineered
heart valves (TEHV) in order to address the issues associated with the longevity of
current artificial heart valves. It was hypothesized that the combination of specific
elements is essential to development of a functional TEHV: biomimetic geometry, flexible
and durable scaffolds, proper cell seeding, and mechanical stimulation. Testing of this
hypothesis included iterations of aortic valve scaffold designs to mimic native heart valve
architecture using stainless steel and bioabsorbable polymer meshes. The functionality of
the valve was tested with a pulsatile flow bioreactor. Preliminary scaffolds were too rigid
and displayed only a minimal effective orifice area (EOA) for blood flow through the valve.
The bioabsorbable polymer mesh provided adequate structural support and greater
flexibility for the gelatin heart valve when compared to the stainless steel mesh. A new
suturing technique was then incorporated to increase the EOA. Initial studies
demonstrated that the new suturing technique allowed for natural movement of the root
and closure of the cusps. However, improvements are still needed to further increase the
EOA during valve opening. Future research plans include modification of suturing
techniques as well as the acquisition of more compliant polymer meshes. The gelatincoated scaffolds were also tested for cytotoxicity by seeding with cells. Preliminary
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results displayed cell attachment, but ingrowth was limited. Long-term goals include
endothelial cell seeding on the most effective polymer scaffold, which will then be cultured
in a bioreactor where it will be subjected to mechanostimulation.
7.2.2 Introduction
The human heart performs approximately forty million cycles a year – an
estimated three billion cycles for the lifespan of the average human.[11] However,
increased applied working loads as a result of patient-dependent factors such as stress,
high blood pressure, and stenosis can lead to degeneration and premature failure of the
native valve.[153] Malfunction of heart valves can also be caused by non-patientdependent factors such as congenital deformation, inadequate leaflet strength,
calcification of leaflets causing stenosis, or inflammation of the valve.[11] The
aformentioned
cause

pathologies

inadequate

blood

can
flow

through the valve when the leaflets
do not fully open, as well as
regurgitation when the leaflets do
not properly seal the pathway upon
closure[154,155] as shown in
Figure 7-1. In modern times, an
increasing
proportionally

lifespan
increased

has
the

occurrence of degradation in heart

Figure 7-1: Normal vs stenotic valves
Comparison in orifice area of aortic valve with normal function
and stenotic aortic valve.

Page | 117

valves. This failure has led to an increased demand for heart valve replacement
surgeries.[156] The aortic and mitral valves are more commonly replaced than the
tricuspid and pulmonary, with more than 100,000 patients requiring replacement of a
diseased or dysfunctional valve every year in the United States.[157]
There are currently two categories of replacement heart valves: mechanical heart
valves constructed from pyrolitic carbon and bioprosthetic heart valves composed of
biological tissue.[59] These heart valves ensure an improved quality of life, but are
hindered by a decrease in their viability over time. Mechanical heart valves are more
durable, but patients who receive them are administered anticoagulants as long as they
have the implant. Bioprosthetic valves are made from animal tissues and materials that
are compatible with the body and therefore do not require the administration of
anticoagulants post implantation. However, the valves are more likely to degenerate
leading to patients requiring revision surgeries.[158] To overcome these issues,
researchers have sought to create an entirely tissue-engineered valve capable of
integration into the body and remodeling to become living tissue. As a deviation from the
ideology of mere disease mitigation, tissue-engineered heart valves promise to be the
ultimate fix, serving as a living replacement for a diseased component of the human
anatomy.[53] Although several groups have demonstrated the feasibility of this new
technology using animal studies, there are a number of unmet design problems.[102,159]
Therefore, it is pertinent for a new aortic valve design to be fabricated.
The focus of the present study was to create living, tissue engineered heart valves
which can surpass the longevity of current artificial heart valves and optimize structural
integrity. It was hypothesized that the combination of specific elements are essential in
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development of a functional tissue engineered heart valve: biomimetic geometry, flexible
and durable scaffolds, proper cell seeding, and mechanical stimulation. In this study,
gelatin-coated polymer mesh sutured to mimic porcine valve geometry was used as a
flexible scaffold and mechanically stimulated in a pulsatile flow bioreactor. Effective
orifice area and movement of the root and cusps without cells seeded were assessed.
Fibroblasts were seeded onto the valve materials and were assesed for reaction and
ingrowth into the materials. This paper describes the design process in an effort to report
both successful and unsuccessful methodologies to assist future tissue engineering heart
valve researchers. The final version of the valve, presented herein, is a result of an
iterative design process, whereby many fabrication techniques were tested to develop the
best method for mimicking the functionality of a native heart valve while also providing
optimal durability and biocompatibility.
7.2.3 Methods and Materials
Valve Design Process
The valve was designed by selecting materials, patterns, and techniques based on
effectiveness and ease of assembly. In general, the desired cusp and wall shapes were cut
from a mesh, assembled in the form of a tri-leaflet valve, coated with gelatin, and tested
to assess valve functionality compared to native valves. The first generation design began
with the use of a stainless steel mesh (Small Parts, Inc., Miramar, Florida, USA) that was
cut using the contiguous scalloped leaflet template (Figure 7-2a) and sutured (Ethicon,
Inc., Somerville, New Jersey, USA) to the valve wall (Figure 7-2b). The sutured mesh was
then fit onto the silicon mold and coated using a gelatin injection technique (described
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below). Initial testing in a heart valve bioreactor showed very little cusp movement and
an opening in the center of the valve where the cusp edges were not large enough to touch
each other upon closing.
The second generation valve was constructed using a high-density biodegradable
polymer mesh sutured together to create the valve scaffold. We used the contiguous
peaked leaflet template (Figure 7-2c) to allow the cusps to touch in the center, and
finalized it with the gelatin injection technique. This valve was tested in the heart valve
bioreactor (see description below) and showed adequate closure. However, cusp
movement was not ideal due to an accumulation of gelatin at the base of each leaflet. For
this reason, a gelatin submersion technique (see description below) was developed and
replaced the injection technique to provide a thinner layer of gelatin that would better
facilitate cusp movement.
This new gelatin submersion technique was used in combination with a more
pliable mesh of the same material that had a lower density (AM6-A) and a new design:
the individual peaked leaflet template (Figure 7-2d) . This new leaflet template was
designed to create more freely flowing movement of the valve with the use of individual
leaflets. After testing, these selections were seen to provide optimal valve function and
served as the third generation valve.
To further improve function and ease of assembly, a number of different meshes
and attachment methods were tested. These included a 19 courses per inch (cpi) low
tension reverse locknit, a 28 cpi low tension reverse locknit, and a 40 cpi low tension
tricot (generously donated by Poly-Med, Inc., Anderson, SC). Mesh materials and
architecture were analyzed for valve functionality as well as cellular compatibility. In
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addition, the suturing method of assembly was compared with a cauterizing method and
a combined suturing/cauterizing method.
Gelation Injection Technique
For

non-sterile

studies,

Knox

gelatin (Kraft Foods, Tarrytown, New
York, USA) was dissolved in boiling water
on a hot plate at a concentration of 0.1
g/mL

and

solution

2%

antibiotic-antimycotic

(Mediatech,

Inc.,

Manassas,

Virginia, USA) was added after cooling.
Once the mixture thickened, it was
injected into a silicone mold containing the
mesh framework and wrapped in plastic
piping to prevent gelatin from seeping out.
The mold was then stored at 4°C in a
refrigerator for 24 hours to allow thermal
gelation to occur.
Gelation Submersion Technique
Gelatin was prepared in the same
method as the gelation injection technique.
Figure 7-2: Leaflet templates

Using tweezers to hold the feet of the valve (2a, b) Contiguous scalloped leaflet design. (2c) Valve
root design as used with original continuous

wall, the valve was submerged in the scalloped leaflet design. (2d) Individual peaked leaflet
design with valve root and valve wall.
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gelatin (Figure 7-3). After each submersion, a
paintbrush was used to evenly distribute gelatin
on the valve and avoid undesirable gelatin
accumulation at the base of the leaflets.
Submersion and painting was repeated four times
and the valve was allowed to set for three minutes.
After setting, the valve was submerged and
painted three more times to allow for sufficient
coverage. The valve was stored in a humidifier box Figure 7-3: Gelatin submersion technique

Photograph of gelatin submersion technique

at 4°C for 24 hours in an inverted position to employed for a polymer mesh scaffold.
encourage the leaflets to remain in the closed
position post thermal gelation.
Bioreactor Studies

To effectively reproduce and measure the effects of the human body on the
proposed tissue-engineered heart valve, a pulsatile flow bioreactor designed for heart
valves[117] was used. The entire assembly has been tested thoroughly and has
performed consistently in more than 30 experiments with various valve designs.[78] It
allowed for testing the opening and closing of leaflets in order to qualitatively assess
similarities to native leaflet movement.
The bioreactor was designed to allow for mounting valves of various sizes and
shapes, as well as allow proper exposure to mechanical stimuli for preconditioning of
valves. To mount a valve in this bioreactor, the valve base must be clamped between two
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o-rings. For these experiments, the valve design consists of a valve wall with attachment
feet (Figure 7-4) that allow for easy installation into this bioreactor.
Manual Heart Valve Tester
This novel tester is intended for quick assembly and testing of valves to assess
integrity and function. By requiring fewer steps during its assembly than the bioreactor
(described above), it provides a faster alternative when evaluating new valve designs. As
shown in Figure 7-5, the primary components in the design are: a ventricular chamber,
bracing rings, an aortic chamber, and a cap. The aortic chamber is attached to the
ventricular chamber via three adjustable draw latches that can quickly secure the two
chambers while allowing for adjustments in height for different valve designs. For
convenience, the tester was designed to utilize the same set of bracing rings as used in
the bioreactor described by Sierad, et al., which are placed between the two chambers.
Three screws are used to ensure the cap stays in the correct position and a seal is
maintained. To manipulate the valve, the user operates two bellows so that when the

Figure 7-4: Dipped mesh scaffold
Apical view (left) and basal view (right) of valve scaffold after dipping showing feet in basal view.
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Figure 7-5: Manual heart valve tester
This tester can be very quickly assembled and is used for quick valve testing. Valves are placed between the
bracing rings and the metal latched hold all other components together with a quick latch. The two rubber
bellows are used to pump fluid through the valve to evaluate opening and closing.

ventricular bellow is squeezed (collapsed), fluid moves through the valve into the aortic
chamber and the valve opens. The user then collapses the aortic bellow to shut the valve
and the fluid travels through the external tubing to return to the ventricular chamber.
The components of the tester in contact with fluid are made entirely from clear acrylic
and are easy to sterilize. This allows the valve being tested to be clearly viewed from all
angles.
Analysis of Effective Orifice Area
One important measure of valve functionality is the effective orifice area (EOA).
EOA is the area between the leaflets when a valve is in the open position. EOA relates to
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the amount of work it takes for the heart to push blood through the valve. The larger the
orifice, the more blood can go through with one pump of the heart and the less work
required when compared to a smaller opening.
Effective orifice area was calculated using ImageJ software (National Institutes of
Health) for valves consisting of high-density bioabsorbable polymer mesh sutured using
the contiguous scalloped leaflet template (second generation valves) and the thin mesh
sutured using the individual peaked leaflet template (third generation valves). The EOA
for an aortic porcine valve was calculated as a control comparison. Images were taken of
the valves during testing in the pulsatile flow bioreactor. From a series of images taken,
images of the valve when open were collected and analyzed using ImageJ. The images
were made binary and inverted so that the valve opening was black. A freehand selection
drawing was made around the opening and the ‘analyze particles’ command was used to
calculate the amount of black space in the freehand selection. The particle size was set to
50-infinity pixels2 and the circularity was 0-1.00. The area reading was recorded. The
oval selection command was used to evaluate the maximum effective orifice area possible
if the leaflets were fully open (the inner diameter of the valve). This evaluation was
performed using the ‘measure’
command. The effective orifice area
was divided by the total area
possible and multiplied by 100. In
this study, EOA is represented as a
percentage of the total possible
opening of the valve.

Figure 7-6: Mesh valve study design
12- well plate used for cell study showing rows for Live/Dead
Assay, H&E staining, and the control.
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Cell Study
To test cytotoxicity and cell integration of the low-density bioabsorbable polymer
mesh coated with gelatin (used in the third generation valves), a 3-week cell study was
performed. 12 samples of the mesh were cut into 1 cm2 pieces, sterilized with ethylene
oxide, and coated with gelatin using the gelatin submersion technique. Once coated, the
samples were placed in a 12-well plate, one sample per well (Figure 7-6). After thermal
gelation, the gelatin coated mesh samples were crosslinked using 0.075% glutaraldehyde
in 0.1 M Hepes buffered saline at pH 7.4 for 24 hours. The glutaraldehyde was then
removed and replaced with a 1:1 ratio of Fetal Bovine Serum (FBS) to Dulbecco’s
Modified Eagle’s Medium (DMEM) for 24 hours for neutralization of glutaraldehyde
residues. After the allotted time, the FBS/DMEM was removed and the mesh was coated
in glycine for 2 hours. 3T3 fibroblasts were seeded at a seeding density of 100,000
cells/well in DMEM/10%FBS media. After 3, 7, 14, and 21 days, samples were examined
using the Live/Dead assay (Invitrogen) and Hematoxylin and Eosin staining. Samples
without cells served as a control.
7.2.4 Results
Effective Orifice Area
Figure 7-7 shows one of the initial valves mounted in the bioreactor. Looking
closely, you can see spaces between the cusps, showing the inability of the initial valves
to completely coapt. For the low-density bioabsorbable polymer mesh valve made using
the individual peaked leaflet template (third generation valve), the average percent
opening was 16.6% for the images from the first day and 15.7% for the second day. A
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student’s T test determined
that

there

significant

was

difference

no
in

EOA between the first and
second day. This shows
consistency in the valve
over the course of the time
spent in the bioreactor. The
average percent opening for
the
bioabsorbable

high-density Figure 7-7: Bioreactor testing of mesh valves

Apical view of the second and third generation valves in the bioreactor,
polymer showing the inability of the initial valves to fully close and open.

mesh valve made using the contiguous scalloped leaflet template (second generation valve)
was 6.6%. The average percent opening for the decellularized porcine valve was 15.4%.
There was no significant difference in average percent opening between the low-density
bioabsorbable polymer mesh valve (third generation valve) and the porcine valve. These
results reveal that the EOA of the low-density bioabsorbable polymer mesh valve (third
generation valve) is comparable to that of the porcine valve and there is a significant
difference between the high-density bioabsorbable polymer mesh valve (second
generation valve) and the porcine valve showing a large increase in valve functionality in
the transition to a thinner mesh and a different scaffold shape.
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Cell Study
The results of the
LIVE/DEAD

Viability

study are shown in Figure
7-8.

The

images

are

overlays of the green and
red

fluorescent

created

using

images
ImageJ

software. The results of

Figure 7-8: Cell coverage on the scaffold
Live/Dead Images at (clockwise from top left) 3 Days, 7 Days, 14 Days,
Day 3 and Day 7 showed
and 21 Days.

only a few dead cells and a
large amount of live cells surrounding the low-density bioabsorbable polymer mesh. Day
14 and Day 21 had an increased amount of dead cells, but still showed an abundance of
live cells surrounding and incorporating within the mesh fibers.
The results of the hematoxylin and eosin stains are shown in Figure 7-9. The
controls and samples were stained and observed under bright field microscopy. The
results of cellular integration with the mesh were inconclusive, but the images depict the
gelatin in purple integrating throughout the circular polymer mesh fibers.
7.2.5 Discussion
Analysis of Valve Efficacy
The first iteration of the valve, constructed with a stainless steel scaffold, was
tested in a pulsatile flow bioreactor for 3 days. This valve exhibited a small effective orifice
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area. Bioreactor testing showed that motion was hindered by an accumulation of gelatin
at the base of each leaflet. Further, complete coaptation was not evident and the leaflets
did not display biomimetic motion. These problems can be attributed to the choice of
material and the template used to make the valve. Understanding that this valve exhibited
poor compliance to flow lead to the development of a new valve design that more
accurately mimics the native valve.
In the second iteration, the high-density bioabsorbable polymer scaffold used a
contiguous peaked architecture that attempted to better represent native leaflets. This
valve, however, showed poor movement due to an accumulation of gelatin at the base of
each leaflet, preventing proper motion in vitro. It was determined that the gelatin
injection technique applied more gelatin than desirable for effective leaflet motion.
In comparison with the stainless steel scaffold, the second iteration using the highdensity bioabsorbable polymer scaffold appeared to allow sufficient motion, but valve
architecture was still a hindrance to valve movement and coaptation. It was determined
that a contiguous design was preventing valve responsiveness to flow and leading to
fabrication of a stenotic valve. With these results in mind, alternatives for gelatin coating,
as well as polymer mesh density and leaflet architecture were considered. A gelatin
submersion technique, as
well as a single peaked
leaflet design and use of
more porous polymers were
developed for the third
iteration of the valve.

Figure 7-9: Gelatin integration around scaffold
Hematoxylin & Eosin sample showing gelatin integration at 100x (left)
and 200x (right).
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In the third iteration valve using low-density bioabsorbable polymer scaffold, each
leaflet was constructed with a mesh of different courses per inch (cpi), allowing for
monitoring of individual leaflet motion. Bioreactor analysis suggested that improvements
were made by switching from the stainless steel to a polymer mesh, but more
improvements are necessary to reach a fully functional tissue-engineered heart valve.
The third valve, a low-density bioabsorbable polymer scaffold, addressed the
issues discussed above and the tests were more successful. The results of testing in the
bioreactor showed an increase in the EOA of the valve during opening. The low-density
bioabsorbable polymer scaffold leaflets presented mechanical properties similar to native
heart valve leaflets, as a result of their compliance to flow. Tight closure of the leaflets
was observed with little or no backflow.
7.2.6 Conclusions
Our data suggests that by using the individual peaked leaflet design, the geometry
and movement of our valve more closely mimicked that of a native human aortic valve.
Combining a low-density, bioabsorbable mesh with a gelatin submersion technique
allowed for an increased EOA as well as more natural and flexible physiological motion
of the scaffold. Further advancements should include modification of suturing techniques
and improved gelation techniques to produce a more compliant scaffold while maintaining
structure integrity, thus increasing EOA.
Growth of fibroblast cells on the gelatin and mesh scaffold demonstrated that the
chosen materials could foster the growth of tissue. The growth of new tissue in parallel
with scaffold degradation will allow for preservation of the original valve architecture
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and ensure normal blood flow. Future work includes the growth of endothelial cells, the
native blood contacting surface, on the low-density bioabsorbable polymer scaffold and
exposing this construct to mechanical stimulation in the bioreactor. Mechanostimulation
is known to promote the growth of cells, and would lead to an improved design.
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7.3 Toward an Endothelial-Cell Covered Mechanical Valve; Surface ReEngineering and Bioreactor Testing of Mechanical Heart Valves
7.3.1 Abstract
Mechanical valve replacements for diseased heart valves have excellent long-term
durability, but necessitate a lifetime anticoagulation regimen. We aimed to create a more
hemocompatible device by modifying the leaflet surfaces to promote adherence and
retention of endothelial cells under physiological shear forces.
St. Jude Medical mechanical valves were autoclaved, plasma treated, coated with
a collagen/fibronectin solution, and seeded with porcine aortic endothelial cells. The next
day, the valves were placed in a custom-made bioreactor where pressures were gradually
increased until pulmonary or aortic pressures were reached. Conditioning continued for
7 days. Cellular retention, viability, and morphology were investigated using
Live/DEAD® staining, immunofluorescence for CD-31, and scanning electron
microscopy.
Results demonstrated successful adhesion of the collagen/fibronectin substrate to
the pyrolytic carbon surface. Complete endothelial coverage of the leaflet surface in the
static control group indicates that our surface modification approach created a suitable
environment for the cells to attach, proliferate, and remain viable. Moreover, after 7 days
of dynamic conditioning at pulmonary pressures, a significant portion of the endothelial
cells remained adherent to valve surfaces, improved cell coverage over static controls,
remained viable, increased cell-cell interactions, and maintained expression of CD31.
Similar results were seen at aortic pressures but with increased cell removal due to higher
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shear stresses. Further work is needed to improve cell retention in areas of high shear
stress, but surface modification and endothelial cell coating may ultimately aid in limiting
coagulation and reduce the need for anticoagulation medication in patients receiving
mechanical heart valve implants.
7.3.2 Introduction
The overall prevalence of heart valve disease, adjusted to the US 2000 population,
was 2.5%[160] with about 99,000 heart valve operations yearly.[157] Most of these
procedures were directed at repairing or replacing the mitral or aortic valve with either
a bioprosthetic or mechanical valve. Whereas the bioprosthetic valves function well with
usually no medication needed, many fail within 15 years of implantation.[56] The
mechanical valves have several positive attributes to their structure including strength,
durability, and ease of operation. However, they initiate thrombosis within the blood
stream because of the foreign surface as well as high shear forces.[161–163] To prevent
this process, the patient must be medicated with anticoagulants and blood-thinning
medication for their remaining lifespan. Even with the prescription of anticoagulants, the
patient is still at high risk for blood clots, which can cause stroke, myocardial infarction,
or pulmonary embolism.[164,165] Thrombosis can also cause the heart valve to
malfunction, requiring the patient to reenter surgery for repairs. Even if the anticoagulant
regimen successfully prevents clotting, there is still the increased risk of hemorrhages
associated with blood thinning medication.[166]
Endothelialization of blood-contacting surfaces with autologous cells to reduce
the implants thrombogenicity is a common procedure in the literature. For example,
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vascular grafts have been seeded with endothelial cells to improve hemocompatibility,
showing successful attachment of cells to vascular prostheses where the surface had been
modified using ePTFE and a collagen matrix.[167–169] Studies have also been
conducted to analyze the morphology of endothelial cells attached to vascular
prosthesis[114,170] as well as heart valves.[15,93,171]
Previous work has been performed with the idea of modifying a mechanical valve
surface to reduce or eliminate the amount of anticoagulants patients would need to
take.[169] In that experiment, researchers modified mechanical valves by seeding a
confluent layer of cells on the surfaces. The valves were then implanted into the mitral
position in pigs for one hour. Although cells initially attached to these leaflets, no cells
remained attached after explantation, possibly due to the shear forces of the blood on the
cells and their lack of initial attachment to the surfaces. A drastic improvement in cellular
retention under physiological shear forces is needed for this method of valve
improvements to be successful.
The long-term goal of the present study is to prevent thrombosis in patients with
mechanical heart valves by improving previous methods[169] of reducing the amount of
coagulation-causing factors and more specifically by generating endothelial cell-covered
mechanical valves. For this study, we hypothesized that surface modification will enhance
initial endothelial cell coverage and further retention under dynamic flow conditions. To
test this hypothesis, mechanical heart valves were treated with plasma for surface
activation, coated with a type I collagen/fibronectin matrix, seeded with endothelial cells
and maintained in static cell culture. Endothelial cell-seeded mechanical valves were then
subjected to flow and simulated pulmonary and aortic pressure conditions using our
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custom-made heart valve bioreactor. Viability tests, scanning electron microscopy and
immunofluorescence of dynamically challenged cell seeded valves showed that surfacebound endothelial cells remained attached to the modified valves, proliferated and
maintained their endothelial phenotype.
7.3.3 Materials and Methods
Overall, we first modified the surfaces of isolated leaflets from St. Jude Masters
Series mechanical heart valve via plasma treatment and matrix attachment. The modified
surfaces were analyzed with Coomassie Blue staining and scanning electron microscopy
to confirm matrix attachment and uniformity. Initial cell viability studies were performed
with fibroblasts. Endothelial cells were then used to further investigate the most effective
surface modification combination for this application. Cellular analyses were performed
by Live/DEAD® staining.
After obtaining the desired surface modification method and confirming its
cellular compatibility, we cultured and attached porcine aortic endothelial cells on the
outflow surface of intact St. Jude Master Series mechanical heart valves. These cell-seeded
valves were then dynamically tested under pulmonic and aortic pressures for seven days
using a previously described heart valve bioreactor.[117] Valves kept under static
conditions overnight and for 7 days were used as controls. We analyzed the cells via
Live/DEAD® imaging, scanning electron microscopy, and immunofluorescence for
morphology, coverage, and expression of the endothelial cell marker, CD-31 (PECAM),
respectively.
Surface Modification
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Sterilization, Surface Modification, & Matrix Attachment
Whole valves or individual leaflets removed from St. Jude Medical (St. Paul, MN)
Masters Series (AJ25) mechanical heart valves ( 1A) were sterilized via steam autoclaving.
After allowing the valves/leaflets to completely cool and dry, they were plasma treated
for 5 minutes using a Expanded Plasma Cleaner (PDC-001) from Harrick Plasma (Ithica,
NY) at 50 mTorr to modify the valve surfaces and promote protein attachment.[172]
Immediately after plasma treatment, the valves were placed in a sterile 6-well plate and
immersed in a collagen solution. The collagen solution was prepared by mixing (on ice)
4 parts 3.1 mg/mL PurCol type I collagen solution (Advanced Biomatrix, San Diego, CA),
4 parts ddH2O, 1 part 10X phosphate buffered saline (PBS) (Mediatech, Manassas, VA)
and 1 part 0.1M NaOH (Fisher Scientific). After matrix deposition was confirmed, 100 uL
of 1 mg/mL fibronectin (Sigma-Aldrich) were added to 7.5 mL of each collagen batch to
complete the collagen/fibronectin solution. The whole valves or individual leaflets were
then placed in a cell culture incubator (37oC, 5% CO2) overnight.
Quantification of Protein Adhesion
Individual leaflets (n=6) were autoclaved and distributed evenly into the following
treatment groups: Group 1 – with plasma, with collagen; Group 2 – no plasma, with
collagen; Group 3 – with plasma, no collagen. Leaflets were modified as above and rinsed
three times with 1X PBS. Following rinsing, 200 µL of Coomassie Blue stain solution (1%
Coomassie Blue R-250 in 10% methanol, 80% ddH2O, 10% acetic acid) was placed on the
leaflets for five minutes at room temperature. Leaflets were then rinsed with ddH2O and
three times with Coomassie Blue wash solution (38% methanol, 60% ddH2O, 2% acetic
acid) before adding 250 µL eluent solution (50% ethanol, 50% 50mM NaOH). After 30
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minutes, 200 µL of the eluent solution was transferred to a 96 well plate and absorbance
was measured in a Biotek plate reader at 620 nm with a reference of 450 nm. Eluent
solution was used as a blank.
SEM Analysis of Modified Surface
Scanning electron microscopy (SEM) was used to visualize the level of
homogeneity of the collagen solution on the leaflet surface. After sterilization, two leaflets
were plasma treated, coated with collagen solution as described above, and allowed to dry.
One additional leaflet was used as a control with no further modification after sterilization.
For SEM analysis, the leaflets were fixed in Karnovsky’s fixative (2.5% glutaraldehyde,
2% formaldehyde in 0.1 M cacodylate buffer, pH 7.4) for at least 24 h. Samples were
dehydrated in increasing ethanol concentrations until absolute alcohol was reached, then
stored in 100% ethanol for up to 12 hours. Following immersion in hexamethyldisilazane
(Polysciences, Inc., Warrington, PA) for 15 min, samples were left to air dry. Samples
were then coated with platinum for 2 min (Hummer 6.2, Anatech LTD, Union City, CA)
before imaging with a Hitachi S4800 or TM3000 Tabletop scanning electron microscope
(Clemson University Electron Microscope Facility, Anderson, SC).
Cellular Attachment
Initial Cell Viability Static Test using 3T3 Fibroblasts
Three leaflets were sterilized and plasma treated before applying the collagen
solution as described above. 3T3 fibroblasts (Cell Applications Inc, San Diego, CA) were
expanded in DMEM (Mediatech, Manassas, VA) with 10% FBS (Atlanta Biologicals,
Lawrenceville, GA) and 1% Antibiotic-Antimycotic (Ab/Am) Solution (Mediatech,
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Manassas, VA) and 80,000 cells were seeded onto each leaflet for 20 minutes before
adding additional media to each well to minimally cover the leaflet. Media was changed
ever 3-4 days for 21 days before analyzing with Live/DEAD® stain for viability as
described below.
Endothelial Cell Culturing
Porcine aortic endothelial cells (pAEC; Cell Applications Inc, San Diego, CA) were
cultured on cell-culture flasks coated with 50 µL/cm2 fibronectin solution (1 mg/mL;
Sigma-Aldrich) in a 20 µg FN/mL dilution. Cell culturing media consisted of MCDB-131
(Mediatech, Manassas, VA) with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1%
Antibiotic/Antimycotic (Mediatech, Manassas, VA), and 0.36 g/L of L-Glutamine
(Fisher Scientific) and passaging occurred at 80-90% confluence.
Live/DEAD® Imaging
Presence of live cells on valves and leaflets was analyzed using Live/DEAD® stain
(Invitrogen, Eugene, Oregon) according to manufacturers’ directions, using 20 µL of
EthD-1 and 5 µL of Calcein-AM in 10 mL of 1X PBS. The Live/DEAD® solution was
added to cover each sample and covered with foil at room temperature for 30 minutes
before fluorescent imaging with an inverted microscope.
Dynamic Bioreactor Conditioning
Mechanical Valve Seeding
The aortic surfaces of sterilized, plasma-treated, and matrix-coated valves were
aseptically seeded with porcine aortic endothelial cells (1,250,000 per leaflet) in 500 µL
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media in a 6-well plate. If any suspension flowed through, it was re-pipetted over the
valve. This process was repeated for 20 minutes. Valves and leaflets were submerged in
culture media (about 10 mL for valves and about 3 mL for individual leaflets) before
placing them in an incubator for overnight attachment. The next day, the valves were
processed according to dynamic and static conditions below. Media was prepared using
MCDB-131 with 10% FBS, 2% Ab/Am, 0.36 g/L L-Glutamine, and 0.2% Gentamycin
(50mg/mL, Sigma-Aldrich).
Dynamic Conditioning
The previously described Clemson Heart Valve Bioreactor[117] was used to
simulate the dynamic conditions placed on the valve. The entire assembly has been tested
thoroughly and has performed consistently in more than 35 experiments with various
reported[78] and unreported valve designs. The bioreactor was designed to allow for
mounting valves of various sizes and shapes, as well as allow proper exposure to
mechanical stimuli for preconditioning of valves.
Three valves tested under dynamic conditions were split between high (aortic
pressures of 120/80 mmHg, one valve) and low (pulmonary pressures of 40/25 mmHg,
two valves) pressure conditions. The valves were inserted into the bioreactor where 1.2
L of media was circulated through the system at 60 beats per minute, and roughly 20 mL
(1200 mL/minute) or roughly 10 mL (600 mL/minute) stroke volume for high and low
pressures, respectively. Both low and high pressure valves began at a pressure of 7 mmHg.
For progressive conditioning, systolic pressure was increased to 20 mmHg after 3.5 hours,
to 30 mmHg after 6.5 hours, and to 40/25 mmHg after 15.75 hours. The valve at low
pressure condition was left at this pressure until 7 days passed. The valve at high pressure
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continued to undergo pressure increases to 64/43 mmHg after 19.83 hours, 85/60 mmHg
after 24.72 hours, 100/75 mmHg after 27.12 hours, and 120/80 mmHg after 47.17 hours,
where it remained until seven days had passed. Media was changed after three days in all
bioreactor studies. On the seventh day, all the valves were removed and prepped for
Live/DEAD® imaging (one low pressure valve) or immunofluorescence (one low pressure
valve and the high pressure valve). After Live/DEAD® imaging, valves were fixed for
SEM as indicated below.
Static Controls
One valve and leaflet were processed after an overnight incubation under static
conditions. After overnight cell attachment, the valve was prepped for Live/DEAD®
imaging and SEM and the leaflet was prepped for immunofluorescence imaging. Another
valve and leaflet were placed in a 6-well plate with 10 mL and 3 mL of media, respectively.
The media was changed every 24 hours for seven days. The valve was then prepped for
Live/DEAD® imaging and SEM and the leaflet was prepped for immunofluorescence
imaging.
Immunofluorescence
Valves or leaflets for immunofluorescence imaging were rinsed with 10 mL of
warm 1X PBS 2 to 3 times and fixed for 30 minutes at room temperature in 4%
formaldehyde (BDH Chemicals). Following rinsing with 1X PBS, the bottom of the valves
was sealed with parafilm and placed into a custom made, pre-formed, silicone mold
(CopyFlex Liquid Silicone, Culinart, Inc.) to minimize volume needed for staining (Figure
7-10B). Samples were then blocked using 5% Bovine Serum Albumin (Rockland
Page | 140

Immunochemicals,
Gilbertsville,
0.05%

PA)

Triton

with
(BDH

Chemicals) in 1X PBS for 2
hours at room temperature.
The blocking solution was
removed and 1000 µL (250 Figure 7-10: Mechanical heart valves and testing methods
µL for leaflets) primary CD31/PECAM1
(VM64)

Antibody

(NBP1-42152;

Novus

Biologicals,

A) Masters Series mechanical heart valves provided by St. Jude Medical
showing the Dacron sewing rings, the inflow side (upper left), the
outflow side (upper right), and isolated leaflets (bottom). B) Silicone
mold used to minimize volume needed for staining during
immunofluorescence. Liquid silicone was poured into the wells and
covered with plastic wrap before pressing a closed valve into the
silicone. After curing, the valve and plastic wrap was removed to create
custom formed wells for mechanical heart valves and leaflets. C)
Absorbance readings of Coomassie Blue staining for proteins on
surface-modified mechanical heart valves. ECM = extracellular matrix.

Littleton, CO) in blocking
solution (1:2 dilution) was added for 1.5 hours at room temperature. The primary
antibody was removed before rinsing 4 times with 1X PBS. The secondary antibody,
Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand Island, NY) diluted in
blocking solution (1:2 dilution) was added for 1 hour at room temperature in the dark
followed by 4 rinses with 1X PBS. Finally, 500 µL DAPI stain (Sigma-Aldrich) was added
to each leaflet for 5 minutes at room temperature in the dark before fluorescent imaging.
Primary antibody was omitted for staining negative controls.
7.3.4 Results
Surface Modification
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The combination of autoclave
sterilization,

plasma

treatment,

and

submersion in the collagen/fibronectin
solution proved to be an effective method
to attach a cell-friendly matrix to the inert
surface of a mechanical heart valve.
Coomassie Blue elution analysis showed

Figure 7-11: SEM of leaflet surfaces

that collagen indeed attached to the Scanning electron microscope images of untreated

(A, B) and ECM-treated (C, D) leaflets at low (A, B) and
surface while confirming the necessity to high (C, D) magnifications.

use the combination of both plasma treatment and matrix submersion rather than either
one alone (Figure 7-10C). Plasma alone and ECM coating alone resulted in negligible
readings, whereas the combination of the two gave an expected reading for the presence
of proteins, demonstrating that significant levels of collagen had strongly bonded to the
pyrolytic carbon surface and were not rinsed away during the coomassie blue procedure.
SEM analysis (Figure 7-11) provided further visual evidence that a collagen-based matrix
formed on the leaflet surfaces in a fairly homogeneous distribution after plasma treatment
and submersion in the collagen solution whereas unmodified leaflets were still smooth.
Cellular Attachment
Initial cell attachment and viability tests using fibroblasts cultured on the leaflets
for three weeks demonstrated that the matrix-coated leaflet was well accepted by the cells
and did not appear to detach from the leaflet surface. Cells had proliferated to become
nearly 100% confluent in most areas (Figure 7-12). Under these static culture conditions,
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over 99% of the cells remained viable, demonstrating excellent cellular compatibility of
the re-engineered mechanical valve surfaces.
Dynamic Bioreactor Conditioning
In order to evaluate the ability of the re-engineered, endothelial cell seeded
mechanical valve surfaces to withstand dynamic conditions, we subjected valves to
conditioning in a valve bioreactor, with valves and leaflets incubated in static conditions
serving as controls. The bioreactor setup seen in Figure 7-13 served to supply and
simulate physiologic pressures and shear stresses on the mechanical heart valves, causing
them to fully open and close (Figure 7-13).
Static Controls
The valve processed after overnight attachment provides a control from which to
gauge cellular changes after seven days on the surface of the valve in the flow and nonflow conditions. Live/DEAD® (Figure 7-14A-C), SEM (Figure 7-15A-C), and
immunofluorescence (Figure 7-16A, B)
imaging
conditions

of

the

valve

revealed

under

the

static

successful

attachment of endothelial cells onto the reengineered surfaces. The Live/DEAD®
stain showed the majority of the cells
fluorescing green rather than red, showing Figure 7-12: Fibroblast coverage of leaflets

Live/DEAD® staining (live=green, dead=red) of
excellent initial cell viability. Endothelial fibroblasts seeded on the surface of a mechanical
heart valve leaflet after 21 days in static culture
conditions. A) shows cells on the rounded edge of the
cell attachment was successful on all areas leaflet, B) in a central region and C) on the straight
edge.
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of the valves, with cells
appearing as spindle to
triangular

shaped

and

exhibiting no uniformity in
cellular alignment. A nearly
confluent layer of cells was
present on the static valves
Figure 7-13: Bioreactor system and valve opening

after overnight incubation. A) Overview of the bioreactor system used for testing endothelial cell-

seeded mechanical valves under dynamic pulmonary and aortic
However, small void spots pressures. The pneumatically driven, pressure controlled valve
bioreactor 18 is housed inside the cell culture incubator and controlled
were still present, which remotely by LabView via a custom made electronics box utilizing the NI6008 controller connected to a desktop computer. B,C) An endothelial
cell-seeded mechanical valve in open (B) and closed (C) positions during
apparently left room for cell dynamic testing.

proliferation

to

provide

almost complete coverage of the valve, which was seen after seven days (Figure 7-14DF, Figure 7-15D-F, and Figure 7-16B). Most of the cells retained their spindle shape and
exhibited tendency to align in swirl patterns, but noticeable distinctions are seen between
cellular alignment and morphology between time points, especially in the higher
magnifications. These results indicate that the extracellular m atrix created through our
resurfacing protocol is a suitable environment for the cells to proliferate and survive. The
positive CD-31 staining (Figure 7-16A, B) demonstrates the ability of our matrix to
facilitate a monolayer coverage of anti-thrombotic endothelial cells, which is a key
component to our objective of reducing thrombogenicity of mechanical heart valves.
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Dynamic Testing
The imaging of the dynamic seven day valves under pulmonic pressures revealed
three distinct zones of cell coverage (Figure 7-14G-I). The first region is the edge of the
valves, where most cells were no longer present after seven days of dynamic conditioning.
This region composed roughly only 10% of the total leaflet area. Moving inward from the
edges, region two is described as the area of slightly less dense cell coverage than the
central regions (region three). In these slightly less dense regions, the cells apparently

Figure 7-14: Cell coverage of leaflets after testing by Live/Dead
Live/DEAD® staining (live=green, dead=red) of aortic endothelial cells on the surface of modified
mechanical heart valves in static overnight group (A, B, C), static seven day group (D, E, F) and dynamic
pulmonary seven day group (G, H, I). The upper row (A, D, G) shows the middle of the valve where the two
leaflets join together. The middle row (B, E, H) shows the hinge or edge of the valve where the leaflet inserts
into the outer ring. White lines in G and H show the edges of the leaflet. H shows the central region (right)
as well as the edge region of the leaflet (left).
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exhibit a larger surface area with a more rectangular morphology than the spindle shape
seen in the central regions. In this third region (about 85% of the leaflet area), the spindle
shaped cells do not exhibit a complete uniformity of alignment, but long bands of 10-30
cells in width are conforming to a single alignment in swirling patterns across the leaflet.
Compared to the static valves, the pulmonic pressure valves had more complete
cell coverage of the pyrolytic carbon. The small gaps that existed after static conditions
were not present in the dynamic valves. This could be seen in the Live/DEAD® images
in Figure 7-14F and Figure 7-15I, but was more clearly noticed in the SEM images in

Figure 7-15: Cell coverage of leaflets after testing by SEM
Scanning electron microscopy images of aortic endothelial cells on the surface of modified mechanical heart
valves in static overnight group (A, B, C), static seven day group (D, E, F), and dynamic pulmonary seven day
group (G, H, I). Note that under dynamic pulmonary conditions endothelial cells are forming a flat sheet
with numerous cell-cell junctions that makes it difficult to distinguish the individual cellular boundaries (I).
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Figure 7-15F and Figure 7-16I where the cells formed more complete junctions almost
appearing as a cell “sheet” with fewer spaces in the dynamic conditions than in the static
conditions. The SEM images in Figure 7-15 also revealed that in both static and dynamic
conditions, the cells appear to be quite flattened on the pyrolytic carbon surface.
Bioreactor conditioning under pulmonic pressures apparently resulted in stronger,
more consistent CD-31 expression than under static conditions (Figure 7-16B, D). Under
aortic pressures, cells remained attached to the valve and continued to express CD-31
(Figure 7-16, F).
Conditioning under aortic pressure conditions had similar results to that of
pulmonary conditions, but fewer cells apparently remained attached to the mechanical
valve surfaces. Lower cell retention was expected for the dynamic valve under high

Figure 7-16: Cell coverage of leaflets after testing by immunofluorescence
Immunofluorescence images for CD-31 marker (red) and dapi stain for nuclei (blue) of aortic endothelial
cells on the surface of modified mechanical heart valves in static overnight group (A), static seven day group
(B), dynamic pulmonary pressures seven day group (C, D), and dynamic aortic pressures seven day group
(E, F). Inserts in A, and B are immunofluorescence negative controls.
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pressure because of the greater shear force and stress. Overall, we noted good cell viability,
retention, and CD-31 expression (Figure 7-16E, F) for the cells under aortic conditions.
7.3.5 Discussion
Surface Modification & Cellular Attachment
The objective of the present study is to modify the surface to allow for complete
endothelial cell coverage of the pyrolytic carbon mechanical heart valve leaflets and
enhanced retention under shear forces. A collagen/fibronectin matrix was used for leaflet
re-engineering because of their biocompatibility and documented facilitation of cell
attachment[167] as well as cellular integrin’s ability to strongly bind to the RGD
sequences found on the fibronectin strand.[173,174] These features allow strong initial
attachment of cells and subsequent extracellular matrix formation.
We successfully attached our collagen/fibronectin matrix to the autoclaved leaflet
surfaces after modifying the pyrolytic carbon surface through plasma treatment, which
proved to be necessary for the matrix to attach. Plasma treatment uses free radical
chemistry to clean, micro-etch, crosslink, and surface activate the material. This
treatment can result in a 2 to 10 fold increase in protein adhesion.[172] From our initial
data, it is apparent that the collagen matrix completely and evenly bonded to the surface
of the pyrolytic carbon through functional groups. Whereas Bengtsson and associates
have previously demonstrated complete endothelial cell coverage on pyrolytic carbon
through manual seeding with no surface modification,[169] our studies show that not
only do both fibroblasts and endothelial cells attach to the collagen/fibronectin coated
valves, but that the matrix actually promotes a more complete cell coverage of the valve
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over non-altered valves at these seeding densities (data not shown). Although not the aim
of this particular study, we speculate that fibroblast pre-seeding, as a preamble to
endothelial cell seeding, might further improve the stability of the ECM bound to the
pyrolytic carbon surface.
Successful seeding of endothelial cells on to the modified mechanical valve was
demonstrated by the results of immunofluorescent and SEM imaging. Images of the
overnight time point under static conditions suggest that the seeding method used was
sufficient in creating an even layer of cells on the entire leaflet. After seven days of growth
in static conditions, a nearly confluent endothelial monolayer was achieved on the
mechanical valve, but small gaps still appeared between cells, possibly signifying a lack
of cell-cell interactions that was present in the dynamic conditions. A more spindle shaped
than triangular shape was also seen after seven days in static conditions. This shape
reduces cell area, and since cell coverage appeared to be similar or greater after seven
days, suggesting that cell spreading, rearrangement, and ultimately proliferation is
taking place. Thus, imaging of the static valves supports the hypothesis that the
collagen/fibronectin matrix bound to plasma-activated pyrolytic carbon surfaces is not
cytotoxic.
Bioreactor Conditioning
Subjecting the cells to mechanical conditions in the heart valve bioreactor was
necessary to demonstrate the ability of the matrix modified leaflet to retain cells under
native conditions before further animal testing. It was also important to test their ability
to maintain their phenotype in dynamic conditions to ensure a non-thrombogenic surface.
The heart valve bioreactor previously developed by our lab,[117] which creates nutrient
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transfer and pressures similar to that of the heart, was utilized to simulate dynamic
conditions. Valves conditioned using the bioreactor showed a difference in cell coverage,
cell morphology and alignment, cell-cell interactions, and CD-31 expression compared to
valves in static conditioning.
The valve under pulmonic pressures of 40/25 mmHg exhibited better cell
coverage in the central 90% of the leaflet compared to valves under static conditions
overnight, as the cells closed the gaps between cells that were present in the static valves.
The outer 10% of leaflet area, especially around the hinges, contained very few cells
possibly due to the shear forces on the cells.[175–177] A further increase of shear forces
on the cells under aortic pressures of 120/80 was correlated to a decrease in final cell
coverage. The large numbers of cells present on the surfaces after 7 days of exposure to
aortic pressures indicate that our approach could yield non-thrombogenic mechanical
valves. However, since mechanical heart valves are already known to cause hemolysis due
to high shear forces around the leaflet edges and hinges, these areas vacant of cell
coverage pose an obstacle to reducing hemolysis. Ideally, full coverage of the leaflets is
desired, especially around the areas with higher shear stress to mitigate the risk of
hemolysis and the resulting cascade of health issues.
Cell morphology, orientation, and alignment under dynamic conditions was
similar to that in static conditions after seven days, but the attached cells appeared longer,
more flattened, and had a larger surface area under the dynamic conditions. The complete
coverage in dynamic conditions also leads us to believe that the cells are proliferating, as
in the static conditions.
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SEM imaging suggested that the cells are not only flattening out, but also
interacting with one another more under dynamic conditions than static conditions. This
might be promising for the creation of a continuous monolayer of cells to reduce
thrombogenic effects of the foreign surface. The expression of the endothelial cell marker,
CD-31, under both static and dynamic conditions demonstrates that the cells appear to
retain their endothelial phenotype and therefore their anti-thrombotic function while
attached to the surface of the mechanical heart valve. Clinically, this means that an
autologous endothelial-cell coated mechanical heart valve would create a nonthrombogenic surface, thus possibly limiting coagulation occurring in patients receiving
mechanical heart valve implants.
Challenges in Heart Valve Recellularization
Providing a confluent endothelial cell surface on any blood-contacting surface is
a common objective among regenerative medicine cardiovascular implants. Achieving
such is not simple. We have faced many obstacles and questions in the search for a method
to do this with a mechanical heart valve. Bonding a matrix to the pyrolytic carbon for
improved cell attachment may be one breakthrough in this challenging task. However,
this study has several limitations and opens avenues for further studies with every
question we face.
First, what treatment to the valve surface would facilitate a more complete cell
coverage and stronger bond for the cells upon subjection to shear stresses, especially on
the inflow side where larger forces are seen than on the outflow side of the valve?
Alternative matrix components or concentrations could yield results that are more
favorable.
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Second, what progressive mechanical conditioning regime would allow more cells
to remain attached? Further studies should examine incubating the cell-seeded valves
under static conditions for several days before subjecting the valves to dynamic conditions
and/or slowing the rate of increase in progressive adaptation to reach physiologic
pressures. Our studies progressed to aortic conditions over two days whereas recent
experiments indicate that progression lasting up to three weeks may be necessary.
Third, if cells can be retained to reach physiological conditions, how would they
phenotypically and morphologically respond to appropriate conditions of shear and valve
opening/closing speeds? Studying cellular response with appropriate flow rates and after
adding a thickening agent such as dextran to the media may help answer these questions.
Finally, will the layer of endothelial cells on a mechanical valve leaflets
functionally reduce thrombogenicity of mechanical heart valves? It is well documented
that high shear forces around the valve – not contact with the pyrolytic carbon surface –
is responsible for hemolysis leading to clotting. Functional thrombogenicity in in vitro
testing with whole blood or purified platelets, as well as in vivo large animal implantation
as valve substitutes are required for validation of this mechanical heart valve re-surfacing
and re-engineering approach.
7.3.6 Conclusions
Surface modification of mechanical heart valves via plasma treatment facilitates
attachment of a cell-friendly surface layer of matrix proteins, which supports endothelial
cell attachment, spreading, and proliferation in static conditions. In short-term dynamic
conditioning under physiologic pressures, the new endothelial monolayer maintains
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viability, cell-cell interactions, and endothelial phenotype. Although the cell retention in
these studies is promising, improvements are greatly needed when subjecting the cells to
physiologic shear stress, especially in areas around the edges and hinges of the leaflets.
This is intensified when considering that the preservation of the endothelial coating on
the leaflet in areas subjected to high shear forces will determine the success of reducing
thrombogenic effects caused by mechanical heart valves. Work is needed to develop a
progressive pre-conditioning regime that maintains cell attachment before steady
subjection to pulmonic or aortic pressures and flow. Additionally, further in vitro and in
vivo testing is necessary to demonstrate the decreased thrombogenicity of endotheliumcovered mechanical heart valves. Success of such advances could ultimately aid in
reducing the need for anticoagulation medication in patients receiving mechanical heart
valve implants.
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7.4 Discussion of Bioreactor Applications
The bioreactor systems developed have numerous applications for tissue
engineering, mechanical testing, and pharmacological development. In all, dozens of
experiments have been performed with these systems and improvements have been made
with each through the knowledge learned about the system. The resulting small footprint,
ease of assembly, modularity, and means of sterile media exchange have led to a truly
platform system that can be utilized in many fields.
Beyond tissue engineering and testing heart valves, the platform bioreactor
system has great potential for developing in vitro models for comparing drugs and
screening potential treatments for diseases. Animal models do not fully reproduce human
pathology and are difficult to combine multiple risk factors seen in dialysis-sustained
ESRD, besides their restrictive cost considerations. A testing platform to would assist in
the development of such a pharmacological treatment for aortic valve disease.
While many systems described in the literature or that are commercially available
can perform a single function well, this system has been shown to perform multiple
functions well with a simple change of module when necessary. It can provide a variety
of normal and pathologic physiological conditions including those for aortic and mitral
valves while maintaining a sterile environment to precondition a tissue-engineered valve.
These conditions can also be made to mimic diseased states for evaluating drug treatment
regimens. It can be used on the benchtop to test the opening of a valve, TAVR valve
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placement, and perivalvular leakage. It can assist in the training of transcatheter
deployment of replacement valves and allows visualization and video capture of cusp
movement regardless of location. Furthermore, it is compact enough to fit four
independently controlled systems inside a standard cell culture incubator. The described
experiments have demonstrated the utility of this system and are but a sampling of its
capabilities.
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CHAPTER 8: TISSUE

ENGINEERED

HEART

VALVE

CONDITIONING
8.1 Introduction
The key to achieving an implant capable of repairing itself in response to micro
tears is the presence of cells to remodel the matrix as necessary.[35,37] In cases where
the valve implant does not have the adequate mechanical properties to function properly
upon implantation, in vitro cellular remodeling must prepare the valve scaffold prior to
implanting.[89–91] Multiple groups have demonstrated cell seeding on the exterior
surface of valve cusps and some have even achieved some interstitial seeding, though full
revitalization has not been realized.[92–94] The surfaces of some valves have even been
repopulated after implantation in animal models,[95,96] but the same is not guaranteed
in the human system. Even if the valve can be initially covered with cells,[73,97,98] it is
likely that these cells will need some sort of progressive conditioning to remain attached
after implantation since application of sudden shear forces can detach cells. Overall, more
progress is needed to achieve full and consistent external and internal recellularization of
the cusps and to determine what methods are needed to allow the cells to remain, but
autologous adult stem cells provide a promising source for this application.[99,100]

8.2 Materials and Methods
8.2.1 Study Overview
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described
in section 3.3.1. Aortic roots were decellularized by 16-day perfusion as in section 4.2.3
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or in the case of one valve, by 8-day immersion as in section 4.2.2. All valves were then
crosslinked with PGG as in section 4.2.4. Prior to seeding, valves were neutralized for
18-24 hours in DMEM with 50% FBS and 1% Antibiotics/Antimycotics at 37°C. Stem
cells were cultured as in 5.2.2. Many cell-seeded valves were tested for this compilation
study, but due to device failures, data for only 13 valves will be reported. Additionally,
valves evaluated for initial cell placement (internal and external) have been reported in
Chapter 5: and details will not be repeated here.
One valve was externally seeded with 16 million cells by method 1 of section 5.2.6
before being placed in the bioreactor for progressive conditioning and testing. Results
from this trial indicated that additional preconditioning was necessary. Following the
first experiment, 10 more valves were internally seeded with 4 million cells at passage 6
per cusp as in section 5.2.5. Six of those valves were also externally seeded with 30 million
cells at passage 6 by method 2 of section 5.2.6. Furthermore, three of the latter group
were seeded as above and successively seeded with an additional 30 million cells at
passage 7 by method 3 of section 5.2.6. A summary of the cell-seeded valves can be seen
in Table 8-1.
Initially seeded valves were described in Chapter 5:. Internally and externally
seeded valves were investigated for each group, but are often contained in the same valve,
leading to a seemingly high total sample size. Final test groups can be seen in Table 8-2
and include:
1) Static controls (ST): Valves kept in the incubator with media changes every
two days, daily, or 2 hours as necessary.
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2) Rotationally conditioned (RC): Valves conditioned by the seeding chamber
frame described in section 5.2.3.
3) Rotationally and bioreactor conditioned (RCBR): Valves rotationally
conditioned then bioreactor conditioned with the third (section 6.2.2) or fourth
(section 6.2.3) edition bioreactor.
4) Bioreactor conditioned (BR): Valves conditioned in the third (section 6.2.2)
edition bioreactor immediately after cell seeding.
After appropriate conditioning, valves were analyzed for cellular attachment,
spreading, retention, alignment, and viability using the Live/DEAD® assay, scanning
electron microscopy (SEM), histology, or immunohistochemistry as appropriate for each
group.
8.2.2 Static Controls
For the static valves, sterile filters were attached to the needleless ports in the lid
of the chambers and the seeding chambers remained in the cell culture incubator for 1315 days. Media was changed every two days, daily, or12 hours as necessary based on pH
colorimetric indicators in the media.

Table 8-1: Summary of cell-seeded valves
Number
Internal Seeding
Primary External Seeding
of Valves
1
0
Method 1: 16e6 cells, p5
6
4e6 cells/cusp, p6
0
6
3
4e cells/cusp, p5/p6
Method 2: 30e6 cells, p5/p6
6
2
4e cells/cusp, p5/p6
Method 2: 30e6 cells, p6
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Secondary External Seeding
0
0
0
Method 3: 26e6 cells, p7

8.2.3 Pulmonic Bioreactor Conditioning and Testing without Rotational Conditioning
After external seeding, distal aortic root stabilizers (section 3.2.5) were added to
each valve root for support during bioreactor conditioning and testing. The valves were
transferred to the pre-assembled third edition bioreactor, where pressure was increased
every 12 hours until final pulmonic parameters were reached, as seen in Figure 8-1.
Upon reaching final pressures of 40/25 mmHg and flow of roughly 30 mL per
stroke at 75 beats per minute (bpm), valves were tested for an additional 13 days before
analysis for a total of 17 days in the bioreactor. Media was changed every 3.5 days (twice
per week) throughout conditioning and testing.
8.2.4 Rotational Conditioning
After the desired internal and external seeding, valves were conditioned further
in the rotating chambers. The end-over-end rotating chamber holding plate was attached
to the frame and needleless ports were attached to each seeding chamber. The chambers
were placed into the chamber holder plate. Rotating and orbital conditions progressively
increased every 12 hours until a shaker speed of 40% and rotational speed of 4 rpms were
achieved for short-term conditioning. Long-term conditioning followed the schedule seen
in Table 8-3 with media changes occurring during every adjustment (roughly every 12
Table 8-2: Test groups for valve seeding experiments
Number Internal
Group
Seeded Vavles
Initially Seeded
2
Static (ST)
1
1
Rotationally Conditioned (RC)
3
1
Rotationally and Biroeactor
Conditioned (RCBR)
1
Bioreactor Conditioned (BR)
2

Days
0
13
13
23-25
8
29
23

Page | 159

Number External
Seeded Valves
2
1
1
1
1
1
1

Days
0
13
13
25
8
29
17

hours) after day 3. Position
A (holder orientation) from
previous rotation angles
was not monitored from
this point on. After 13-15
(short term) or 23-25 (long
term) days of rotational
conditioning, valves were

Figure 8-1: Bioreactor preconditioning without rotation conditioning
This trial reached pressures of 40/25 within 4 days.

analyzed or transferred to the bioreactors for adaptive conditioning and testing.
Media was changed every two days, daily, or every 12 hours as necessary based
on pH colorimetric indicators in the media. For these changes, the chambers were
removed from the frame and drained by vacuum through a needleless port with an empty
50 mL syringe attached to the other port to allow sterile air into the system. Following
draining, about 130 mL of cell culture media was added to each chamber (until the media
just covered the stainless steel mounting rings). The syringes were removed and the
chambers placed back into the chamber holders with the 0° mark aligning with the set
mark on the holding plate and rotated.
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Table 8-3: Conditioning regimen
Position B
(rotation in
Time
holder)
Set
Day #
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark
0° on set mark

16:00
05:20
13:40
22:15
10:05
23:15
14:00
20:32
11:35
21:45
11:25
23:45
13:00
22:45
11:00
22:00
13:30
04:30
20:30
11:45
20:00
16:30
13:00
21:00
Missed
18:45
12:00
22:30
14:00
22:00
12:00
23:30
20:00**
12:45
02:00
20:00
10:50
23:00
17:30
09:00
20:00
14:00
22:45
17:30
10:30
23:45

1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23

Shaker
Speed
10%
20%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%

Rotator
Speed
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20

Rotating
Time
(seconds)
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800
1800

Pause Time
(seconds)
540
540
360
360
180
180
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Cycles
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

8.2.5 Pulmonic Bioreactor Conditioning and Testing with Rotational Conditioning
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After 5 or 25 days of the above rotational conditioning, distal aortic root
stabilizers (section 3.2.5) were added to each valve root for support during bioreactor
conditioning and testing. The valves were transferred to pre-assembled third (for 5 day
conditioned valves: “short pre-conditioned”) or fourth (for 24 day conditioned valves:
“long pre-conditioned”) edition bioreactors (see section 6.2.3 for details of this system).
The short pre-conditioned valve was increased to 25/15 mmHg at 75 bpm and a
stroke volume of 35 mL over the course of eight days (Figure 8-2). Increases in pressure
occurred every 12 hours. At each increase, systolic pressure was increased by 0.5 mmHg
each time for the first five days and 4 mmHg each time for the final 3 days. Media was
changed every 3.5 days (twice per week) throughout conditioning. Upon reaching final
pressures of 25/15 mmHg and flow of 35 mL per stroke, valves were analyzed by
Live/DEAD, histology, and immunohistochemistry.
8.2.6 Live/DEAD® Imaging
Presence of live cells on tissue surfaces was analyzed using Live/DEAD® stain
(Invitrogen,
Oregon)

Eugene,
according

to

manufacturers’ directions,
using 20 µL of EthD-1 and
5 µL of Calcein-AM in 10
mL

of

1X

PBS.

The

Live/DEAD® solution was
added to cover each sample Figure 8-2: Bioreactor preconditioning without rotation conditioning

This trial reached pressures of 25/15 within 7 days after rotation
conditioning for 5 days.
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and covered with foil at 37°C for 20 minutes before fluorescent imaging with an inverted
microscope.
8.2.7 Histology and Immunohistochemistry
For histology studies, samples collected from the aortic wall, sinus, cusp and
muscle were fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm (3 µm for the
aorta), and stained with DAPI for nuclei, Hematoxylin & Eosin (H&E), and Movat’s
Pentachrome.
Immunohistochemistry (IHC) was performed to detect remaining components
after decellularization. Biotinylated Griffonia simplicifolia (GS) lectin was used to detect
Gala1–3Gal (a-Gal), the main porcine antigen responsible for acute rejection of
xenotransplants. IHC for laminin, and type IV collagen was also performed. Tissue
samples were rinsed with 1X PBS fixed at room temperature in 4% formaldehyde (BDH
Chemicals). Following rinsing samples were blocked using 5% Bovine Serum Albumin
(Rockland Immunochemicals, Gilbertsville, PA) with 0.05% Triton (BDH Chemicals) in
1X PBS for 2 hours at room temperature. The blocking solution was removed and 250
µL primary CD-31/PECAM1 Antibody (VM64) (NBP1-42152; Novus Biologicals,
Littleton, CO) in blocking solution (1:2 dilution) was added for 1.5 hours at room
temperature. The primary antibody was removed before rinsing 4 times with 1X PBS.
The secondary antibody, Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand
Island, NY) diluted in blocking solution (1:2 dilution) was added for 1 hour at room
temperature in the dark followed by 4 rinses with 1X PBS. Finally, 500 µL DAPI stain

Page | 163

(Sigma-Aldrich) was added to each slide for 5 minutes at room temperature in the dark
before fluorescent imaging. Primary antibody was omitted for staining negative controls.

8.3 Results and Discussion
8.3.1 External Cell Response
As shown previously and repeated in Figure 8-3, initial cellular attachment to the
cusp surfaces was very successful with method 1. However, the surfaces of the sinus and
aortic wall required additional seeding. Utilizing methods 2 and 3 have resulted in
excellent initial cell coverage of those areas as well.
Cell-seeded valves were placed directly into the bioreactor for 17 days. As a result
some cells remained attached to the valve and were further spread and aligned than static
controls and initial time points. However, many of the cells had been removed from the
scaffolds, presumably because of the applied shear stresses. We believed that a gentler
pre-conditioning regimen, including more time in the rotating seeding chambers, would
increase cellular retention. Studies were performed to evaluate the effect of increasing the
cell quantity, rotational conditioning time, and the time it took for the bioreactor to reach
full pulmonic conditions. A summary of this data can be seen in Figure 8-3.
Valves conditioned in the rotating conditioner for 13 days are subjected to lower
shear stresses than those in the bioreactor and thus, they retained full cell coverage on
both sides of the cusp with similar, but less noted spread and alignment compared to
bioreactor valves. This indicates that a substantial layer of cells was growing on the
surface of the cusps prior to bioreactor conditioning.
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Figure 8-3: External and Internal cell seeding and retention
Live/DEAD® and H&E imaging of fresh valve cusps (A-C) in comparison to valves initially seeded (DE), static for 13 days (G-I), bioreactor conditioned for 13 days (J-L), rotating conditioned for 13 (MN, R), 15 (O), and 24 (S) days, and rotating conditioned for 5 days then bioreactor conditioned for
8 days (P-Q). (R) is internally and externally seeded.
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Valves were placed in rotational conditioning regimens for 5 and 25 days prior to
being placed into the bioreactor. Once in the bioreactor conditions were slowly increased
until 25/15 mmHg at 75 bpm was reached. The first set of valves achieved 35 mL per
stroke and was cultured in the bioreactor for a total of 8 days. The second set of valves
achieved 70 mL per stroke and 2.5% dextran and was cultured in the bioreactor for a total
of 29 days. Surface imaging indicated that the 5-day rotational pre-conditioning was
inadequate. Similar or fewer cells remained on the valve surfaces for this experiment than
the previous bioreactor experiment having no rotational conditioning. The second set of
valves took that into consideration and had an extensive rotational conditioning step
before being placed into the bioreactor.
Unfortunately, during the rotational conditioning, it is likely that many of the
cells died due to a pH imbalance. As the conditioning progressed, the pH in the media
inside the seeding chambers was dropping, as indicated by the phenol red indicator
turning orange faster and faster). At one point, an extended period elapsed between media
changes (indicated by ** in Table 8-3). After this time point, the media did not change to
orange nearly as fast. Initial evaluations of the valves indicated that most of the cells had
been removed from the scaffold surfaces. Despite this, one valve was placed in the
bioreactor in case external cells remained on that valve or the internally seeded cells were
still viable.
Overall, additional rotational conditioning is necessary for cell retention once the
valves are placed in the bioreactors. However, improved devices, methods of gas exchange,
and protocols must be investigated to reduce the chances of the seeded cells dying during
this phase.
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8.3.2 Internal Cell Response
Internal seeding of hADSCs into porcine aortic valve cusps yielded promising
results. Initial cell placement was concentrated in boluses at the injection sites with
improved initial distribution near the base of the cusps. Static and short-term rotational
conditioning yielded little to no cellular migration. However, after 24 days in rotational
conditioning and bioreactor conditioning, cells were beginning to migrate into the
surrounding tissue layers (see especially Figure 8-3O). Although slow and not ideal, this
method of repopulating the internal areas of the aortic cusps has yielded promising results.
Immunohistochemistry (Figure 8-4) of the injected cells immediately after
injection and after 24 days in the rotating conditioner or bioreactor conditioner

Figure 8-4: Immunohistochemistry of conditioned internal cells
Slides stained for Vimentin, alphs-SMA, and P4HA3 immediately after injection and after 24 days in the
bioreactor or rotating conditioner.[140]
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demonstrated some changes in marker expression. Notably, alpha-smooth muscle actin
had a higher expression after bioreactor conditioning than rotating conditioning. The
expression of this marker indicates a myofibroblast-like phenotype typical of cells that
are remodeling their matrix.
Further IHC analysis suggests that the cells undergoing rotational conditioning
resemble q-VICs. There is strong expression of vimentin and little to no true staining for
α-SMA and prolyl-4-hydroxylase. These reports are promising, as the goal of achieving
a quiescent-VIC phenotype is ideal prior to further mechanical conditioning.
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CHAPTER 9: ANIMAL IMPLANTS OF TISSUE ENGINEERED
HEART VALVES
9.1 Introduction
Laboratory research is often disconnected from clinical practice. One day, we may
be able to develop a functional tissue engineered valve, but if the technology cannot be
utilized in a clinical setting, it may be necessary to revise the technology from a
fundamental level. If we can adapt our laboratory practices to consider clinical
requirements during the research and development stage, translation into clinical practice
will be more easily realized. Initial animal trials must be performed to reveal hurdles we
will need to overcome in our process of translating tissue engineered heart valves into
clinically relevant products. We will then be able to adapt our laboratory practices to
consider clinical requirements during the research and development stage.
Our initial investigations into animal implantation revealed a necessity for many
of the specific features of the devices described in previous chapters. For example, it was
vital to have a user-friendly valve mounting system that will be used to house the valve
from initial cleaning to just before implantation with minimal to no handling of the valve
itself. This chapter will describe the experiments made possible by the technologies and
research previously described. Herein, we aim to generate implantable tissue engineered
heart valves by optimal integration of three main factors: acellular heart valve root
scaffolds, autologous stem cells, and construct preconditioning in a bioreactor. As the
study continues, additional translational challenges will inevitably necessitate further
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alterations to our laboratory protocols for valve preparation as we translate the
laboratory research into a clinical setting
By implanting these tissue engineered heart valves, we will be implanting the first
stem cell seeded heart valve in an animal model to eliminate the risk of immune response
due to remaining cells. These studies will also help to demonstrate that translational
regenerative medicine is feasible with autologous stem cells for tissue engineering
replacement therapy – a vital stage in the ability to remove barriers in commercializing
tissue engineered products.[68,123–125]

9.2 Materials and Methods
The research team in Targu Mures, Romania has prepared acellular porcine valve
scaffolds using the devices and methods developed in chapters 3 and 4. They will isolate
adipose derived stem cells from sheep, multiply them in culture, and use them to
repopulate the acellular scaffolds as in chapter 5. They will then precondition the cellseeded scaffolds using rotational conditioning methods developed in chapter 8. After
preconditioning, the surgical team will implant the autologous cell-seeded tissueengineered valves in a right ventricle to pulmonary artery shunt in the young adult sheep
from which the cells were originally taken. Future studies will analyze these valves at 6and 12-month time points at the macroscopic and microscopic level for calcification,
necrosis, structural damage, cell infiltration, and cell retention.
9.2.1 Primary Stem Cell Isolation and Culture
Sheep adipose-derived stem cells (sADSCs) were isolated (Figure 9-1) from wellvascularized, soft subcutaneous fat samples in the rear subscapular region under sterile
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conditions and anesthesia from
individual

animals.

Established

collagenase

digestion

protocols[178]

were

used

to

isolate the stem c ells, which
involved

cutting

the

tissue

fragments into small pieces and
digesting with 20 mL/50 mL tube Figure 9-1: Stem cell isolation from sheep
collagenase

type

I

After cleaning and antiseptic treatment (A), fat tissue is

(Sigma) collected from subcutaneous, highly vascularized subscapular

regions (B), and transported to the lab for immediate stem cell
1mg/mL 1% BSA, PBS at 37°C, 1 isolation (C) before the wound is closed and treated with local
antiseptic (D).

hour with agitation in the water
bath. Tissue digest was filtered through 100 µm sieves into new 50 mL tubes and
centrifuged at 1000 rpm for 5 minutes before aspirating the supernatant. The cell pellet
was resuspended in 155 mM NH4Cl with 0.1 mM EDTA in PBS and incubated 5-10
minutes at room temperature to lyse red blood cells. After another centrifugation at 1000
rpm for 10 minutes, the supernatant was aspirated and the pellet was resuspended in
DMEM with 10% FBS and 2% Antiobiotics/Antimycotics and plated. Media was changed
every 3-4 days and passaged with trypsin at 70% confluence
9.2.2 Scaffold Preparation
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described
in section 3.3.1 with the restriction that the donor pigs weigh between 45-50 kg. Aortic
roots were decellularized by 16-day perfusion (section 4.2.3) techniques, crosslinked with
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PGG as in section 4.2.4 (later trials also utilized RapidGlut as in section 4.2.5), and
neutralized for 18-24 hours in DMEM with 50% FBS and 1% Antibiotics/Antimycotics
at 37°C.
9.2.3 Stem Cell Seeding
Stem cells were isolated from sheep and cultured as described above. Each primary
source of cells was tracked and a single source of cells was used to seed valve scaffolds
internally with 4-6 million cells per cusp as in section 5.2.5. The remaining cells from the
culturing were is suspension, but the valve position was not controlled during rotation
and pausing.
9.2.4 Valve Conditioning and Preparation for Implantation
After seeding, the valves were conditioned further in the rotating chambers by
simple rotation in the incubator. Media was changed every two days until implantation.
Each valve was tracked for final implantation into the same sheep from which the cells
came for an autologous tissue engineered implant.
Before implantation, conduits of decellularized bovine pericardium were attached
to the proximal and distal segments of the valve root by a continuous suture (Figure 9-2A
& B). This created a pipeline for the valve that will be intercalated between implant
locations for routing of the host circulation.
9.2.5 Surgical Procedure: Right Ventricle to Pulmonary Artery Conduit Implant
Juvenile male sheep (5-6 months, 35-40 kg) are chosen for these studies because
of several benefits including growing in size, similar anatomy and hemodynamic
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parameters to young adults, and
prior

testing

of

heart

vavle

bioprostheses degeneration and
calcification.[179] Animals were
obtained from the local Animal
Research Station and the sheep
were

housed

under

optimal

conditions and monitored pre and
post-operatory for general health,
food intake, behavior, and blood
tests.
Animal

Figure 9-2: Tissue engineered valve preparation,

implantation implantation, and follow up

Pericardium tubes are attached to the valve (A&B) before

protocols were approved by the implanting the conduit between the right ventricle and
pulmonary artery (C-D). Postoperative housing is indoors (F)

Institutional Review Board of the before longer term outdoor housing. (F) Echocardiogram and
other methods are used for follow up.

University

of

Medicine

and

Pharmacy of Târgu Mureş. The shunting procedure (Figure 9-2C&D) involves attaching
pericardial tubes to each side of the valve (Figure 9-2A&B) then attaching those tubes to
their respective portions of the right ventricle or pulmonary artery. Animals were set
under general anesthesia with controlled ventilation and continuous monitoring of ECG,
arterial pressure, pulse-ox, and temperature. Surgical procedure generally followed the
steps here:
1. Access via left thoracotomy at the level of the 4th intercostal space.
2. Incision of the parietal pleura and pericardium.
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3. Lateral clamping of the right ventricle followed by a 3 cm long
ventriculotomy.
4. The proximal end of the valved conduit was anastomosed to the ventricle
at this level using a continuous suture (Surjet with Prolene 5.0),
strengthened by Teflon pledgets where needed.
5. The pulmonary trunk was then clamped and the distal end of the valved
conduit was sutured to the pulmonary trunk with same suturing method.
6. After declamping, the pulmonary trunk was ligated shut at 1-2 cm above
the level of the pulmonary valve.
7. After hemostasis and checking sutures and conduit for leaks, the
pericardium and pleura were left open to prevent tamponade.
8. Finally, cavities were drained and the thoracic cavity was closed with
Dexon 2.0. Closing was in layers and isolated sutures at the tegument.
9.2.6 Postoperative Care
Following surgery, the sheep are temporarily placed in indoor monitoring
facilities (Figure 9-2E) before being released to their outdoor living spaces until explant
and analysis. Animals are cared for by standard techniques concerning monitoring,
supervision, pain killer medication, X-ray monitoring of the chest, laboratory tests and
food, with the consultation of a veterinarian, surgeon, anesthesiologist and cardiologist.
Animals will be monitored post-op for respiration (frequency, thoracic X-ray, blood
gases), cardiac frequency, hydration status, pH equilibrium, nutrition, hematology
(hemoglobin, hematocrit and electrolytes). Sheep will be sacrificed at 6 months (n=6) and
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12 months (n=6). At explanation, valves will be analyzed for morphology and function.
Those future studies will analyze these valves at the macroscopic and microscopic level
for calcification, necrosis, structural damage, cell infiltration, and cell retention.

9.3 Results and Discussion
9.3.1 Scaffold Preparation
Aortic valves were harvested from pigs of various ages and weights to assess the
anatomical details of the aortic valve (size, diameter, and position) that best corresponds
to implantation in sheep hearts in the pulmonary position. The optimum weight was
identified at 45-50 kg to obtain an aortic valve corresponding to the size of the sheep
pulmonary tract. Additional modifications to the research protocol were necessary to
accommodate the surgical setting. One such change has been the method of valve cleaning
and mounting during decellularization to allow pericardial tubes to attach to the valve.
The resultant conduit is necessary for the current placement of the valves and gives
relevant information about the ability to suture the resulting valve root scaffold.
9.3.2 Preliminary Sheep Results
Progress has been made toward testing a revitalized valve root in an ovine right
ventricle to pulmonary artery shunt model. Three surgeries have been performed with
glutaraldehyde treated valves to increase familiarity with the surgical procedure before a
tissue-engineered valve is utilized. The first resulted in animal death due to anesthesia
difficulties. The animals survived both the second and third procedures and operating
time decreased for each case.
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In all, at least 25 surgeries have been performed and they are still ongoing. More
recent trials utilizing tissue-engineered valves have had varied success. Surgical
procedures are still being adjusted to meet the needs of the sheep. Initial trials with valves
crosslinked only with PGG indicated that the valves were deteriorating more rapidly than
expected. This has also led to the modification of our research protocols as seen in the
addition of RapidGlut crosslinking treatment to later valve trials.
Overall, the implantation of tissue-engineered valve implants seeded with
autologous stem cells is one of the first such trials being performed in large animals. As
the teams become more familiar with the procedures and modifications are made to
improve outcomes, the advancement of a clinically relevant product will take great strides.
The knowledge gained by these studies will contribute important information for a
commercial valve replacement product.

9.4 Acknowledgements
Research funded by NIH grant RO1 HL093399 and a grant of the Romanian
National Authority for Scientific Research, CNCS – UEFISCDI, project number PNIIID-PCCE-2011-2-0036. Many thanks to the scientific and surgical team in Romania
including Marius Harpa, Ovidiu Cotoi, Terezia Preda, Lucian Harceaga, Radu Deac,
Victor Raicea, Horatiu Suciu, Klara Branzaniuc, Imre Egyed, Zoltan Pavai, Annamaria
Szanto, Agneta Simionescu, Dan T. Simionescu, and others.

Page | 176

PART 4: CONCLUSIONS AND REFLECTIONS
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CHAPTER 10: DISCUSSION, CONCLUSIONS, AND FUTURE
WORK
10.1 Conclusions of Research and Recommendations
The advance of heart valve replacements is moving in the direction of tissueengineered devices. This research has shown how core devices are a vital part to
developing and commercializing valve replacements. This research has also served to
progress the field of tissue-engineered heart valves forward by means of the novel devices
as well as scientific findings.
10.1.1 Valve Holding Device
A tool to handle a scaffold for a tissue-engineered product is integral to the many
components and processes used for developing those products. Without appropriate
handling, the scaffold could be damaged or even unable to transition between the various
treatments involved in developing these products. The valve holder developed through
this research provides an excellent hold on the tissue during assembly and use, provides
a reliable seal around the tissue in all processes, and is easy to use with many versatile
applications.
Recommendations
•

The distal root stabilizer currently utilizes sutures to hold the root up during
bioreactor functioning. This method is very versatile, but can also be time consuming,
even with the relatively few sutures needed. A means of quickly attaching the distal
aortic root to the stand and stabilizer would prevent the valve and cells from drying
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out during valve preparation and would also greatly decrease the time necessary to
prepare a valve for bioreactor functioning. Initial designs and prototypes have utilized
an internal retaining spring that can be applied with plier tools. Concave grooves in
the upper ring or stand itself would help seat the retaining spring and prevent
dislocation during valve functioning.
•

Nonmetal materials should be sourced for the potential use of the valve in an MRI
device or for disposability. However, care should be taken to ensure chemical
compatibility with all decellularization, crosslinking, and culturing solutions. An inert
ceramic or plastic that would provide adequate strength would serve well.

10.1.2 Perfusion Decellularization Method and Device
Immersion

decellularization

techniques

are

inadequate

for

whole-root

decellularization. The thick, elastin-rich areas require a more robust method of
decellularization. The perfusion system designed for this research is the first of its kind
for heart valve roots. Its capabilities to treat individual components of the valve root with
independent conditions allows it to be rigorous enough to decellularize the aortic root
while gentle enough not to destroy the cusps. Any scaffold to be implanted must be free
of all animal cells and the valve root is no exception. Each area of cusp, sinus, aorta, and
muscle must be free of native cells. However, we are currently unaware of the effects of
this process on the mechanical durability of the valve root components.
Recommendations
•

The current device uses nearly 4 liters of fluid for each media change. While an
adequate fluid-to-tissue ratio is necessary, this system is excessive and potentially
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wasteful. A main chamber that reduces the area around the valves should be built.
This chamber would essentially be contoured to the shape of the valve roots while
allowing adequate circulation. Alternatively, individual chambers or a reduced
number of valves could be processed with the above in mind.
•

Future versions of the system should be manufactured with slight variances to the
layers and materials to ease assembly and reduce components. For instance, the
central holding plate (layer 3) can be combined with the main chamber portion (layer
4) and the material should be a rigid plastic such as Delrin. Additionally, by thickening
the other layer that holds the valves (layer 2), a dampening section can be dug out of
that layer along one side. That dampening section would be full of air while not
increasing the volume of solution used to eliminate the dampening bottle.

•

Individual chambers could also allow the valves to be crosslinked inside the system
without the need for packing the cusps with cotton balls. By reversing the flow, a
slight pressure gradient can be created to crosslink the valves in the naturally position.

•

Upgrades to the software should include connecting the peristaltic pump to the
computer so it can be monitored and controlled via a feedback loop by the software.
The pump includes that capability and software, but LabView programming and
potentially another piece of hardware will be necessary to provide the interface.

•

Mechanical evaluation should be performed on the valve roots. Compliance data can
be obtained through the clear wall of the system by inserting a ruler into the main
chamber of the decellularization system and diameters measured at varying pressures
using the existing setup. Biaxial or uniaxial testing should be performed on the aortic
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root to determine if excessive damage is being done to the elastic properties and
strength of the native tissue.
•

The decellularization protocol may also be optimized. A shorter time for various steps
of the process could reduce the overall time required to achieve full decellularization.

10.1.3 Cell Seeding by Injection and Rotational Seeding and Conditioning Device
Cell seeding by injection is much more effective than relying on cellular migration,
but it is not the optimal means of revitalizing a tissue because of its damaging and
inconsistent aspects. It is also technically difficult and reproducibility is user-dependent.
The rotational seeding device works well, but requires routine user input and observance.
The optimal methods of achieving a confluent layer of cells on all surfaces of the valve
root are also deficient. Current methods achieve the goals, but may be using too many
cells and supplies.
Recommendations
•

A new method of recellularizing the internal portions of valve cusps is necessary. This
method should provide more uniform coverage and result in less tissue damage. Other
methods currently being investigated in the lab are promising. Details are
purposefully omitted to maintain confidentiality.

•

External seeding could be optimized by clamping the distal aorta with existing
equipment and sealing the inflow with o-rings as done in other places. This would
localize the cell seeding solution within the valve lumen to allow a much higher
concentration of cells to attach to the valve, resulting in higher seeding densities with
fewer cells used. Care should be taken to ensure that the devices fit inside the chamber
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and that the external surfaces of the root maintain moisture, although concern for the
second point is minimal given the small air volume in the system.
•

Seeding protocols should also be optimized. A combination of method 2 and 3 should
be compared with method 3 alone to determine the most efficient means of fully
recellularizing all of the aortic root surfaces. Reducing the number of cells or
repetitions could also yield results that are just as effective.

•

Improvements to the frame and software should allow monitoring of rotation angles
to enable pausing at specified angles. Automated control of the speed of the shaker
plate should also be incorporated into the controls of the system. The seeding method
and regimen should be entered into LabView in “spreadsheet style” instead of “on/off”
style. These upgrades will allow complete customization of rotational scenarios. Bob
Teague is currently working on automated control of the shaker plate and Charlie
McDonald is currently working on spreadsheet style of entering data into LabView.

•

Gas exchange inside the seeding chambers needs immense improvement. Securing the
lids and flowing appropriately mixed gases through the ports and sterile filters by
pressure or vacuum would improve this, but must be compatible with the rotation of
the system. Preliminary designs have been discussed that involve routing a
pressure/vacuum line through the axle of the chamber holder and incorporating a gas
line inside the holding plate that would protrude next to each chamber position.
Hydrophobic sterile filters could be attached to the system to allow gas movement
and timing could be aligned appropriately with the placement of the gasses near the
ports if necessary.
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10.1.4 Fourth Edition Heart Valve Bioreactor Device
The fourth edition of the bioreactor is a sophisticated system that provides
capabilities not seen in most other systems in the research or commercially available. In
addition, its small footprint, relatively simple assembly, and ability to fine-tune make it a
valuable component to the laboratory’s research. The current edition is nearing
completion to provide pulmonic or aortic conditions of flow, pressure, and viscosity, but
additional improvements and modifications are necessary to reach those conditions or
improve ease of use.
Recommendations
•

The first objective should be to finalize the size and shape of the bottle used as an
aortic compliance chamber. The means of providing an internal balloon membrane
should also be finalized. A component of this chamber will include an input pressure
regulator and filter to control the internal air pressure of the chamber without
opening it to non-sterile air or using excessive amounts of fluid.

•

The quick-connect latches of the quick-connect bioreactor fittings should be adjusted
to function with the 3-D printed materials. Although the o-rings provide a reliable
seal, there is potential risk that the fittings could slide out of the main bioreactor
chamber without the latches in place. External design services of the inventors can be
sourced for this task.

•

Additional tools should be developed to assist in the assembly of the bioreactor. These
include a membrane cutting and placement tool, a camera holder, a pressure
transducer holder, and any required supports for the modules.
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•

As with all future devices made of a clear plastic, future versions of the chambers
should be machined out of polysulfone rather than acrylic. This material is semitransparent and can be sterilized by autoclave.

•

A manifold system should be developed inside the incubator that allows the small
through-wall port of the incubator to provide enough real-estate to service four or
more bioreactors within the same incubator.

•

A more aseptic method of adding media to the bioreactor should be developed.
Current methods work well, but have risks of contamination. If media could be
delivered by attaching bagged media to the bioreactor through one of the needleless
ports and applying a small vacuum force to the main chambers, the media could be
added very quickly without drying out the valve sample.

•

Studies should be performed to evaluate the cytotoxicity of all printed or other
materials on cells. While no effects have been seen, validation of the appropriate choice
of material should be performed.

•

Additional modules should be developed to provide capabilities to test mitral valves
and transcatheter implantations. The validation an in vitro system for creating
diseased states and testing drug treatments is still a possible use for the bioreactor
systems that should not be abandoned.

•

Living aortic valves should be collected from the slaughterhouse and mounted into
the bioreactor. The bioreactor should be run for at least four weeks to demonstrate
its capabilities to provide a healthy, native environment to heart valves. This scientific
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evidence will be the bedrock to support claims that this bioreactor system can
adequately prepare a tissue-engineered valve for implantation.
•

Additional case studies should be performed to widen the applicable uses of the heart
valve bioreactor. From providing physiologically relevant flow to enabling another
technology, the bioreactor system is truly a platform system that can be applied in
many areas.

10.1.5 Tissue-Engineered Heart Valve Conditioning and Animal Implants
Progressive adaptation regimens to allow seeded cells to remain attached to
scaffold surfaces are vital to a valve’s self-modulation of the repair of the cusps. Included
studies have shown that this progressive adaptation is necessary for cell retention and a
select few trials have been performed to develop the appropriate protocol. Factors of other
systems (gas exchange in the seeding chambers, etc) have prevented further study herein.
Autologous stem cell-seeded scaffold being implanted into large animals is new in
this field. Many hurdles have been faced in translating this research project into clinical
applications, but the animal studies have revealed very important aspects of our research
that must continuously be adapted to fit the need.
Recommendations
•

Trials should be performed to determine the necessary pre-conditioning regimens for
adequate cell retention after reaching pulmonary and aortic conditions. A period of
gentle conditioning followed by more rigorous conditioning in the seeding
chambers/rotating frame before transferring the valves to the bioreactor has shown
great promise, but needs to be optimized and validated.
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•

Cell staining (such as for focal adhesion kinases, FAK) to observe the cell-cell
interactions as well as the cell-matrix interactions should be performed to evaluate
cellular attachment to the scaffolds.

•

Overall, fewer cells should be used to revitalize the scaffold. Current methods employ
more cells than reasonably collected from a patient without in vitro culturing.

•

One ongoing question is if externally seeded cells are necessary for these implants.
After pre-conditioning regimens are developed to retain cells at physiological
conditions, trials should be performed using externally seeded valves.

10.2 Final Discussion of Progress
The field of heart valve devices has come far since the advent of mechanical valves
in the middle of last century. There have been improved hinge designs, alternative
bioprosthetic materials, minimally invasive implantation procedures, and even animal
trials with decellularized or tissue-engineered valve replacements. As our understanding
of this complex and astounding structure increases, we will continue to develop better
replacement products that perform closer and closer to the way the valve was designed
to work in a healthy person. There is much work to be done, but we stand on a hill of
giants gone already deeply entrenched and dedicated to its progress. We look forward to
where our future innovations, learning, worldwide need, and even funding will lead us.
There is no doubt that a robust tissue-engineering replacement heart valve will soon be
available to improve lives all around the world.
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